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ABBREVIATIONS 
Abbreviations for chemicals are listed in Table 2.1. 
A  Ampère 
bp  Base pair(s) 
Da   Dalton 
DNA  Deoxyribonucleic acid 
e.g.  Exempli gratia; for example 
EMSA  Electrophoretic mobility shift assay  
FPLC  Fast protein liquid chromatography 
g  Gram  
h  Hour 
HE  Homing endonuclease 
i.e.   id est; that is 
k  Kilo 
l  Liter 
LB  Luria-Bertani 
m  Milli/meter 
M  Molar 
min  Minute 
MW  Molecular Weight 
n  Nano 
o/n  Overnight 
OD  Optical density 
PAGE  Polyacrylamide gel electrophoresis 
PCR  Polymerase chain reaction 
Pfu  Pyrococcus furiosus 
rpm   Rotations per minute 
sec  Second 
Taq  Thermus aquaticus 
TM  Melting temperature 
UV  Ultraviolet 
V  Volt 
v/v  Volume/volume 
wt  Wild type 
w/v  Weight/volume 
x g  Gravity 
Ω  Ohm 
µ  Micro 
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1. INTRODUCTION 
1.1 GENE TARGETING 
After deciphering the first genome of an organism in 1995, i.e. from Haemophilus 
influenzae [1], a large number of sequences followed until finally the human genome was 
published in 2001 [2,3]. This opened several possibilities for gene therapy and gene targeting, 
e.g. the genetic information for hereditary monogenic diseases are now available and the 
genes can be addressed directly. This can be realized by several tools, summarized in Figure 
1.1, which create specific double-strand breaks next to the mutated sequence responsible for 
the disease or in a certain locus where transgenes should be introduced. These double-strand 
breaks can increase the number of homologous recombination events [4], whose frequency is 
naturally quite low. By providing the correct gene in trans this can be used as repair matrix 
and exchanged for the defect gene. 
 
Figure 1.1: Overview of possibilities for gene targeting. Specific double-strand breaks in 
proximity to a mutated sequence introduced by several tools, namely Zinc-finger nucleases, 
homing endonucleases, TALE-nucleases, TFO-linked nucleases and fusion proteins will be 
repaired via stimulating homologous recombination using the newly introduced sequence (blue, 
pink) as matrix. Modified after [5].   
  
Introduction 
 
13 
1.1.1 HOMING ENDONUCLEASES 
Comparing the highly specific nucleases presented in Figure 1.1 it is striking that 
homing endonucleases (HE) are the only ones already existing in nature. All the others were 
engineered by fusing specific DNA-binding modules to DNA-cleavage modules, i.e. 
restriction endonucleases, and by this prolonging their recognition site. Homing 
endonucleases, usually encoded by group I or group II introns or existing as inteins or 
freestanding open reading frames, are able to recognize sequences of up to 40 bp in length [6], 
which makes them perfect candidates for gene targeting tools.  
 
Figure 1.2: The homing process. PI-nucleases, existing as inteins, are spliced out of a 
precursor-protein, while I-nucleases are encoded in introns which are translated after RNA-
splicing. The homing process is the same for both, they recognize a sequence in the intronless 
allele, cleave there and this double-strand break is then repaired by using the intron-containing 
allele as repair matrix, resulting in a homozygous situation. Modified after [7] 
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The main function of these enzymes is the propagation of their genes, which is 
realized by cleavage of a sequence on the allele lacking their own coding sequence, and this 
double-strand break will be repaired via homologous recombination using the other allele 
containing the coding sequence for the HE as matrix (Figure 1.2). By this, the maintenance of 
the HE-coding gene in both alleles is assured. The fact that this process, called homing is 
quite similar to the above described mechanism of gene targeting is another good reason for 
choosing HEs as specific cleavage tools. 
 
Figure 1.3: Overview of the five homing endonuclease families with one representative for 
each. I-CreI (pdb: 1G5Y) as LAGLIDADG, I-HmuI (pdb: 1U3E) as HNH, I-PpoI (pdb: 1A73) 
as His-Cys Box, I-Ssp6803I (pdb: 2OST) as PD-(D/E)xK and the DNA-binding domain of I-TevI 
(pdb: 1T2T) as GIY-YIG family member. 
According to their active center five families of homing endonucleases, namely 
LAGLIDADG, His-Cys Box, HNH, GIY-YIG and PD-(D/E)xK, have been described so far. 
For representatives of all these families structural data are available, revealing how these 
enzymes manage to recognize and bind their large recognition sequences (Figure 1.3). The 
best studied and largest of these families are the LAGLIDADG homing endonucleases. This 
family can be furthermore divided into two subgroups, monomeric and homodimeric proteins. 
The homodimeric LAGLIDADG homing endonucleases contain only one LAGLIDADG-
motif per subunit (e.g. I-CreI) whereas the monomeric enzymes harbor two motifs (e.g. 
I-SceI). Monomeric LAGLIDADG homing endonucleases can be further divided into intron 
encoded proteins and those existing as inteins (e.g. PI-SceI). The last mentioned harbor an 
additional domain which is responsible for splicing the enzyme out of the precursor protein 
and also extends the DNA-binding ability. Common feature of all LAGLIDADG enzymes is 
their conserved αßßαßßα core topology, with the LAGLIDADG motif being at the end of the 
Introduction 
 
15 
first α-helix. The ß-sheets normally form a saddle-like structure binding specifically to the 
DNA [6]. 
 
Figure 1.4: Overview of published crystal structures representing the structural subfamilies 
of LAGLIDADG homing endonucleases, homodimeric, monomeric intron encoded and 
monomeric inteins. The LAGLIDADG motif is indicated in yellow and the catalytically active 
residues are red. In the homodimeric enzymes just one subunit is colored green and in the case 
of the monomeric inteins the additional DNA-recognition-region (DRR) and the splicing domain 
are dark-gray. 
Due to the relatively large recognition sequence and the tolerance of single base 
changes, homing endonucleases seem to have a higher plasticity in DNA binding/recognition 
compared to restriction enzymes. This feature might be an advantage in engineering and 
designing them for genomic applications (see review: [8]). Therefore, a lot of effort is 
currently undertaken to create homing endonucleases with an altered specificity. The four 
most important of these approaches are: domain/subdomain shuffling [9-11], computational 
redesign [12,13], screening of variants with mutations at residues predicted to be involved in 
DNA-binding [14-16] and in vivo selection assays [17-19] which are also part of the work 
described here and will therefore be discussed later in more detail. 
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Successful examples for using homing endonucleases as gene targeting tools are given 
by the company Cellectis, SA (Romainville, France), which developed a high-throughput 
screening method for variants of I-CreI [20-22]. With this assay, they screened millions of 
variants containing two to four amino acid changes in positions known to be responsible for 
protein-DNA contacts against any potential target site. This resulted in hundreds of I-CreI 
variants with locally changed recognition patterns, which were then used in combinatorial 
approaches by combining different sets of mutants in one protein, ending up with fully 
reengineered meganucleases (Figure 1.5).With this building-block like approach, Cellectis 
was able to create a library of > 30,000 I-CreI derived variants recognizing in principle almost 
every desired target sequence.  
 
Figure 1.5: Overview of combinatorial strategy pursued by Cellectis. In a screening approach 
I-CreI variants with altered specificity were selected, whose local mutations were later on 
combined, creating libraries of engineered I-CreI derived meganucleases. (from [23]) 
From this library of I-CreI variants two enzymes were selected so far, targeting human 
gene loci, namely XPC involved in Xeroderma pigmentosum [23] and RAG1 involved in the 
X-chromosome linked severe combined immunodefiency (X-SCID) [24,25]. Furthermore, 
meganucleases were used for so-called virus clipping, meaning the nuclease targets viral 
sequences and thus is able to cleave these sequences integrated into the host genome. If no 
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repair matrix is available this double-strand break will be repaired via non-homologous end 
joining (NHEJ) leading in most cases to insertions or deletions (indels) [26], and the viral 
DNA will be rendered harmless. An example of this concept is reported by Grosse et al. [27] 
where recombinant Herpes-simplex viruses (HSV-1) were produced harboring an I-SceI site 
in their genome or meganucleases based on I-CreI were created to cleave inside the natural 
HSV-1 genome. In this study, they showed a 50 % reduction of viral infection when the 
meganuclease gene was transfected before virus infection. The repair mechanism of NHEJ is 
unwanted in the case of directed gene targeting, where homologous recombination should be 
preferred, inserting the correct gene sequence into the double-strand break.  
Since Metzger et al. [28] reported that nicking of DNA is sufficient for stimulation of 
homologous recombination and provokes a lower frequency of NHEJ, mega-nickases which 
were studied years before [29,30], offer also an alternative as gene targeting tools. 
1.1.2 ZINC-FINGER NUCLEASES 
This group of chimeric nucleases is, until now, the most prominent and most widely 
used one. They consist of zinc-finger proteins linked to the catalytic domain of FokI. Zinc-
finger proteins contain three to six zinc fingers each of about 25 amino acids with five amino 
acid spacers between the individual fingers. In each zinc finger a zinc ion is coordinated by 
two cysteine and two histidine residues, leading to the characteristic three dimensional 
structure (Figure 1.6).  
 
Figure 1.6: Co-crystal structure of the Zinc-finger protein ZIF268 (pdb: 1A1L) consisting of 
three zinc finger motifs, each recognizing approximately three base pairs. Zinc ions are 
depicted in yellow. 
Residues -1, 3 and 6 in every helix form specific hydrogen bonds to a base pair triplet 
leading to specificity of the zinc finger and by this being the programmable part. Using phage 
display technology, it was possible to generate zinc-finger proteins recognizing a large 
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number of sequences, a method optimized and widely used by the company Sangamo 
Biosciences, Inc (Richmond, CA, USA) (for review see [31]). Having this powerful tool to 
target any possible sequence the next step was using it in combination with a cleavage module 
as a highly specific nuclease, so-called Zinc-finger nucleases (ZFN) (Figure 1.7) [32-34]. As 
cleavage module the catalytic domain of the restriction endonuclease FokI was used, which 
by itself is not able to recognize a specific sequence [35]. Since FokI has to dimerize prior to 
catalysis [36], a 16 to 36 bp sequence could be recognized. The problem in this case is that 
FokI can also cleave if only one subunit is properly bound to the DNA [37], which leads to 
cleavage of halfsites of the recognition sequence and by this to cytotoxicity. For this reason, it 
was aimed to change the dimerization interface of FokI and by this creating functional 
heterodimers [38-40]. 
 
Figure 1.7: Model of a typical zinc-finger nuclease (ZFN) consisting of the catalytic domain of 
FokI fused to a three zinc-finger protein recognizing 9 bp sequences. The FokI subunits 
dimerize for activity and by this an 18 bp tandem repeat sequence could be recognized. 
Modified after [31]. 
Until now, ZFNs have been widely used for genome modifications in several 
organisms, including fruit fly, nematodes, tobacco, zebrafish and human (for review see [41]).  
In case of human genome modification two examples have to be highlighted. The first one is 
based on homologous recombination stimulated by a double-strand break at the human IL2γR 
gene locus leading to exchange of the defect gene involved in X-SCID [42,43]. The second 
approach, which already reached clinical trials, is based on NHEJ by creating a ZFN targeting 
the human CCR5, a co-receptor for HIV infection. If this receptor is not functional the 
patients show resistance against HIV infection [44], which implies possibilities for anti HIV 
therapy. Perez et al. [45] reported a ZFN cleaving a sequence in the CCR5 locus in primary 
CD34+ T-cells, which is then repaired via error-prone NHEJ leading to disruption of the 
CCR5 coding sequence and can confer resistance against HIV infection. 
In summary, until now ZFN are the tool of choice regarding gene targeting and 
genome modification, but it has to be considered that they have been investigated since 
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15 years, which is an advantage compared to for example TALE nucleases, which have been 
discovered to be good candidates for gene targeting only two years ago. 
1.1.3 TALE NUCLEASES 
After decoding the DNA-binding and recognition mechanism of the transcription 
activator like effectors (TALE) from the plant pathogen Xanthomonas in 2009 [46], these 
proteins were thought to be perfect candidates for DNA-binding modules for highly specific 
nucleases. DNA-binding by these proteins is mediated through a tandem repeat domain 
containing repeat units of usually 33 - 35 amino acids, while amino acids at position 12 and 
13 display the so-called repeat-variable diresidue (RVD) responsible for specific base pair 
contacts (Figure 1.8A) [47]. The NMR structure of 1.5 repeats of the TALE PthA revealed 
that one repeat consists of three α-helices forming a tetratricopeptide repeat (TPR)-like 
structure (Figure 1.8C) [48] with the RVDs located on the top of the helix turns. It is 
suggested that these repeat units encircle the DNA with the RVDs forming the base specific 
contacts [49]. 
 
Figure 1.8: Domain organization of TALE AvrBs3 from Xanthomonas campestris pv. and 
NMR structure of PthA from Xanthomonas axonopodis pv. citris (A) the repeat domain in 
red containing 17.5 repeat units each with a length of 34 amino acids, with residue 12 and 13 
(shaded gray) being variable. (B) Amino acid residues 12 and 13 from all 17.5 repeats of 
AvrBs3, with the respective nucleotide recognized by them. From [46] (C) NMR structure 
(pdb: 2KQ5) showing 1.5 repeats, with one repeat in red and the other half-repeat in pink, the 
RVDs are depicted in gray. 
A certain combination of these diresidues recognizes a distinct base pair sequence 
(Figure 1.8B), which makes TALEs a programmable DNA-binding module. In contrast to 
zinc fingers, there are well defined rules for specific recognition by the TALEs, making the 
use of extensive screening procedures unnecessary. This new DNA-binding module was also 
fused to the catalytic domain of FokI, as it was reported for ZFNs, to generate so-called 
TALENs (TALE-nucleases) [50-52]. Until now, these new chimeric enzymes seem to offer an 
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alternative to the ZFN used so far, especially because of their predictability, but further 
studies have to be made and particularly co-crystal structures of these enzymes should answer 
some open questions. 
1.1.4 TFO-LINKED NUCLEASES 
In this class of highly specific nucleases the DNA-binding module is a triple helix 
forming oligonucleotide (TFO), which can bind duplex DNA in a sequence-specific manner 
and by this provides a high degree of programmability [53]. This module was fused to 
different DNA cleavage modules, as for example restriction enzymes [54] or psoralen [55]. 
Disadvantage of TFO-linked nucleases is that in contrast to all other highly specific nucleases 
the specificity is mediated by a non-proteinaceous DNA-binding module, which makes 
expression of the fusion construct in cells difficult and needs direct delivery of the TFO-
linked nuclease into the cells. 
1.2 MEGANUCLEASES 
In the beginning of the gene targeting era all highly specific nucleases were 
summarized by the term “meganucleases” [56], while in the meantime this name is reserved 
only for homing endonucleases and engineered variants thereof as they will be presented in 
this work. 
1.2.1 DIRECTED EVOLUTION 
Enzymes evolved during millions of years due to natural selection. The properties 
evolved, such as activity, solubility or specificity are often not suitable for applied sciences or 
industry. For this reason directed evolution approaches for finding optimized enzymes were 
developed. Usually, libraries of enzyme variants were created either by error-prone PCR [57] 
or DNA-shuffling [58], if for instance the structure of the enzyme is not available or by site-
directed mutagenesis, if residues involved for example in DNA-binding or catalysis are 
known. These libraries can then be screened or selected for the desired property of the 
enzyme (for review see [59]). Since the work presented here deals with meganucleases or 
highly specific nucleases to create double-strand breaks into DNA, only systems for directed 
evolution of this class of enzymes will be discussed.  
Screening systems for meganucleases with altered specificity were mainly developed 
and used by Cellectis, as already mentioned above. These assays were either performed in 
yeast or CHO (chinese hamster ovary) cells, where recombination events due to double-strand 
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cleavage of the HE at the desired target sequence were detected by blue/white screening based 
on restoration of the lacZ locus [21,22]. Since screening methods are normally time-
consuming, because every possible variant will be investigated individually and this could 
only be realized by high-through-put systems, most other systems for directed evolution of 
meganucleases are based on selection. In most cases, these selection systems link the activity 
and specificity of the meganuclease for a certain target site directly to the survival of E.coli 
cells. Figure 1.9 shows the principle strategy of such two-plasmid assays. E.coli cells were co-
transformed with two plasmids, while one expresses the meganuclease library and the other 
one contains the target site to select for. The latter mentioned is called reporter plasmid and 
normally encodes a toxin. Expression of the meganuclease library is induced first and if there 
is no enzyme able to recognize and cleave the target sequence on the reporter plasmid, 
following induction of this toxin will lead to cell death. If there is a variant in the library 
which can cleave the target site, the reporter plasmid will be linearized and subsequently 
degraded by the RecBCD system of the cell [60]. Since there is no reporter plasmid available 
anymore, no toxin expression will be induced and the cells will survive. These surviving 
colonies should express homing endonuclease variants with an altered specificity. To increase 
the stringency of the assay, the surviving colonies are usually pooled, DNA extracted and 
again used to co-transform E. coli cells with reporter plasmid, repeating this several times. 
 
Figure 1.9: Principle of a two-plasmid selection assay. E.coli cells were co-transformed with 
the plasmid expressing the homing endonuclease or variants thereof and a reporter plasmid 
expressing a toxin and harboring the target sites for selection. (A) The expressed HE is not able 
to recognize and cleave the target site on the reporter plasmid and therefore the cells will not 
survive toxin expression. (B) One of the HE-variants can cleave the reporter plasmid at the 
target site, which will be degraded by the RecBCD system of the cell and the E.coli cells will 
survive induction of toxin expression. 
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The first such assay trying to find new variants of the homing endonuclease I-SceI was 
developed by Gruen et al. [17] in 2002. As toxic reporter they used Barnase (RNAse from 
Bacillus amyloliquefaciens) and the problems they were facing were a too high background of 
false positive cells and a too low sensitivity of the assay. These obstacles could be solved by 
Chen and Zhao [18] and Doyon et al. [19], both using CcdB (control of cell death B) as toxic 
reporter.  
PI-SceI, a LAGLIDADG homing endonuclease existing as intein, was thought to be a 
suitable candidate for a gene targeting nuclease, but so far only one assay was available for 
selecting PI-SceI variants based on binding ability of the enzyme to different substrates [15]. 
For this reason, the before mentioned CcdB selection assay was used by a colleague of mine 
(Tobias Ullrich) to select new variants of PI-SceI. Unfortunately, the number of surviving 
cells in the CcdB-based selection assay was very low and it turned out that the cells only 
survived because of mutations in the gene encoding the toxin CcdB and not because PI-SceI 
cleaved its target site. A severe disadvantage of this system was that the homing 
endonuclease-encoding plasmid was controlled by a low-copy number promoter while the 
reporter plasmid was present in a high copy number in the cell. Since PI-SceI tends to stay 
bound to its cleavage product and by this shows a low activity rate, the number of enzyme 
molecules should be higher than the number of cleavage sites. In preliminary work (Diploma 
thesis Ines Fonfara, Giessen 2008) the existing assay was optimized to work for selection of 
PI-SceI variants. This optimization included the use of a high-copy plasmid for expressing the 
homing endonucleases and a low-copy plasmid for expressing the toxin, so that there are more 
homing endonuclease-expressing plasmids in the cell, than reporter plasmids. Furthermore the 
PL-promoter from bacteriophage λ [61] was used to control the toxin expression, which has 
the advantage of tight regulation of expression by the temperature sensitive repressor cI857 
[62]. This system by itself has the advantage that no additional chemical compound has to be 
added to the cells, only a temperature shift from 28 °C to 42 °C was needed. Another 
improvement was the use of a different reporter toxin, namely gvpA (gas vesicle protein A 
from Anabaena flos-aquae [63]). In contrast to the previously used toxins, this protein is only 
a structurally acting toxin, by building up gas vesicles inside the E.coli cells and the idea was 
that single mutations in the reporter gene would not necessarily lead to inefficacy of the toxin.  
1.2.1.1 PI-SceI 
This homing endonuclease from the LAGLIDADG family, existing as intein has a size 
of about 50 kDa. It is produced by protein splicing of the 119 kDa precursor protein VMA1 
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from Saccharomyces cerevisiae. For this reason, PI-SceI was called VDE (VMA1 derived 
endonuclease) [64] at first. After discovering an increasing number of homing endonucleases 
it was decided to have a common nomenclature [65], as it was done for restriction enzymes 
and it was renamed PI for “protein-intron” (intein) and Sce for S.cerevisae. PI-SceI recognizes 
a long asymmetric sequence of 31 bp, which is unique in the 13 million bp genome of yeast. 
This is one of the reasons why it was thought to be a good candidate for gene targeting. The 
second reason is its two-domain organization, with domain I being responsible for DNA-
binding and also harboring a protein splicing activity while domain II with the two 
LAGLIDADG motifs is responsible for DNA-cleavage but also involved in DNA-binding 
(Figure 1.10) [66]. It was also shown that domain I alone is able to specifically bind DNA 
while domain II cannot bind DNA when expressed alone [67,68]. 
 
Figure 1.10: Co-crystal structure of PI-SceI (pdb: 1LWS) showing the two domains. Domain I 
contains the DNA-recognition region (DRR, yellow) and the loop 53-70 (blue) which makes a 
flipping motion after DNA-binding [69] and domain II harbors the catalytic LAGLIDADG 
motifs (red). 
As observed in the co-crystal structure (Figure 1.10), PI-SceI bends the DNA by 
~ 75 ° towards the major groove [70]. In this publication, it was also reported that PI-SceI 
tends to stay bound to one of the products after cleavage, which is the reason that this enzyme 
does not show a real turnover activity. The active center residues Asp 218 and Asp 326 are 
responsible for catalysis [71,72], both being the second Asp in the two LAGLIDADG motifs. 
PI-SceI cleaves its target site by leaving a 4 bp 3’overhang and requires divalent cations as 
cofactors. While these could be Mg
2+
 or Mn
2+
 the enzyme shows a higher activity in presence 
of Mn
2+
, but also a more relaxed specificity [73]. Furthermore, the temperature optimum for 
cleavage activity is between 40 - 45 °C and the pH optimum is between 8.5 and 9 [64]. 
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1.2.2 FUSION ENZYME ENGINEERING 
As already reported, all generated chimeric nucleases so far, except the TFO-linked 
nucleases, consist of a DNA-binding module (zinc finger or TALE) and the catalytic domain 
of FokI as cleavage module. An alternative binding module could be also I-SceI due to its 
large recognition sequence and specificity, which was already reported [74], where a 
catalytically inactive variant of I-SceI was fused to the catalytic domain of FokI. The 
disadvantage of using the catalytic domain of FokI as cleavage module might be that it does 
not contribute to the specificity of the fusion enzymes itself, which could always result in 
potential off-site target cleavage. For this reason, specific nucleases, as for example type IIP 
restriction endonucleases, would offer an opportunity to create highly specific chimeric 
endonucleases, since they can contribute to some extent to the specificity of the fusion 
enzymes. 
1.2.2.1 I-SceI 
I-SceI is another member of the LAGLIDADG homing endonucleases encoded by a 
mitochondrial intron in Saccharomyces cerevisiae. This monomeric enzyme, with a size of 
27.6 kDa, recognizes an asymmetric 18 bp sequence leading to 4 bp 3’ overhangs, although it 
has to be mentioned that I-SceI shows some tolerance to mutations in the recognition site 
[75]. Furthermore, I-SceI tends to stay bound to one of the products after cleavage leading to 
a slow turnover number of this enzyme [76]. As for PI-SceI the two catalytically important 
aspartates 44 and 145 correspond to the second aspartate in the LAGLIDADG motifs [77]. 
I-SceI binds its recognition site with a KD of ~ 9.7 nM [19], with the C-terminus binding to the 
upstream part and the N-terminus binding downstream where most of the protein-DNA 
contacts are made [77]. Since the early 90s, this enzyme is widely used for genome 
modification and initiation of recombination events in different cell types and organisms [78-
83] and for this is still called the “gold-standard” [56]. 
1.3 AIM 
In this work, two different approaches for generating meganucleases were pursued. 
The first aims at finding variants of the homing endonuclease PI-SceI with an altered 
specificity by directed evolution approaches. A library of variants was generated by mutating 
certain residues in the DRR of PI-SceI and this library was to be assayed with a previously 
developed two-plasmid selection system. The second approach is more rational by using the 
homing endonuclease I-SceI as specific DNA-binding module and fusing it to the 
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homodimeric restriction endonuclease PvuII. By this the recognition site of PvuII would be 
extended and a highly specific nuclease cleaving only a tripartite site, consisting of a PvuII 
site flanked by two I-SceI sites, would be generated. With the first assay, it was planned to 
show the possibilities of changing the specificity of an already existing meganuclease to 
eventually target a genomic locus. The second assay represents a proof-of-principle study to 
show PvuII as an alternative to the catalytic domain of FokI used as cleavage module so far. 
The here generated meganucleases would be used later in the so-called “safe harbor” 
approaches using I-SceI sites already introduced into plant genomes as “landing platform” 
[84].   
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2. MATERIAL AND METHODS 
2.1 MATERIAL 
2.1.1 CHEMICALS 
All chemicals used listed in Table 2.1 were of high purity.  
Table 2.1 
Chemical Abbreviation Company 
[α32P] Deoxyadenosin-triphosphat [α32P]ATP Hartmann Analytic 
2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic acid HEPES AppliChem 
2-Mercaptoethanol 2-Me Merck 
Acetic acid  Roth 
Acrylamide-bisacrylamide solution (29:1) 40 %  AppliChem 
Adenosin-triphosphat ATP Sigma 
Agar  AppliChem 
Agarose Ultra Pure 
TM
  Invitrogen 
Aluminium sulfate  AppliChem 
Ammonium persulfate APS Merck 
Ampicillin Amp AppliChem 
Anhydrotetracyclin  IBA 
Bacteriophage λ-DNA λ-DNA Fermentas 
Bovine serum albumin BSA NEB 
Bromphenol Blue  Merck 
Chloramphenicol Cm AppliChem 
Coomassie ® Brilliant Blue G250  AppliChem 
Deoxynucleotide triphosphates dNTPs Fermentas 
Desthiobiotine  Sigma Aldrich 
Di-potassium hydrogen phosphate  Merck 
Di-sodium hydrogen phosphate  Merck 
Dithioerythritol DTE AppliChem 
Dithiothreitol DTT AppliChem 
Ethanol  Roth 
Ethidium bromide  Roth 
Ethylene diamine tetraacetate EDTA AppliChem 
Glycerol  AppliChem 
Glycine  Merck 
Hydrochloric acid HCl Merck 
Imidazole  Merck 
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Isopropyl-1-thio-ß-D-galactopyranoside IPTG Roth 
Kanamycin sulfate Kan AppliChem 
Magnesium acetate Mg-acetate Merck 
Magnesium chloride MgCl2 Merck 
Manganese chloride MnCl2 Merck 
Ni-NTA-agarose  Quiagen 
o-Phosphoric acid 87 %  Roth 
Poly(deoxyinosinic-deoxycytidylic) acid sodium salt Poly (dI-dC) Sigma Aldrich 
Polyethylene glycol PEG Merck 
Potassium chloride KCl Roth 
Potassium dihydrogen phosphate  Merck 
Potassium glutamate  Merck 
Sodium acetate NaAc AppliChem 
Sodium chloride NaCl Merck 
Sodium di-hydrogen phosphate  Merck 
Sodium dodecyl sulfate SDS Roth 
Sodium hydroxide NaOH Merck 
Strep-Tactin® Sepharose®  IBA 
Tetracyclin hydrochloride Tet AppliChem 
Tetramethyl ethylene diamine TEMED Merck 
Tris-(hydromethyl)-aminomethane Tris AppliChem 
Tryptone  AppliChem 
Xylene cyanol  Merck 
Yeast extract  AppliChem 
 
2.1.2 ENZYMES 
All restriction enzymes and homing endonucleases listed in Table 2.2 were used in the 
recommended buffer according to the manufacturer’s manual.  
Table 2.2 
Enzyme Cleavage site (5’ 3’) Company 
BamHI G|GATCC Fermentas 
BshTI A|CCGGT Fermentas 
Bsp68I TCG|CGA Fermentas 
DpnI GA|TC Fermentas 
Eco105I  TAC|GTA Fermentas 
Eco47III AGC|GCT Fermentas 
EcoRI G|AATTC Fermentas 
EcoRV GAT|ATC Fermentas 
EheI GGC|GCC Fermentas 
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FspI TGC|GCA Fermentas 
HindIII A|AGCTT Fermentas 
HpaII C|CGG Fermentas 
I-SceI TAGGGATAA|CAGGGTAAT Fermentas 
KpnI GGTAC|C Fermentas 
KspAI GTT|ACC Fermentas 
NaeI GCC|GGC Fermentas 
NcoI C|CATGG Fermentas 
NheI G|CTAGC Fermentas 
NsiI ATGCA|T Fermentas 
Pfl23II  C|GTACG Fermentas 
PmlI CAC|GTG Fermentas 
PsiI TTA|TAA NEB 
PvuII CAG|CTG Fermentas 
SacI GAGCT|C Fermentas 
SphI GCATG|C Fermentas 
StuI AGG|CCT Fermentas 
XhoI C|TCGAG Fermentas 
ZraI GAC|GTC NEB 
 
All other enzymes are listed in Table 2.3 and were also used according to the 
manufacturer’s suggestion. 
Table 2.3 
Name Company 
CIAP Fermentas 
Phusion TM High-Fidelity DNA polymerase NEB 
Proteinase K NEB 
T4 DNA ligase Fermentas 
Taq-DNA polymerase over-expressed and purified in our institute 
Pfu-DNA polymerase over-expressed and purified in our institute 
 
2.1.3 OLIGONUCLEOTIDES 
The oligonucleotides used for site-directed mutagenesis are listed in Table 2.4, with 
introduced restriction enzyme sites indicated in bold letters. (N= A, G, C or T; K= G, T; M= 
A, C)  
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Table 2.4 
Name Sequence (5’ 3’) Comment 
PL GATACTGAGGACGTCAGCAGGACGCAC introduce ZraI site in PL 
promoter of  reporter plasmid 
newsubrev_B CTGCCATTGAGCGACCTCTTTCTCCGCAC 
CCGACATAGA 
PI-SceI newsubB 
newsubrev_C CTGCCATCGAGCGCCCTCTTTCTCCGCAC 
CCGACATAGA 
PI-SceI newsubC 
I-SceI_KpnI_3_rev GATGCGTCCGGCCTCTATCAGCGGTACCA 
CCCTGTTATCCC 
pAT_I3P, pAT_I7P 
I-SceI_KpnI_8_rev GATGCGTCCGGCCTCGATAGGTACCATAT 
TACCCTGTTATC 
pAT_I8P 
I-SceI_KpnI_10_rev CCACGATGCGTCCGGCGAGAGGTACCCTA 
TATTACCCTG 
pAT_I10P 
I-SceI_KpnI_12_rev GATGCGTCCGGCCGAGGTACCAGCTATAT 
TACCCTGTTATCCC 
pAT_I12P 
pAT_IxP_P CGATCACTGGACAGCTGATCGTCACGGCG 2
nd
 PvuII site in pAT_IxP 
I-SceI_D44S CTGATCCTGGGATCCGCTTACATCCGTTC 
TCG 
I-SceI_D44S 
I-SceI_N152K GTGGTAAATGGGATTATAAGAAAAACTCT 
AC 
I-SceI_N152K 
I-SceI_D150C GTAAATGGTGTTATAAGAAGAATTCTACC 
AAC 
I-SceI_D150C 
Oligo_078 CCATTTACCGCCGGCATCCATGAACCAG I-SceI_D145A 
Oligo_079 CCTGGGAAACGCTTACATCCGTTCACGT 
GATGAAG 
I-SceI_S44N 
VDE_T225A GATTGTCTGACCGGGCAGCTTTTTCGGTTG PI-SceI_T225A 
VDE_D218A GGTTTATGGATTGGCGCCGGATTGTCTGA 
CAGGG 
PI-SceI_D218A 
VDE_ran_Q55H56 CAGAAAAGTNNKNNKAGAGCCCATAAAAG 
TGACTCAAGTCGTGAA 
PI-SceI_pool Q55H56 
VDE_ran_R90_L92_R94 CGTAGTGTCNNKCGTNNKTCTNNKACCAT 
TAAG 
PI-SceI_pool R90L92R94 
VDE_ran_S169H170 AGCTTTACGAACMNNMNNACCCAACAG PI-SceI_pool S169H170 
Oligo_185 TAAATTACTCGAGGAATGGCCGCATATAC PvuII_L12E 
Oligo_196 GTGTGGCCACTCCTCGAGCAGTTTGTTC PvuII(A)_L12E 
Oligo_194 ATTATTAGAGCTCTGGGGTCATATACAGG PvuII_P14G 
Oligo_198 GAATGTGACCCCAGAGCTCCAGCAG PvuII(A)_P14G 
Oligo_186 TGGCCGGATATCCAGGAATATCAAGACTTAG PvuII_H15D 
Oligo_197 GATCCTGGTACTCTTGGATATCTGGCCAC PvuII(A)_H15D 
ww09_048 CTTCTAATTGGAGGGTTAACAGTACTACCAG 
GACG 
PvuII_T46G 
Oligo_152 GGTGCTGCTGATCGGAGGCCTGACCGTGC 
TGCCGG 
PvuII(A)_T46G 
scPvuII_H83A_rev GATTCATGTGGTGCGCAGTTGAAAAACC PvuII_H83A 
Oligo_162 GGTTCATATGATGCGCAGTGCTAAAGCC PvuII(A)_H83A 
scPvuII_Y94F_rev GGTACTTGTCTGAATTTCGCGATAATTAAGG PvuII_Y94F 
Oligo_161 CCACGGTACCTGGCGGAATTTCGCGATG PvuII(A)_Y94F 
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Table 2.5 lists the complementary oligonucleotides containing certain target sites 
which were annealed and ligated into plasmids to create substrates for cleavage assays. 
Table 2.5 
Name Sequence (5’  3’) Comment 
I-SceI_upper CTATATTACCCTGTTATCCCTAGCGTAACT I-SceI 
cleavage site I-SceI_lower AGTTACGCTAGGGATAACAGGGTAATATAG 
wt2006 upper TCTATGTCGGGTGCGGAGAAAGAGGTAATGAAATGGCAG PI-SceI 
cleavage site wt2006 lower CTGCCATTTCATTACCTCTTTCTCCGCACCCGACATAGA 
Sce6PvuII_up GATCTTACGCTAGGGATAACAGGGTAATATAGGTCAGCTGGACGCA S6P substrate 
Sce6PvuII_low GATCTGCGTCCAGCTGACCTATATTACCCTGTTATCCCTAGCGTAA 
Oligo_093 GATCTAGGGATAACAGGGTAATGGTACTCAGCTGATTCATATTACC 
CTGTTATCCCTA 
S6P6S 
substrate 
Oligo_094 GATCTAGGGATAACAGGGTAATATGAATCAGCTGAGTACCATTACC 
CTGTTATCCCTA 
 
Oligo_217 GATCTAGGGATAACAGGGTAATGGTACTGGTACCATTCATATTACC 
CTGTTATCCCTA 
S6x6S 
substrate 
Oligo_218 GATCTAGGGATAACAGGGTAATATGAATGGTACCAGTACCATTACC 
CTGTTATCCCTA 
 
Oligo_219 GATCTAGGGATAACAGGGTAATCAGGTACTCAGCTGATTCATCGAT 
TACCCTGTTATCCCTA 
S8P8S 
substrate 
Oligo_220 GATCTAGGGATAACAGGGTAATCGATGAATCAGCTGAGTACCTGAT 
TACCCTGTTATCCCTA 
 
Oligo_226 GATCTAGGGATAACAGGGTAATGGCTCAGCTGATTCATTACCCTGTA  
TATCCCTA 
S4P4S 
substrate 
Oligo_227 GATCTAGGGATAACAGGGTAATGAATCAGCTGAGCCATTACCCTGT 
TATCCCTA 
 
 
Table 2.6 lists the complementary oligonucleotides which were annealed and ligated 
between the NheI and AgeI cleavage sites located between the genes for PvuII and I-SceI to 
create different linker variants. 
Table 2.6 
Name Sequence (5’3’) linker name  amino acid sequence 
Oligo_087 CTAGCGGTGGCTCTGGTTCTGGTT L(N)                        ASGGSGSGSG 
Oligo_088 CCGGAACCAGAACCAGAGCCACCG  
Oligo_089 CTAGCACCAAACAGCTGGTTAAGT L(+)                          ASTKQLVKSG 
Oligo_090 CCGGACTTAACCAGCTGTTTGGTG  
Oligo_091 CTAGCGGTGACTCTGGTTCTGATT L(-)                        ASGDSGSDSG 
Oligo_092 CCGGAATCAGAACCAGAGTCACCG  
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Oligonucleotides for generation of PCR fragments as cleavage, competition or binding 
substrates are listed in Table 2.7; the corresponding template is listed as well. 
Table 2.7 
Name Sequence (5’  3’) template 
plasmid 
obtained fragment 
(length) 
CorrACYC 5’ GCCGACATGTTCTAGATCACGAGGC 
AGACCTCAGCGCC 
gvpA_PL_I I-SceI_star (454 bp) 
corr_rev GGAAACACGAACCCAAGCGTC   
pATlindiff 1for CCGCCCAGTCCTGCTCGCTTC pAT_I_10 S (292 bp) 
2 Bend 3’ ATGCAAGGAGATGGCGCCCAACAGT   
pATlindiff 1for CCGCCCAGTCCTGCTCGCTTC pAT_I8P S8P (298 bp) 
2 Bend 3’ ATGCAAGGAGATGGCGCCCAACAGT   
HgiCI_1for GGTAGATGACGACCATCAGGGAC pAT_I6P6I P (224 bp) 
HgiCI_1rev CGCCGGCTTCCATTCAGG   
lin diff kurz 5’ GCTTCGCTACTTGGAGCCACTATCGA pAT_I6P6I S6P6S (400 bp) 
BBseqA783 ATCTCGACGCTCTCCCTTATGCG   
 
All other oligonucleotides used for screening (S), as second primer for generation of 
megaprimer (M) or amplification (A) of ligation inserts are listed in Table 2.8. As before, 
introduced restriction enzyme site are indicated by bold letters. 
Table 2.8 
Name Sequence (5’ 3’) Comment 
pQe_for GTATCACGAGGCCCTTTCGTCT S 
pQe_rev CATTACTGGATCTATCAACAGGAG S, M 
VDE_SnaBI_rev AGCTTTACGTACATGGGAACCCAACAG S, M 
VDE_rev  GGATTCTCAGTATTAAGATTATTGCG S, M 
VDE_SacI_rev TCTTTGAAACTTCCTTGACGAGCTCAACA M 
VDE_BsiWI TCCGCCGTTTGTCTCGTACGATTAAGG M 
VDE_R147A TTGGTAGAATCATATGCAAAGGCTTCAAA S 
scPvuII-I-SceI delprom 5’ GATAACAATTTCACACCTCGAGCCATGGGCATG 
CACCACCCAGAT 
A 
scPvuII_KpnI_NsiI_rev GCGATGCATGGTACCGTGGTGATGATGATGGTGTGATC A 
T5lac 5’ CTTCACCTCGAGAAATCATAAAAAATTTATTTG A 
T5lac 3’ GTTATGCATGCTTAATTTCTCCTCTTTAATG A 
PvuII_S81C TACAGGATTCATATGGTGGTGAGTGCAAAAACCTT S 
HgiCI rev2 CAGTTCTCCGCAAGAATTGATTGG M 
pACYC seq rev GCAAGAATTGATTGGCTCCAATTCTTGG S 
PvuIISceI 5’ GGAGAAATTAACCATGGGTCACCCAGATC A 
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PvuIISceI 3’ GCGAGCGCTTTTCAGGAAAGTTTCGGAGGAG A 
PvuIISceI short 3’ GGAAGCGCTGTTCGGCAGTTTGTACATCATC A 
Oligo_071 CGCTAGCCGTACGACCGGTATGCATAACATCAAA 
AAAAACCAGG 
A 
Oligo_072 ACCGGTCGTACGGCTAGCGTAAATCTTTGTCCCATGTTCC A 
omp 5’ GAGTTATTTTACCACTCCCTATCAG S, M 
omp 3’ CGCAGTAGCGGTAAACGGCAG S 
PvuII-KpnI CAAAGATTTACGGTACCCACCATCATCATCAC S 
I-SceI_rev GTCTGGGCGCCCCAGGTGATTACC S 
scPvuIIR129C fwd AAATGGGAATGCAAATGGTATTCAGATGG S 
Oligo_100 TGTATTCTTTCAGCAGTTTAGAGTTCGGAC S 
Oligo_162 GGTTCATATGATGCGCAGTGCTAAAGCC S 
 
2.1.4 MARKERS 
Markers used for DNA and protein electrophoresis are listed in Table 2.9. 
Table 2.9 
Name Company 
pUC 8 Mix marker Fermentas 
GeneRuler
TM
 1kB DNA Ladder Fermentas 
PageRuler
TM
 unstained Protein Ladder Fermentas 
 
2.1.5 E.COLI STRAINS 
LK111λ 
 ((rK
-
mK
+
) thi-1 thr-1 leuB6 ton A21 supE44 lacI
q
YZ ∆M15 hfr λ+)  
This strain was used in the directed evolution approach for cloning of the reporter plasmids, 
since it harbors the gene for a strongly expressed cI-repressor. 
TGE900 
F
-
 su
-
 ilv
-
 bio (λcI857∆Bam∆HI) 
The cI-repressor variant expressed by this strain is the temperature sensitive form cI857, 
which is why these cells were used for the selection assays. 
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JM109 
F’traD36 proA+B+ lacIq ∆(lacZ) M15/e14- (McrA-) ∆(lac-proAB) endA1 gyrA96(Nalr) thi-1 hsdR17 
(rK
-
mK
+
) glnV44 relA1 recA1 
For all cloning steps of the homing endonuclease expressing plasmids this strain was used. 
XL10 Gold (pLGM) 
endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 tetR 
F'[proAB lacI
qZΔM15 Tn10(TetR Amy CmR)] 
This strain was used for cloning and amplification of all fusion enzymes and PvuII variants, 
since it also contains a plasmid coding for the PvuII methyltransferase (pLGM) [85], which 
protects the DNA from autodigestion by PvuII. To maintain this plasmid, these cells were 
always grown in the presence of kanamycin. For the in vivo assays of the fusion enzymes the 
same strain, but without pLGM, was used. 
DH5α 
F
-
 endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ80dlacZΔM15 Δ(lacZYA-argF)U169, 
hsdR17(rK
-
 mK
+), λ– 
For amplification and cloning of the substrate plasmids in the fusion enzyme engineering part 
this strain was used. 
2.1.6 BUFFERS 
Water for preparing the buffers was used from MilliQ-Synthesis (Millipore) water 
purification system. 
2.1.6.1 Protein Purification Buffer 
I-SceI (Heparin column) 
Lysis/Binding buffer 50 mM Tris/HCl pH 8, 0.1 mM EDTA, 200 mM NaCl 
Washing buffer 10 mM Tris/HCl pH 8, 200 mM NaCl, 1 mM DTT 
Elution buffer 0.5-2 10 mM Tris/HCl pH 8, 0.5, 1, 1.5 or 2 M NaCl, 1 mM DTT 
Dialysis buffer 10 mM Tris/HCl pH 8, 100 mM NaCl, 1 mM DTT, 10 % (v/v) 
glycerol 
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PI-SceI (His6-tag, Ni-NTA agarose) 
Lysis buffer  10 mM HEPES/KOH pH 7, 1 M KCl, 15 mM imidazole 
Washing buffer 10 mM HEPES/KOH pH 7, 200 mM KCl, 15 mM imidazole 
Elution buffer  10 mM HEPES/KOH pH 7, 200 mM KCl, 200 mM imidazole 
Dialysis buffer  10 mM KPi pH 7.2, 200 mM KCl, 0.1 mM EDTA, 50 % (v/v) 
glycerol 
scP-L(H)-S(D44S) (His6-tag, Protino Ni-IDA column) 
Lysis/Washing buffer  50 mM NaH2PO4 pH 8, 300 mM NaCl 
Elution buffer 50 mM NaH2PO4 pH 8, 300 mM NaCl, 250 mM imidazole  
FPLC gelfiltration buffer 50 mM NaPi pH 7.5, 500 mM NaCl, 0.5 mM EDTA 
Dialysis buffer 50 mM NaPi pH 7.5, 100 mM NaCl, 0.5 mM EDTA, 60 % (v/v) 
glycerol 
All further fusion enzymes and PvuII variants (Strep-tag, Strep-Tactin® Sepharose®) 
Lysis/Washing buffer  100 mM Tris/HCl pH 8, 1 M NaCl, 1 mM EDTA 
Washing buffer 100 mM Tris/HCl pH 8, 300 mM NaCl, 1 mM EDTA 
Elution buffer 100 mM Tris/HCl pH 8, 150 mM NaCl, 1 mM EDTA, 2.5 mM 
desthiobiotin    
FPLC gelfiltration buffer 50 mM NaPi pH 7.5, 500 mM NaCl, 0.5 mM EDTA 
Dialysis buffer 50 mM NaPi pH 7.5, 100 mM NaCl, 0.5 mM EDTA, 60 % (v/v) 
glycerol 
AUC dialysis buffer 50 mM NaPi pH 7.5, 100 or 500 mM NaCl, 4.4 % (w/v) 
glycerol 
2.1.6.2 Cleavage buffer 
Commercially purchased (Fermentas) 
Buffer Tango  33 mM Tris-acetate pH 7.9, 10 mM Mg-acetate, 66 mM 
K-acetate, 0.1 mg/ml BSA 
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Buffer Green 10 mM Tris/HCl pH 7.5, 10 mM MgCl2, 50 mM NaCl, 
0.1 mg/ml BSA 
PI-SceI 
Mg
2+
 buffer 8.5 10 mM Tris/HCl pH 8.5, 100 mM KCl, 2.5 mM MgCl2, 1 mM 
DTT, 10 µg/ml BSA 
Mg
2+
 buffer 7.5 10 mM Tris/HCl pH 7.5, 100 mM KCl, 2.5 mM MgCl2, 1 mM 
DTT, 10 µg/ml BSA 
Mn
2+
 buffer 7.5 10 mM Tris/HCl pH 7.5, 100 mM KCl, 2.5 mM MnCl2, 1 mM 
DTT, 10 µg/ml BSA 
KGB 100 mM potassium glutamate, 25 mM Tris-acetate pH 7.5, 
10 mM Mg-acetate, 500 µM 2-Me, 10 µg/ml BSA 
Fusion enzymes 
KGB optimized 100 mM potassium glutamate, 25 mM Tris-acetate pH 7.5, 
0.8 mM Mg-acetate, 100 mM KCl, 0.5 mM 2-Me, 10 µg/ml 
BSA, for binding experiments Mg-acetate was left out 
2.1.7 PLASMIDS 
2.1.7.1  Selection assay reporter plasmids 
These plasmids are based on pACYC184, in which the gene coding for the toxin gvpA 
(gas vesicle protein A from Anabaena flos-aquae) together with the phage λ promoter PL was 
inserted in preliminary work. The target sites for I-SceI and PI-SceI were inserted either in the 
5’ coding region of gvpA or in the promoter region resulting in the plasmids called gvpA_I, 
gvpA_P, gvpA_PL_I and gvpA_PL_P respectively. The site-directed mutagenesis was done 
on gvpA_PL_P using the primer described in Table 2.4 to change the PI-SceI target site 
(gvpA_PL_PA, gvpA_PL_PB, gvpA_PL_PC). These plasmids mediate chloramphenicol 
resistance. 
2.1.7.2  I-SceI and PI-SceI expressing plasmids 
The plasmids coding for the homing endonucleases were also created in preliminary 
work. Both plasmids mediate ampicillin resistance; contain a pBR322 derived origin of 
replication and the gene for the lacI
q
 repressor. The expression of the enzymes is controlled 
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by the T5 lac promoter. The plasmid pHisPI-SceI codes for PI-SceI with an N-terminal 
His6-tag and pT5-I-SceI codes for I-SceI without any additional tag. These plasmids were the 
basis for creating the different variants or pools of the corresponding enzymes by site-directed 
mutagenesis (Table 2.4). 
2.1.7.3  Fusion enzyme and PvuII expressing plasmids 
The used plasmids for creating the fusion enzymes were pT5-I-SceI(D44S), 
pRIZ’R.PvuII-GSH, pscPvuII-HGC, pASK IBA63b-plus (IBA) and pPvuII(A)His, where 
PvuII(A) is a synthetic gene produced by Geneart coding for PvuII, but with a different codon 
usage. The cloning procedure is described in chapter 2.2.2.5. 
2.1.7.4 Substrate plasmids for fusion enzymes 
All substrate plasmids are based on pAT153, where the cassettes for the target sites 
(Table 2.5) were ligated into the BamHI cleavage site, resulting in the plasmids called 
pAT_S6P, pAT_S4P4S, pAT_S6P6S, pAT_S6x6S and pAT_S8P8S. The additional PvuII 
cleavage site was introduced via site-directed mutagenesis (Table 2.4). The substrate with 
only one PvuII site was pATPEB, where also the I-SceI target-site cassette was ligated in the 
PvuII site resulting in pAT_S. To insert PvuII sites next to this I-SceI site in distinct distances 
a KpnI cleavage site was inserted via site-directed mutagenesis at different distances and the 
PvuII target-site cassette was ligated into this site (pAT_S3P, pAT_S7P, pAT_S8P, 
pAT_S10P, pAT_S12P). 
2.2 METHODS 
2.2.1 MICROBIOLOGICAL METHODS 
For all microbiological approaches LB-medium (10 g/l tryptone, 5 g/l yeast extract, 
5 g/l NaCl, pH 7.5) and LB-agar plates (LB-medium with 1.5 % (w/v) agar) were used. The 
corresponding antibiotics were added after sterilization, before use. Table 2.10 lists the 
antibiotics and the used concentrations.  
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Table 2.10 
Antibiotic concentration (µg/ml) 
LB-medium             agar plate 
ampicillin 75 100 
chloramphenicol 20 30 
kanamycin 25 25 
tetracycline 10 10 
 
2.2.1.1 Preparation of electrocompetent cells 
Electrocompetent E.coli cells for normal use were prepared using the following 
protocol. A 500 ml LB-medium culture (depending on the cells supplemented with 
antibiotics) was inoculated with 10 ml of a preculture of the corresponding cells and grown at 
37 °C until OD600 0.5-0.8. The cells were cooled down on ice for 30 min and then centrifuged 
for 15 min at 4200 rpm (Beckman, J6-HC). The cell pellet was washed with cold, sterile 10 % 
(v/v) glycerol 3-times (250 ml, 150 ml, 40 ml consecutively). After the last centrifugation step the 
pellet was resuspended in 2 ml 10 % (v/v) glycerol and 80 µl aliquots were shock-frozen with 
liquid nitrogen and stored at -80 °C. 
For the selection system, TGE900 cells were made electrocompetent with the gvpA 
reporter plasmid. The procedure was the same as described above, except that the medium 
contained 60µg/ml chloramphenicol and cells were grown at room temperature (~ 23 °C). 
2.2.1.2 Electroporation 
Electrocompetent E.coli cells were thawed on ice, mixed with the plasmid DNA 
(usually 20-100 ng) and filled into an electroporation cuvette. The transformation was done in 
an electroporator (EasyjecT, EquiBio) at 1250 V, 25 mA and 25 Ω. Immediately after 
transformation, cells were resuspended in 800 µl LB-medium and incubated for 1 h at 37 °C (if 
not described differently). Afterwards usually 30-100 µl of cells were spread on an agar-plate 
containing the corresponding antibiotic and incubated overnight at 37 °C (if not described 
differently). 
2.2.1.3 Selection assay “in liquid” 
Electrocompetent TGE900 cells harboring the reporter plasmid were transformed with 
the plasmid coding for the corresponding homing endonuclease or a variant thereof. After 
incubation for 1 h at 28 °C, 3 ml LB-medium (+ Amp) were inoculated with 100 µl of the 
transformed cells, as control 100 µl of the transformation mixture were also spread on agar 
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plates (+ Amp/Cm) and both were incubated overnight at 28 °C. The next day, the OD600 of 
the liquid culture was measured and two times 25 ml LB-medium (+ Amp) were inoculated 
with a certain volume of the pre-culture according to a distinct OD600. One 25 ml culture was 
incubated at 28 °C, the other one at 42 °C with measuring the OD600 every 30 min. OD600 
values were plotted against the time and fit by non-linear regression analysis using the 
formula:       
    , where N0 is the starting OD600 and N the measured OD600 at the 
time t. Doubling time (Dt in h) was calculated with the formula:    
   
 
. 
2.2.1.4 Selection assay “on plate” 
TGE900 cells harboring the respective reporter plasmid were transformed with 50 ng 
of the homing endonuclease expressing plasmid; the transformation mix was resuspended in 
600 µl LB-medium and incubated 90 min at 28 °C. 150 µl were spread on two agar plates 
supplemented with Amp and 0.5 mM IPTG. One of the plates was incubated overnight at 
28 °C (growth control) and the other one for 1 h at 28 °C to induce the expression of the 
homing endonuclease and then incubated overnight at 42 °C. After another 12 h at 28 °C the 
colonies were counted and the percentage of survival was calculated by dividing this number 
by the number of colonies on the control plate. To perform more rounds of selection the 
colonies from the 42 °C plate were pooled and the plasmid DNA was extracted. The possibly 
still existing reporter plasmid in this DNA preparation was removed by AgeI digestion and 
again TGE900 cells with the distinct reporter plasmid were transformed with 50 ng of this 
DNA. This assay was repeated up to four-times.  
2.2.1.5 In vivo activity test of selected PI-SceI variants 
E.coli TGE900 harboring gvpA_PL_PC were transformed with the same amount of 
plasmid DNA coding for PI-SceI_T225A, PI-SceI_B1, PI-SceI_C1 or PI-SceI_C2 
respectively and spread on two agar plates supplemented with Amp and 0.5 mM IPTG. One 
plate was incubated at 28 °C as growth control and the other one was incubated for 1 h at 
28 °C and over-night at 42 °C. The next day, the survival rate was calculated as percentage of 
colonies grown on the 42 °C plate with respect to the colonies grown on the control plate. 
2.2.1.6 In vivo test for fusion enzymes 
When transforming E.coli cells with plasmids coding for restriction enzymes, they 
usually have to be co-transformed with plasmids expressing the companion methyltransferase 
to protect the E.coli genome against autodigestion. To test if the created fusion enzymes are 
specific and do not cleave unaddressed PvuII sites anymore, an in vivo test was performed. 
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For this, E.coli cells Xl10 Gold either harboring the plasmid for the PvuII methyltransferase 
or not were transformed with 50 ng of plasmid coding for the fusion enzyme or for PvuII or 
one of its variants as a control. After incubation of both transformation mixtures (with or 
without plasmid pLGM coding for M.PvuII) for 1 h at 37 °C, 30 µl were spread on agar plates 
supplemented with Amp (without pLGM) or with Amp/Kan (with pLGM). The plates were 
incubated overnight at 37 °C and analyzed the next day. 
2.2.2 MOLECULAR BIOLOGY METHODS 
2.2.2.1 DNA extraction 
Purification of plasmid DNA was done either low-scale with the Promega PureYield™ 
Plasmid Miniprep System or high-scale with the Promega PureYield™ Plasmid Midiprep 
System according to the manufacturer’s instruction. The Promega Wizard® SV Gel and PCR 
Clean-Up System was used according to the manual to purify PCR products for EMSA, site-
directed mutagenesis or to gel-purify restriction enzyme digested plasmid fragments for 
ligation. The concentration of nucleic acids was determined by measuring the absorbance at 
260 nm in a spectrophotometer NanoDrop® 1000 (Thermo Scientific). 
2.2.2.2 Electrophoresis 
Polyacrylamide gel electrophoresis 
For small DNA fragments from 100 - 1200 bp polyacrylamide gel electrophoresis was 
used with 6 % polyacrylamide in 1 x TPE (0.9 M Tris-H3PO4 pH 8.2, 2 mM EDTA). The 
samples were mixed with 5x loading buffer (250 mM EDTA pH 8, 30 % (v/v) glycerol, 
1.2 % SDS, 0.3 mg/ml bromphenol blue, 0.3 mg/ml xylencyanol) and loaded on the gel. The 
electrophoresis was performed in 1 x TPE for 1 h at 45 mA, stained with ethidium bromide 
and bands visualized using the BioDocAnalyze (Biometra) gel documentation system. 
Agarose gel electrophoresis 
Larger DNA fragments like plasmid DNA or λ-DNA were analyzed on 0.8 % agarose 
gels in 1 x TPE. The samples were also mixed with loading buffer, loaded on the gel and 
electrophoresis was performed in 1 x TPE for 1 h at 8 V/cm. DNA was stained with ethidium 
bromide and visualized with the BioDocAnalyze (Biometra) gel documentation system. 
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EMSA 
The gels for the binding experiments contained 6 % polyacrylamide in 20 mM Tris-
acetate pH 8.5. Before loading the samples supplemented with 8 % (v/v) glycerol the gel was 
pre-run for 30 min at 10 V/cm. The separation was in 20 mM Tris-acetate pH 8.5 for 2 - 3 h at 
10 V/cm. Afterwards the gel was transferred to Whatman® paper, dried, wrapped with 
polythene foil and radioactivity was counted using an IstantImager system (Packard). 
SDS-PAGE 
Proteins were analyzed using SDS-polyacrylamide gel electrophoresis. The stacking 
gel contained 6 % polyacrylamide in 130 mM Tris/HCl pH 6.8, 0.1 % SDS and the separating 
gel contained 10 - 15 % polyacrylamide (depending on the size of the protein to be detected) 
in 420 mM Tris/HCl pH 8.8, 0.1 % SDS. Samples were mixed with 2x Lämmli-loading buffer 
(160 mM Tris/HCl pH 6.8, 2 % SDS, 5 % 2-Me, 40 % (v/v) glycerol, 0.1 % bromphenol blue) 
heated up to 95 °C for 5 min and loaded on the gel, which was run in 1 x SDS buffer 
(25 mM Tris, 0.19 M glycine, 0.1 % SDS) at 35 mA for 1 h. Afterwards, the gel was washed 
three times for 5 min in hot water and stained with colloidal coomassie staining solution 
(0.1 % Coomassie ® Brilliant Blue G250, 2 % (v/v) H3P04, 5 % aluminum sulfate, 
10 % ethanol). The bands were visualized using BioDocAnalyze (Biometra) gel documentation 
system. 
2.2.2.3 Polymerase chain reaction (PCR) 
PCR was used either to amplify certain genes for cloning approaches, to introduce 
site-directed mutations into genes or to screen for the accuracy of the two before mentioned 
processes. When genetic integrity of the product was important Pfu-polymerase or even 
Phusion TM High-Fidelity DNA polymerase (NEB) was used, while for mere screening 
purposes Taq-polymerase was sufficiently accurate. Taq- and Pfu-polymerase were used in 
the following activity buffers. 
Taq 10x 100 mM Tris/HCl pH 8.8, 500 mM KCl, 1 % Triton X-100, 
15 mM MgCl2 
Pfu 10x 200 mM Tris/HCl pH 9.0, 100 mM (NH4)SO4, 100 mM KCl, 
1 % Triton X-100, 25 mM MgSO4 
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The PCR reaction profile and the reaction mixture also differed for both enzymes: 
Taq PCR profile 1. Initial step: 3 min at 95 °C 
   2. Denaturing: 30 sec at 95 °C 
   3. Primer annealing: 45 sec at 3 °C above TM of primer with lowest TM 
   4. Extension: 1 min/1000 bp at 72 °C 
   5. Final step: 5 min at 72 °C 
   Steps 2-4 repeated 29 times 
Taq reaction mix 250 µM dNTPs 
   400 nM forward primer 
   400 nM reverse primer 
   1x Taq activity buffer 
   10-50 ng template DNA or resuspended colony 
   3 U Taq-polymerase 
   ad 30 µl H2O 
 
Pfu PCR profile 1. Initial step: 5 min at 93 °C 
   2. Denaturing: 30 sec at 93 °C 
   3. Primer annealing: 45 sec at 3 °C above TM of primer with lowest TM 
   4. Extension: 1 min/500 bp at 68 °C 
   5. Final step: 5 min at 68 °C 
   Steps 2-4 repeated 29 times 
Pfu reaction mix 250 µM dNTPs 
   400 nM forward primer 
   400 nM reverse primer 
   1x Pfu activity buffer 
   10-50 ng template DNA 
   10 U Pfu-polymerase 
   ad 100 µl H2O 
The commercial enzyme Phusion TM High-Fidelity DNA polymerase (NEB) was used 
according to the manufacturer’s manual. 
2.2.2.4 Site-directed mutagenesis  
To substitute certain amino acids the site-directed mutagenesis protocol reported in 
[86] was used. Primers were planned to carry the desired mutation and an additional 
restriction enzyme site (Table 2.4). Pfu-PCR was performed by using the plasmid coding for 
the enzyme to be mutated as template and a second primer which together with the mutagenic 
one creates a fragment of 150 - 300 bp. The resulting PCR product, so called “megaprimer”, 
was purified (2.2.2.1) and used as primer on the same plasmid template in a second Pfu-PCR 
(“rolling circle” PCR): initial step 5 min 93 °C, 15 cycles of denaturing 1 min 93 °C, 
annealing 50 sec 60 °C, extension 15 min 68 °C and final step 20 min 68 °C. The obtained 
PCR product was digested with DpnI for 3 h at 37 °C to remove the template plasmid.  
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2.2.2.5 Cloning 
To transfer genes from one plasmid to another, they were amplified using primers 
covering the 5’- and 3’-ends of the desired region and carrying specific restriction enzyme 
sites. The PCR was done with Pfu as described before (2.2.2.3). The obtained PCR product 
was purified (2.2.2.1) and digested with the corresponding restriction enzymes following the 
respective company’s manual. The target vector was also digested with the same enzymes and 
gel purified (2.2.2.1). For ligation, usually 50 - 100 ng of vector were incubated with a 
3 - 5 times molar excess of insert in a total volume of 20 µl together with 2 µl 10 x T4 ligase 
buffer, 2 µl PEG 4000 (for blunt ends) and 1 µl T4 DNA ligase. The ligation mix was usually 
incubated overnight at 16 °C. 
Cloning of fusion enzyme and PvuII 
For fusing scPvuII with its C-terminal His6-tag to the N-terminus of I-SceI first the 
T5lac-promoter was cut out of the plasmid pT5-I-SceI(D44S) with XhoI and NsiI and the 
PCR fragment generated from pscPvuII_HGC with primers scPvuII-I-SceI delprom 5’ and 
scPvuII_KpnI_NsiI_rev was ligated into the cleaved plasmid. Afterwards, the T5lac-promoter 
gene sequence was inserted again by amplifying it with primer pair T5 lac 5’ and T5 lac 3’ 
from pT5-I-SceI and ligating it into the XhoI and SphI cleavage sites. The same was done for 
the fusion of PvuII to I-SceI. The resulting plasmids coded for scP-L(H)-S(D44S) and 
P-L(H)-S(D44S). These plasmids served as template for exchanging Ser44 to Asn and Asp145 to 
Ala by site-directed mutagenesis on I-SceI. The subsequent plasmids coding for 
scP-L(H)-S(D44N,D145A) and P-L(H)-S(D44N,D145A) were the basis for further experiments. For easier 
purification the whole fusion constructs were PCR-amplified with PvuIISceI 5’ and 
PvuIISceI 3’or PvuIISceI short 3’ for the full-length version or a ∆C9 version of I-SceI 
respectively and cloned into the multiple cloning site of pASK IBA63b-plus (IBA). From now 
on, S* stands for I-SceI(D44N, D145A) and Ss* stands for the ∆C9I-SceI(D44N, D145A). To remove 
the His6-tag between PvuII and I-SceI, which served as linker L(H), the whole plasmid was 
amplified with Oligo_071 and Oligo_072 which introduced the restriction sites for NheI, 
Pfl23II and BshTI. The resulting PCR fragment was cleaved with Pfl23II and religated, so 
that there are now the three restriction sites between the genes coding for PvuII and I-SceI: 
this sequence encodes L(6). To exchange the linker, the plasmids were cleaved with NheI and 
BshTI and the different linker cassettes (Table 2.6) could be ligated into the plasmid DNA. 
All site-directed mutagenesis steps to substitute certain amino acids in PvuII were done with 
the resulting plasmid. To obtain the PvuII gene alone in the same vector background, a 
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synthetic gene coding for PvuII, but with different codon usage (PvuII(A)), was cut out of the 
vector pPvuII(A)His using NcoI and Eco47III and cloned into these restriction sites of pASK 
IBA63b-plus (IBA), resulting in pASK_PvuII(A). This plasmid was then used as template for 
further site-directed mutagenesis of PvuII alone and for over-expression and purification of 
Strep-tagged PvuII and variants thereof. 
2.2.2.6 Ethanol precipitation 
To purify either DpnI-digested “rolling circle” PCR products or ligation mixtures 
before electroporation, usually ethanol precipitation was used. Therefore the solution 
(volume V) was kept on ice, 1/3 V of 3 M sodium acetate and 3 V pure ethanol were added 
and everything was incubated for 30 minutes on ice. Afterwards the sample was centrifuged 
for 30 min at 4 °C, the pellet washed once with 3 V 70 % ethanol and again centrifuged for 
15 min. After removing the supernatant the pellet was dried and then dissolved in 15 µl water. 
Electrocompetent E.coli cells were transformed with 5 µl of the solution, spread on an agar 
plate supplemented with the corresponding antibiotic and incubated overnight at 37 °C.  
2.2.2.7 Screening 
To identify successful mutagenesis or cloning events, grown colonies were picked and 
examined with the help of analytical PCR. This PCR was a Taq-PCR described above 
(2.2.2.3) using a primer pair covering the genetic region of interest. Usually the PCR product 
was afterwards digested with the marker restriction enzymes, whose site was introduced in the 
course of cloning or mutagenesis and analyzed by polyacrylamide gel electrophoresis 
(2.2.2.2). Positive clones were used to inoculate LB-medium containing the corresponding 
antibiotics, the plasmid-DNA was purified (2.2.2.1) the next day and sent for sequencing to 
confirm the correctness of the changed gene. 
2.2.2.8 Protein over-expression  
A single colony harboring the plasmid coding for the protein to express was used to 
inoculate 25 ml LB-medium (with antibiotics), which was incubated overnight at 37 °C. 5 ml 
of this preculture were used to inoculate a 500 ml culture, which was then grown at 37 °C 
until an OD600 of ~1 was reached. In case of I-SceI and PI-SceI, protein expression was 
induced by adding 0.8 mM IPTG and further growth at 37 °C for 3 - 4 h. In case of the fusion 
proteins and PvuII in pASK vector, protein expression was induced by adding 
200 µg/l anhydrotetracycline and further growth at 20 °C overnight. To control the expression 
in both cases, 500 µl samples before and after induction were taken, centrifuged, the pellet 
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was dissolved in 20 µl Lämmli-loading dye, heated up to 95 °C for 5 min and analyzed by 
SDS-PAGE (2.2.2.2). According to the measured OD600, the same amount of cells was 
loaded. After the induction time, cells were harvested by centrifugation for 20 min at 
4200 rpm (Beckman, J6-HC), the pellet was washed with 40 ml 1 x STE (10 mM Tris/HCl 
pH 8, 100 mM NaCl, 0.1 mM EDTA) and centrifuged again for further 15 min. The cell pellet 
was either frozen at -20 °C for later purification or used immediately for protein purification. 
2.2.2.9 Protein purification  
Buffers used for protein purification of the individual proteins are listed in 2.1.6.1 and 
therefore not described further in the following sections. 
I-SceI 
Since I-SceI does not carry any purification tag it was purified using a HiTrap
TM
 
Heparin HP 1ml column (GE Healthcare). The pellet was thawed on ice in 10 ml lysis/binding 
buffer, lysed by sonification (Branson sonifier; 6 x 1 min, with a 30 sec break, duty cycle 
50 %, output control 5) and centrifuged for 30 min (20,000 rpm Beckman, JA20) to remove 
cell debris. After equilibrating the column with 5 ml lysis/binding buffer, the clear lysate was 
loaded and the column was washed with 5 ml washing buffer. Protein was eluted by adding 
1ml of the elution buffer each with increasing salt concentration consecutively. Four fractions 
per salt concentration were collected and 15 µl of each fraction were analyzed on SDS-PAGE 
(2.2.2.2) for detection of I-SceI which was usually found in fraction 9 (corresponds to elution 
at 0.5 M NaCl). The protein containing fractions were dialyzed overnight at 4 °C against 
dialysis buffer. 
PI-SceI 
PI-SceI carries an N-terminal His6-tag and by this could be purified using Ni-NTA 
agarose affinity chromatography. The cell pellet was thawed in 20 ml lysis buffer on ice, 
lysed by sonification and centrifuged for 30 min (20,000 rpm) to remove cell debris. 400 µl of 
Ni-NTA agarose suspension were equilibrated with 10 ml lysis buffer for 15 min. Before 
adding the clear lysate the Ni-NTA agarose had to be centrifuged 5 min at 1000 rpm 
(Beckman, J6-HC) to remove the buffer. The lysate and Ni-NTA agarose were incubated 1 h at 
4 °C, followed by one washing step with 20 ml lysis buffer and one washing step with 20 ml 
washing buffer, each 10 min. The protein was eluted with 2 x 1 ml elution buffer. Fractions of 
each purification step were analyzed by SDS-PAGE (2.2.2.2) and protein-containing eluates were 
dialyzed overnight at 4 °C against dialysis buffer.   
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scP-L(H)-S(D44S) 
The His6-tag of this fusion enzyme is located between the two proteins, scPvuII and 
I-SceI, and for this Protino® Ni-IDA 2000 packed columns (Macherey-Nagel) were used for 
purification, since purification with these columns results in purer products and a higher yield 
than Ni-NTA agarose. The purification was performed as described in the manufacturer’s 
manual. The SDS-PAGE following purification showed that the protein was not pure and that 
the eluates contained also free I-SceI and scPvuII. To remove them, subsequent preparative 
gel filtration using a Superdex 200 10/300 GL column (Tricorn) on an ÄKTA purifier 
(Amersham Biosciences) was performed using FPLC gel filtration buffer. Fractions of 500 µl 
were collected and purity of the fractions, showing an absorbance at 280 nM in the 
chromatogram, was checked with SDS-PAGE (2.2.2.2). These fractions containing the pure 
fusion enzyme were pooled and dialyzed overnight at 4 °C against dialysis buffer. 
All other fusion enzymes and PvuII variants 
Since the genes coding for these enzymes were cloned into pASK IBA63b-plus (IBA) 
all these proteins carry a C-terminal Strep-tag, this is why they could be purified by using 
Strep-Tactin® Sepharose®. The cell pellet was thawed on ice in 20 ml lysis/washing buffer, 
lysed by sonification and centrifuged for 30 min (20,000 rpm) to remove cell debris. 2 ml 
Strep-Tactin® Sepharose® were equilibrated with 5 ml lysis/washing buffer, the clear lysate 
was applied and afterwards the column was washed once with 3 ml lysis/washing buffer and 
once with 3 ml washing buffer. The protein was eluted with 500 µl elution buffer first and 
then with 4 x 1 ml elution buffer. The purity of the eluates was controlled by SDS-PAGE 
(2.2.2.2) and fractions containing the pure enzyme were dialyzed overnight at 4 °C against 
dialysis buffer. 
To prepare the enzyme P-L(6)-Ss* for analytical ultracentrifugation, the fractions 
containing the protein were further purified by preparative gel filtration using a Superdex 200 
10/300 GL column (Tricorn) on an ÄKTA purifier (Amersham Biosciences) after elution 
from Strep-Tactin® Sepharose®. The protein-containing fractions were pooled and one half 
was dialyzed overnight at 4 °C against high-salt dialysis buffer (500 mM NaCl) and the other 
half against low-salt dialysis buffer (100 mM NaCl). 
Determination of protein concentration 
The concentration of the proteins was determined by measuring the absorption at 
280 nm in a spectrophotometer NanoDrop® 1000 (Thermo Scientific) and using the 
Material and Methods 
 
46 
Lambert-Beer-Law (          ). The extinction coefficient ε of the proteins was 
calculated based on the amino acid content [87]. Protein concentrations are given as dimer 
concentrations throughout the text. 
2.2.2.10 Analytical ultracentrifugation 
To determine the oligomeric state of P-L(6)-Ss* analytical ultracentrifugation was 
performed at the Hannover Medical School in the lab of PD Dr. Ute Curth in an analytical 
ultracentrifuge (Beckman Coulter Optima XL-A). 
2.2.2.11 Activity assays 
The following described activity assays for the individual proteins were partially 
performed in buffers described in 2.1.6.2. In some cases, the following described protocols 
are just basic descriptions which could differ in incubation time or concentration, which is 
then mentioned in the results section. 
I-SceI 
To compare the activity of the different I-SceI variants, 8 nM plasmid containing one 
I-SceI site were incubated with 1 µl of eluate 9 of each I-SceI variant in Buffer Tango at 
37 °C. Since the purification of I-SceI did not result in pure enzyme and by this the 
concentration of I-SceI could not be measured, the same volume of eluate was always used. 
After 10, 30 and 60 min consecutively 10 µl of the reaction were withdrawn; the reaction was 
stopped by adding 5 x loading buffer and the reaction products analyzed on 0.8 % agarose 
gels. 
PI-SceI 
The activity of different PI-SceI variants was compared by incubating 3 nM plasmid 
DNA containing one PI-SceI site with 5 µM of each enzyme in Mg
2+
 buffer 8.5 (2.1.6.2). 
After 10, 30 and 60 min samples were withdrawn consecutively and the reaction was stopped 
by adding 5x loading buffer and analyzed on 0.8 % agarose gels. To test the activity of the 
newly selected variants of PI-SceI, DNA cleavage assays were performed. Usually 3.7 nM of 
plasmid DNA (gvpA_PL_P, gvpA_PL_Pb or gvpA_PL_Pc) were incubated with 100 nM 
protein for 1 h at either 37 °C or 42 °C in different buffers listed in 2.1.6.2. The reactions 
were stopped by adding 5x DNA loading buffer and analyzed on 0.8 % agarose gels.  
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scP-L(H)-S(D44S) characterization and buffer determination 
The first activity assay of scP-L(H)-S(D44S) was performed with 50 nM of a 454 bp PCR 
fragment containing only an I-SceI site incubated with either 5U I-SceI (Fermentas) in 
1x Buffer Tango, 100 nM PvuII or 100 nM scP-L(H)-S(D44S) in Buffer Green for 45 min at 
37 °C. Cleavage products were separated on a 6 % polyacrylamide gel (2.2.2.2), stained with 
ethidium bromide and visualized on a BioDocAnalyze system (Biometra). The cleavage 
products of scP-L(H)-S(D44S) were gel-purified (2.2.2.1) and sent for sequencing.  
To compare the activity with scPvuII and determine the best distance between the 
I SceI and the PvuII target site a kinetic DNA cleavage assay with the plasmids pAT_S3P, 
pAT_S8P, pAT_S10P and pAT_S12P was performed. For this, 8 nM plasmid DNA were 
incubated with 800 pM of either scPvuII or scP-L(H)-S(D44S) in Buffer Green without MgCl2 
for 10 min at 37 °C. Then 10 mM MgCl2 was added and after 1, 2, 5, 10 min samples were 
withdrawn consecutively from the reaction mixture and mixed with 5x DNA loading buffer. 
The samples were analyzed on 0.8 % agarose gels. To test if the fusion enzyme would also be 
active under nearly physiological conditions, KGB (2.1.6.2) with different concentrations of 
Mg-acetate (0.2, 0.4, 0.6, 0.8 and 1 mM consecutively) was tested as reaction buffer. 8 nM 
pAT_S8P were incubated with 400 pM scPvuII or scP-L(H)-S(D44S) in KGB with 100 mM KCl 
for 10 min at 37 °C and then Mg-acetate was added, followed by further incubation for 
20 min at 37 °C. The reaction was stopped by adding 5 x DNA loading buffer and analyzed 
on 0.8 % agarose gels. 
PvuII activity in different buffers 
The activity of PvuII was tested by incubating 8 nM PvuII with 8 nM plasmid DNA 
containing one PvuII site in either recommended Buffer Green (Fermentas), in KGB with 
100 mM KCl and 10 mM magnesium acetate or KGB with 100 mM KCl and 0.8 mM 
magnesium acetate (optimized KGB (2.1.6.2)) for 3 h at 37 °C. The reaction was stopped by 
adding 5 x loading buffer and analyzed on 0.8 % agarose gels. 
Plasmid cleavage assay by fusion enzymes 
Activity assays were performed, if not described differently, by incubating equimolar 
amounts of fusion enzyme and DNA (usually 8 nM each) in optimized buffer conditions 
(described in 2.1.6.2) for a certain time at 37 °C. Reaction was stopped by adding 5 x loading 
buffer and analyzed on 0.8 % agarose gels. Kinetic experiments were done by withdrawing 
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samples from the reaction mixture after distinct time intervals and mixing them with 
5 x loading buffer to stop the reaction. 
Specificity test on plasmid DNA 
Plasmid pAT_PEB which contains only one PvuII site or plasmid pAT_S6P6S_P 
which contains the addressed tripartite site and an additional PvuII site were linearized using 
HindIII according to the manufacturer’s description and purified using Promega Wizard® SV 
Gel and PCR Clean-Up System. 8 nM of linearized plasmid were incubated either with 8 nM 
PvuII in Buffer Green (Fermentas) or with 8 nM of P-L(H)-Ss*, P-L(6)-Ss*, P-L(N)-Ss*, 
P-L(+)-Ss* or P-L(-)-Ss* in optimized KGB overnight at 37 °C. The reaction was stopped by 
adding 5 x loading buffer and analyzed on 0.8 % agarose gels. 
Product release test 
To test if the fusion enzymes P-L(6)-Ss* and P-L(+)-Ss* remain bound to the cleavage 
product after cleavage, 2 nM of an internally [α32P]dATP-labeled PCR fragment containing 
the tripartite recognition site S6P6S was incubated with 80 nM of fusion enzyme in KGB 
containing 10 mM Mg-acetate for 30 min at 37 °C. One half of the cleavage reaction was 
stopped by heating for 10 min to 80 °C and the other one not. Samples were loaded onto a 
6 % polyacrylamide Tris-Acetate (pH 8.5) gel, which was run for 2 h at 10 V/cm; to find out 
whether stable enzyme-DNA product complexes are formed. The gels were analyzed using 
the InstantImager system (Packard). 
Bacteriophage λ-DNA digestion 
For bacteriophage λ-DNA (contains 15 PvuII sites) digestion, the DNA concentration 
was chosen in a way that 8 nM of PvuII sites (corresponds to 564 pM λ-DNA) were incubated 
with 8 nM fusion enzyme or PvuII in optimized KGB (2.1.6.2) or Buffer Green respectively 
for 3 h at 37 °C. The reaction was stopped by adding 5 x loading buffer and analyzed on 
0.8 % agarose gel. 
Molecular beacon assay 
The beacon assay for determining kinetic parameters of PvuII variants was performed 
in accordance to [88]. The molecular beacon 5’ (6-Fam) CGCAGCTGGGAC(T)16GTCC 
CAGCTGCG (Dabcyl) 3’ was purchased from Biomers. For steady-state experiments 1 nM of 
the respective PvuII variant was used to cleave beacon at concentrations ranging from 
1 - 50 nM in Buffer Green. The fluorescence increase due to cleavage was measured with an 
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InfiniteF200Pro plate-reader (Tecan) for 5 min every 5 sec. Initial velocity was calculated by 
linear regression of the first 20 measurement points and then plotted against beacon 
concentration. KM and kcat were determined by fitting this graph with non-linear regression 
using the formula   
        
      
 , with v being the initial velocity, [S] the beacon concentration 
and vmax the maximal velocity, which was divided by the protein concentration to get kcat. 
Competition cleavage experiments 
To test the specificity of the fusion enzymes for the addressed site, radiolabeled 
PCR fragments using [α32P]dATP containing either the addressed site (S6P6S) or the 
unaddressed site (P) were created by Taq-PCR (2.2.2.3). These fragments, each 10 nM, were 
both incubated with 10 nM of the fusion enzymes in optimized KGB (2.1.6.2) at 37 °C and 
after defined time intervals samples were withdrawn and analyzed on 6 % polyacrylamide 
gels (2.2.2.2). Cleavage products were analyzed with the InstantImager system (Packard) and 
quantified with InstantImager software. The percentage of cleavage was then plotted against 
time. Initial velocities were calculated by linear regression analysis. 
2.2.2.12 Binding Assays 
Anisotropy 
The binding constant determination via anisotropy was done by annealing 
oligonucleotide Sce6PvuII low with oligo 5’ (Hex) TTACGCTAGGGATAACAGGGTAAT 
ATAGGTCAGCTGGACGCA 3’ to have a fluorescently labeled DNA fragment containing 
an I-SceI site and 6 bp away a PvuII site. The fluorescence anisotropy with an excitation at 
535 nm and an emission at 556 nm was measured in a FluoroMax®4 spectrofluorimeter 
(HORIBA Jobin-Yvon). The excitation and emission slits were set for 10 nm band widths and 
for every protein concentration five measurements were taken, which were in turn the mean of 
data points taken in 5 seconds. A cuvette (Quartz Ultra-Micro Cell, Hellma) was filled with 
100 µl solution containing 2 nM Hex-labeled DNA in 1x KGB (2.1.6.2) without magnesium-
acetate to prevent cleavage. After measuring the starting anisotropy 1 µl fusion enzyme, 
which was diluted in 1 x reaction buffer, was added to the final concentrations of 1.0; 2.0; 3.9; 
5.8; 9.6; 19.1; 56.4; 93.4 and 166.8 nM consecutively. The anisotropy values were plotted 
against the protein concentration and data were fitted using non-linear regression analysis 
using the formula:    
      
 
   
      
 
 
 
    , with AB: the amount of bound 
DNA, A: the protein concentration and B: the DNA concentration.  
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Electrophoretic mobility shift assay (EMSA) 
For determination of binding constants for the fusion enzymes, EMSAs with 
radioactively labeled PCR fragments were performed. The shift fragments were created via 
Taq-PCR (2.2.2.3) using [α32P] dATP. One fragment contained the addressed site (S6P6S) 
and one just an I-SceI site (I). For KD-determination 2 nM of the radiolabeled substrate were 
incubated with fusion enzyme concentrations ranging from 1 - 150 nM in optimized KGB 
(2.1.6.2) without magnesium for 30 min at room temperature. To inhibit unspecific 
interaction, poly (dI-dC) was also added to the reaction at a final concentration of 10 µg/ml. 
For the unaddressed substrate the enzyme concentration ranged from 20 - 180 nM. After 
adding 1 µl 87 % glycerol the samples were loaded onto a 6 % polyacrylamide Tris-acetate 
(pH 8.5) gel (2.2.2.2) and run for 2 h at 10 V/cm. The bands were visualized using the 
InstantImager system (Packard). The band intensities for free and bound DNA were measured 
by the InstantImager software and the percentage of bound DNA was calculated. The data 
were fitted and the KD determined using non-linear regression analysis, as described above.  
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3. RESULTS 
In order to find highly specific nucleases which could be used in gene targeting, two 
different approaches have been used. The first deals with changing the specificity of a 
naturally occurring meganuclease, namely PI-SceI, by directed evolution experiments and the 
second is a more rational approach by fusing the homing endonuclease I-SceI to the type IIP 
restriction endonuclease PvuII and thus extending its specificity.  
3.1 DIRECTED EVOLUTION OF HOMING ENDONUCLEASE PI-SCEI 
Based on already published selection systems for directed evolution of homing 
endonucleases [17-19], a two-plasmid selection assay was developed and optimized in 
preliminary work (Diploma thesis Ines Fonfara, Giessen 2008).  
 
Figure 3.1: Two-plasmid selection assay developed for selection of PI-SceI variants. (A) None 
of the variants in the PI-SceI library is able to cleave the target site on the reporter plasmid and 
the toxin can be expressed, leading to cell death. (B) A variant of the PI-SceI library can cleave 
the target site and the linearized reporter plasmid will be degraded by the RecBCD system, 
leading to survival of the E.coli cell. 
This assay relies on the presence of two plasmids which were introduced into E.coli 
cells (Figure 3.1). One plasmid is the reporter harboring a gene coding for a toxin and the 
respective target site of the homing endonuclease. The other plasmid encodes the homing 
endonuclease gene or variants thereof. The toxin expression is induced by a temperature shift 
from 28 °C to 42 °C.  If one of the encoded homing endonuclease variants is able to cleave 
the target site on the reporter plasmid, which will be degraded afterwards by the RecBCD 
system, the cells will survive incubation at 42 °C, meaning toxin expression. If none of the 
variants can cleave the target site, under inducible conditions the toxin will be expressed and 
the cells will die. 
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Figure 3.2: Flowchart describing the two-plasmid selection assays used in this work. The first 
tests were done by the selection in liquid medium (A), where the growth of the cells under 
inducible conditions (42 °C) was measured directly. The final selection assay to select for 
variants of homing endonucleases, which cleave new sequences, was performed on agar plates 
(B). 
To investigate the limitations and feasibility of this two-plasmid system, the first 
experiments were done in liquid medium (Figure 3.2A), because the survival of the cells 
could be measured in real time. For this, cells harboring the reporter plasmid containing a 
respective target site were transformed with plasmid expressing the homing endonuclease. 
The transformation mixture was used for inoculating a 28 °C overnight pre-culture, which 
was divided the next day into two flasks, where one was incubated at non-inducible 
conditions (28 °C) and the other one at inducible conditions (42 °C). The OD600, which is an 
indicator for cell growth, was measured every 30 min and doubling time was calculated (see 
2.2.1.3). Since the selection assay should be used later on to find enzyme variants with new 
specificities, an assay “in liquid” is not suitable. For this, an assay “on plate” (2.2.1.4) was 
developed (Figure 3.2B). Again, cells harboring the reporter plasmid with the desired target 
site were transformed with plasmid DNA coding for the respective homing endonuclease or a 
library of homing endonuclease variants. The transformation mixture was spread on two agar-
plates, where one was incubated overnight at non-inducible conditions (28 °C) to control the 
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growth and transformation efficiency. The other plate was incubated for a certain time at 
28 °C to give the homing endonuclease some time to cleave the reporter plasmid if possible. 
Afterwards, the plate was incubated under inducible conditions (42 °C) to induce toxin 
expression. Only the cells expressing a functional homing endonuclease should be able to 
grow and could be used for further rounds of selection or investigation of the expressed 
enzyme. 
3.1.1 TWO-PLASMID SELECTION ASSAY “IN LIQUID” 
3.1.1.1 I-SceI 
Until now, it was not possible to develop a selection system for the directed evolution 
of PI-SceI. All known assays are based on I-SceI, which is called the “gold-standard” [56] in 
terms of stimulation of homologous recombination. To determine the limitations of the 
developed selection assay, different I-SceI variants with stepwise decreased activity compared 
to the wild type were created. The substituted amino acids are depicted in Figure 3.3 [19] and 
mutagenesis was performed as described in 2.2.2.4. Variant I-SceI_D44S is the negative 
control, since the catalytically active aspartate from the first LAGLIDADG motif is mutated 
to serine which makes the enzyme inactive. The variant I-SceI_N152K was used, since it was 
reported to have ~ 80 % of the wt-activity and the double variant I-SceI_ D150C, N152K was 
constructed to decrease the activity of the enzyme even more. 
 
Figure 3.3: Co-crystal structure of I-SceI (pdb: 1r7m). The LAGLIDADG helices harboring 
the active site with Asp 44 and Asp 145 are indicated in red. The changed amino acids are 
shown in blue. 
The listed variants were created, expressed and purified (2.2.2.9) and their in vitro 
activity was tested on plasmid DNA (2.2.2.11) containing an I-SceI site (Figure 3.4A). After 
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20 min I-SceI_wt cleaved 100 % of the substrate, while I-SceI_N152K cleaved 80 %, 
I-SceI_D150C,N152K ~ 40 % and I-SceI_D44S did not cleave at all after 1 h incubation. 
Since now enzyme variants with stepwise decreased activity were available, the selection 
assay could be tested for its limitations. For this, the variants of I-SceI were used in the two-
plasmid selection assay “in liquid” (Figure 3.4B). The doubling times of the active variants 
(I-SceI_wt; I-SceI_N152K; I-SceI_D150C,N152K) were nearly the same at both 
temperatures, meaning that the cells grew normally at 28 °C as well as at 42 °C when toxin 
expression was induced. Only the inactive variant I-SceI_D44S showed a ~ 5 - fold increased 
doubling time, meaning the cells did not grow properly, which could be due to the expressed 
toxin. The doubling time under inducible conditions of I-SceI_D150C, N152K, the variant 
with the lowest in vitro activity, was 1.5 - fold lower than the activity of I-SceI_wt. An over 
50 % decreased in vitro activity does not necessarily reflect the activity in vivo under selection 
pressure.  
 
Figure 3.4 : Comparison of in vitro versus in vivo activity of I-SceI variants. The in vitro 
activity is presented as percentage of cleavage of plasmid DNA containing an I-SceI target site 
plotted against time (A). The in vivo activity is indirectly measured as doubling time at 42 °C in 
the “in liquid” selection system (B).White bars represent the doubling time of cells containing 
the reporter plasmid gvpA_PL_I and the plasmid expressing the respective I-SceI variant at 
28 °C. Shaded bars represent the doubling time at 42 °C. The respective number of experiments 
is indicated by the number inside the bars. 
3.1.1.2 PI-SceI 
It was decided to test PI-SceI as well in this selection system. To have a control 
variant, the active site aspartate from the first LAGLIDADG motif was also mutated to 
alanine (PI-SceI_D218A, Figure 3.5). Furthermore, a variant with an improved catalytic 
activity compared to the wild type was created (PI-SceI_T225A, [89]). 
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Figure 3.5: Co-crystal structure of PI-SceI (pdb:1lws) The LAGLIDADG helices harboring the 
active site Asp 218 and Asp 316 are colored red. The mutated residues are indicated in blue. 
The three variants PI-SceI_wt, PI-SceI_D218A and PI-SceI_T225A were expressed 
and purified (2.2.2.9) and the in vitro activity of PI-SceI_wt and PI-SceI_T225A was tested 
on plasmid DNA (2.2.2.11) containing one PI-SceI site (Figure 3.6A). PI-SceI_T225A 
cleaved 100 % of the substrate after 1 h incubation, while PI-SceI_wt cleaved ~ 60 % in the 
same time, which is consistent with the 3-fold increased activity of PI-SceI_T225A reported 
before [89]. PI-SceI_D218A did not show any cleavage activity in comparable assays (data 
not shown). 
 
Figure 3.6: Comparison of in vitro and in vivo activity of PI-SceI_wt and PI-SceI_T225A. 
The percentage of cleavage of plasmid DNA containing one PI-SceI site representing the in 
vitro activity is shown in (A) and the in vivo activity represented by the doubling time during the 
“in liquid” selection assay using the reporter gvpA_PL_P is shown in (B). Labeling is 
according to Figure 3.4. 
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To test the in vivo activity of both PI-SceI variants and their suitability for the 
developed selection system, the same selection assay “in liquid”, as described above, for 
I-SceI, was performed. This time cells harboring the reporter plasmid with the PI-SceI site in 
the promoter region were transformed with plasmids coding for the PI-SceI variants. The 
obtained doubling times shown in Figure 3.6B confirmed the in vitro data. At 28 °C the 
doubling times were comparable to these from I-SceI, but at inducible conditions the doubling 
time of cells expressing PI-SceI_wt was increased, whereas the doubling time of the more 
active variant PI-SceI_T225A was comparable to that of I-SceI_D150C, N152K. 
3.1.2 TWO-PLASMID SELECTION ASSAY “ON PLATE” 
3.1.2.1 Determining the parameters 
In the assay developed in preliminary work, the target site for the homing 
endonuclease was inserted in the 5’ coding region of the toxic reporter gene (gvpA_P). To see 
if there is an increased effect, this target site was also inserted in the promoter region of the 
reporter plasmid (gvpA_PL_P). Both reporter plasmids were used in a selection assay “on 
plate” to determine which has the best efficiency. Furthermore in this first assay it has been 
tested how long the incubation time of the plate at 28 °C should be, before the toxin 
expression at 42 °C is induced (Figure 3.7A). Since PI-SceI_T225A was the better variant in 
the previous test, cells harboring one of the two reporter plasmids were transformed with 
DNA coding for this enzyme variant. The transformation mixture was spread as described 
above on one control plate which was incubated overnight at 28 °C and on four other plates 
containing also 0.5 mM IPTG to induce homing endonuclease expression. These four plates 
were incubated for 1 - 4 h at 28 °C and than overnight at 42 °C. The position of the target site 
has a large effect on the survival of cells under inducible conditions: when the target site is 
located in the promoter region, the cells were able to grow on the plate incubated at 42 °C, 
while when the target site is located in the coding region of the toxin, only a small number of 
cells grew on these plates. Furthermore, the incubation time at 28 °C before inducing the 
toxin expression seems to be an important parameter. The longer this incubation, the more 
cells can grow. This may be due to the fact that expressed PI-SceI has more time in the cell to 
cleave and by this destroys the reporter plasmid. 
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Figure 3.7: Comparison of different reporter plasmids and PI-SceI variants for the selection 
assay “on plate”. (A) TGE900 cells containing one of two reporter plasmids harboring the 
PI-SceI recognition site either in the 5’ coding region of gvpA (gvpA_P, shaded bars) or in the 
promoter region (gvpA_PL_P, black bars) were transformed with plasmid coding for 
PI-SceI_T225A. The number of colonies on the control plate grown at 28 °C was set to 100 % 
growth and the percentage of colonies on the other plates was calculated accordingly. (B) Cells 
containing the reporter plasmid gvpA_PL_P were transformed with plasmid coding for the 
different PI-SceI variants PI-SceI_wt (white bars), PI-SceI_T225A (light gray bars) and 
PI-SceI_D218A (gray bars), the percentage of growth was calculated as for (A). 
To confirm that PI-SceI_T225A would be the best starting point for further selection 
experiments, all three variants of PI-SceI, namely PI-SceI_wt, the more active variant 
PI-SceI_T225A and the inactive variant PI-SceI_D218A were also tested in the selection 
assay “on plate” (Figure 3.7B). This assay was performed with the reporter plasmid 
gvpA_PL_P which showed the best results in the previous experiment. Again, the cells 
transformed with plasmid coding for PI-SceI_T225A showed a higher survival under inducing 
conditions (42 °C) compared to wild type which corresponds to the lower doubling time and 
the higher in vitro cleavage activity of this enzyme (Figure 3.6). When the plates were 
incubated for 3 h at 28 °C before inducing the toxin expression, the cells transformed with 
plasmid coding for the inactive variant PI-SceI_D218A also showed ~ 20 % surviving 
colonies, which could be due to a loss of the reporter plasmid. Summing the so far obtained 
results up, further experiments will be done with reporter plasmid containing the target site in 
the promoter region, variant PI-SceI_T225A as starting point for mutagenesis and 1 h 
incubation of the plate at 28 °C before incubating at 42 °C overnight, to start the toxin 
expression.  
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3.1.2.2 Validation of the assay 
The goal of this assay would be to select single variants of a library which are able to 
cleave a certain target site. To imitate this situation, the selection assay “on plate” was 
performed with a mixture of plasmids coding for the active PI-SceI_T225A and the inactive 
PI-SceI_D218A, while the ratio of active to inactive was one to hundred. This mixture was 
used to transform E.coli harboring gvpA_PL_P and the assay was performed as described 
above. The next day the colonies from the 42 °C plate were pooled, plasmid DNA was 
extracted (2.2.2.1) and a sample digested with EheI, which specifically cleaves the plasmid 
pHisPI-SceI_T225A only once and pHisPI-SceI_D218A twice. By this procedure, the 
plasmids having the same size could be separated on an agarose gel (Figure 3.8A, red and 
green bars). The extracted DNA was then used for another round of selection assay (see also 
Figure 3.2). Again the next day the colonies grown on the 42 °C plate were pooled, DNA 
extracted and the same procedure as described above was performed four times. The agarose 
gel in Figure 3.8A shows the EheI-digested samples of the DNA extraction after every round 
of generation, and it is obvious that the amount of pHisPI-SceI_T225A (red bar) increased in 
every generation, while the amount of pHisPI-SceI_D218A (green bar) decreased.  
 
Figure 3.8: Enrichment of pHisPI-SceI_T225A trough four generations of selection assay 
“on plate”. (A) Cells harboring the reporter plasmid gvpA_PL_P were transformed with a 
mixture of pHisPI-SceI_T225A and pHisPI-SceI_D218A in a molar ratio of 1:100. After every 
round of selection assay, the colonies grown at 42 °C were pooled, DNA extracted, a sample 
digested with EheI (cleaves pHisPI-SceI_T225A once, pHisPI-SceI_D218A twice) and analyzed 
on an agarose gel. Then the next round of selection was started by using the previously 
extracted DNA for transformation of TGE900 cells (gvpA_PL_P). pHisPI-SceI_T225A which is 
linearized by EheI is indicated by a red bar, pHisPI-SceI_D218A which is cleaved twice by 
EheI is indicated by a green bar. M: Gene Ruler 
TM
 1kb DNA ladder (B) The fractions of 
pHisPI-SceI_T225A and pHisPI-SceI_D218A in percent plotted over four generations, while 
generation 0 represents DNA used for the first transformation containing 1 % 
pHisPI-SceI_T225A and 99 % pHisPI-SceI_D218A. 
To make this effect clearer the percentage of both plasmids on the total amount of 
extracted DNA were calculated for every generation (Figure 3.8B), while generation 0 means 
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the input, i.e. 1% pHis_PI-SceI_T225A and 99 % pHisPI-SceI_D218A. It can be seen, that 
already after two generations the relation between both plasmids was inverted and the plasmid 
coding for the active form of PI-SceI was enriched after 3 generations. 
3.1.2.3 Selection of PI-SceI variants with new specificity 
Since the two-plasmid selection assay was now tested for feasibility to select for new 
PI-SceI variants, the next step would be the creation of enzyme variant libraries and creation 
of new target sites to select for. One approach to create mutant libraries of enzymes is by 
error-prone PCR [57,90], where the whole gene coding for the enzyme is mutated randomly. 
Since this would result in a large library of variants, where the catalytic center of the enzyme 
could also be affected and by this the number of inactive variants would be too high, it was 
decided to do a semi-rational approach. Only a few residues, known from the co-crystal 
structure to be involved in base pair contacts to the target site, were mutated using 
degenerated primers [91]. The main principle of this technique is, that the primer (Table 2.4) 
used to amplify the area of interest contains any possible nucleotide (NNN) at the position 
where a certain amino acid should be mutated randomly. Thus at this position all 
combinations of the 4 nucleotides are possible. This could result, in theory, in every possible 
amino acid at this position. In this approach, the triplet “NNK” was chosen in the degenerated 
primers VDE_ran_Q55H56 and VDE_ran_R90_L92_R94, where “N” stands for A, G, T or C 
and “K” for G or T and “MNN” in the primer VDE_ran_S169H170 where “M” stands for A 
or C. By using these triplets the probability of creating stop codons (TGA, TAA, TAG) is 
decreased. Three groups of 2 - 3 residues have been chosen according to published binding 
studies (summarized in [92]). These groups are called pool QH (residues Q55, H56; orange), 
pool RLR (residues R90, L92, R94; yellow) and pool SH (residues S169, H170; magenta) and 
their position in the PI-SceI enzyme and respective contacts to the DNA are indicated in 
Figure 3.9. Pool QH was generated for later approaches, where the changes in the recognition 
site were planned to be extended. All these residues were also chosen because they are 
situated in another domain than the active site residues D218 and D326, and thus the catalytic 
activity of PI-SceI is not affected. According to the marked binding positions of the 
designated amino acid residues, these base pairs of the target site were changed to create the 
new targets B and C as described in 2.2.2.4 using the primers listed in Table 2.4 respectively 
(Figure 3.9B), which were later on called gvpA_PL_PB and gvpA_PL_PC. The base pair 
changes are based on studies of [93], where they reported the lowest cleavage efficiency of 
PI-SceI_wt on these changed nucleotides. 
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Figure 3.9: Overview of amino acids used for creating pools of PI-SceI and the new target 
sites. (A) Co-crystal structure of PI-SceI with annotated amino acids to create pool QH 
(residues Q55, H56; orange), pool RLR (residues R90, L92, R94; yellow) and pool SH (S169, 
H170; magenta), respectively. (B) PI-SceI wt-target and the two new targets B and C with the 
cleavage site indicated by a red line. The known contacts formed by the amino acids to be 
mutated are indicated in the upper panel (color coding according to (A)). The base pairs 
changed in the new targets B and C are shaded gray. 
The mutagenesis was done as described in 2.2.2.4 by using pHisPI-SceI_T225A as 
template and the primers reported in Table 2.4. The created libraries were sent for sequencing 
to validate the success of the mutagenesis and to see if the nucleotides are equally distributed 
or if there was a bias. Figure 3.10 shows the summary of these results and except for some 
nucleotide positions the distribution was mostly equal. It has to be mentioned again, that for 
pool QH and pool RLR the last position of every triplet should be only guanine or thymine 
and for pool SH the first position of every triplet should be only adenine or cytosine. 
 
Figure 3.10: Summary of sequencing results for the created PI-SceI libraries. The percentage 
of every nucleotide appearing in the sequencing results of pool QH (A), pool RLR (B) and pool 
SH (C) is represented as fraction of 100 %. On the x-coordinate the nucleotides of the wild type 
sequence are indicated, with the corresponding amino acid shown below. T: thymine, 
G: guanine, C: cytosine, A: adenine  
Since pool RLR, with three residues to be mutated, has the highest variability and is 
the most distant from the active center, this library was used in the first approach to transform 
E.coli harboring the reporter plasmids gvpA_PL_PB or gvpA_PL_PC respectively. The 
selection assay “on plate” was performed, as described above, over two generations. After the 
last round two colonies were chosen from the 42 °C plate selected against gvpA_PL_PB and 
three colonies were chosen from the 42 °C plate selected against gvpA_PL_PC, DNA was 
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extracted (2.2.2.1) and sent for sequencing to see which variants appeared. Table 3.1 lists the 
variants selected against gvpA_PL_PB (PI-SceI_B1 and PI-SceI_B2) and against 
gvpA_PL_PC (PI-SceI_C1, PI-SceI_C2, PI-SceI_C3).  
Table 3.1: Overview of selected amino acids at positions 90, 92 and 94 after two rounds of selection 
against the new targets B and C respectively. The triplets coding for these amino acids are given in 
brackets. The variants were named after the corresponding target site, they were selected for. Variants 
B1, C1 and C2 were over-expressed and purified. 
name position 90 position 92 position 94 
PI-SceI_wt Arg (CGC) Leu (TTG) Arg (GGT) 
PI-SceI_B1 Gly (GGT) Gly (GGG) Arg (AGG) 
PI-SceI_B2
a
 Arg (CGG) Leu (TTG) Arg (GGT) 
PI-SceI_C1 Arg (AGG) Gly (GGG) Val (GTT) 
PI-SceI_C2 Gly (GGG) Ser (TCG) Arg (AGG) 
PI-SceI_C3
b
 Arg (AGG) Gly (GGG) Val (GTT) 
a
 same as wild type  
b
 same as c1 
For all selected variants only one or two of the three amino acids had been changed. In 
case of PI-SceI_B2 the amino acids of PI-SceI_wt had been recovered, while against the new 
target C the same variation of amino acids had been selected twice. It is also to mention that 
all amino acids were substituted by small uncharged amino acid residues, such as glycine, 
valine or serine. Overall, the observed changes in nucleotide sequence could be regarded as 
expected from the sequencing results (Figure 3.10).  
Variants PI-SceI_B1, PI-SceI_C1 and PI-SceI_C2 were over-expressed and purified as 
described for PI-SceI_wt (2.2.2.9). To see if they cleave the target sites they were selected for, 
specifically over the wild type target (Figure 3.11), their in vitro activity was tested as 
described in 2.2.2.11. The activity was always compared to PI-SceI_wt under different buffer 
conditions listed in 2.1.6.2 and using the wt target or the new target B or C as substrate. The 
first test was done under conditions optimal for PI-SceI_wt (Mg
2+
 buffer pH 8.5, 37 °C, [70]), 
but at these conditions the new variants did not cleave the new target sites more preferably, 
but the wt target with comparable efficiency as PI-SceI_wt, with PI-SceI_C1 having the 
lowest cleavage activity of 15 % after 1 h.  
Since the selection assay was mainly performed at 42 °C and it also has been reported 
that PI-SceI shows a better activity at this temperature [64] all activity tests were performed at 
42 °C as well (right panel Figure 3.11). Under these conditions (Mg
2+
 buffer pH 8.5, 42 °C) 
the new variants did not cleave their respective target sites, but only the wt-target. The only 
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difference was that PI-SceI_wt cleaved its target site to ~ 80 %, while PI-SceI_C1 did not 
cleave this site at all and the other two variants only to 30 %.  
 
Figure 3.11: Summary of in vitro activity assays of the selected variants PI-SceI_B1, 
PI-SceI_C1 and PI-SceI_C2 under different buffer and temperature conditions. The selected 
variants and PI-SceI_wt were tested on plasmid DNA containing either the wt-target or the new 
targets B or C. The tested buffers are indicated on the left side and were tested either at 37 °C 
(left panel of gel pictures) or at 42 °C (right panel of gel pictures). The percentage of linearized 
DNA is indicated below each gel picture; if there is nothing written, no cleavage occurred. 
M: Gene Ruler 
TM
 1 kb DNA Ladder, oc: open circle, li: linear, sc: super coiled plasmid DNA 
It is known that PI-SceI shows a higher activity but also a more relaxed specificity in 
presence of Mn
2+ 
instead of Mg
2+
 [73]. For this, the activity of the variants was also tested in 
Mn
2+
 buffer at 37 °C and 42 °C (second row Figure 3.11). Under these conditions the 
wt target site was cleaved by all enzymes completely after 1 h incubation. The new target B 
was completely cleaved only by the variants selected against target C. PI-SceI_wt and 
PI-SceI_B1 cleaved this substrate only to 70 - 80 %. The target C was only cleaved to 
completion by PI-SceI_C2, while the other variants cleaved only to 60 - 70 % at 37 °C. This 
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is in contrast to incubation at 42 °C, where only PI-SceI_wt and PI-SceI_C1 cleaved this 
substrate nearly completely and PI-SceI_C2 cleaved just 26 % and PI-SceI_B1 just 10 %.  
To test if the pH has an influence on the specificity of the selected enzymes, the 
activity assay was also performed in Mg
2+
 buffer pH 7.5. Still, the new variants did not cleave 
their respective target sites, but showed increased cleavage activity on wt target. Finally, the 
activity assay was performed in KGB, which was reported to be a more physiological buffer 
[94], at 37 °C and 42 °C (last row Figure 3.11). Still, even under these “quasi”-physiological 
conditions the new variants did not cleave target B or target C, although they must have been 
active in E.coli cells. 
In summary, to our surprise, the new variants cleaved the target sites they were 
selected for only in the presence of Mn
2+
 which is not physiological. Even under these 
conditions there was only a slight preference of PI-SceI_B1 for the target B at 42 °C 
detectable, while the other variants PI-SceI_C1 and PI-SceI_C2 showed no preference for the 
target C under the conditions tested. The lack of specificity is also represented by cleavage of 
the wt target by all variants under all conditions. For this reason, the in vivo specificity of 
these variants was tested as described in 2.2.1.5. The obtained survival rates are listed in 
Table 3.2.  
Table 3.2: In vivo activity of selected PI-SceI variants, represented by survival rate in a two-plasmid 
assay on plate using gvpA_PL_PC as reporter plasmid. The survival rate is the percentage of colonies 
grown on the 42 °C plate in relation to the number of colonies on the control plate. 
enzyme survival rate 
PI-SceI_T225A 0.02 % 
PI-SceI_B1 0.8 % 
PI-SceI_C1 1.0 % 
PI-SceI_C2 1.7 % 
 
All selected variants showed a 40 - 85 times higher survival rate than PI-SceI_wt, 
meaning that in the cell these variants were obviously able to cleave the new target C, which 
is in contrast to the obtained in vitro data. 
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3.2 ENGINEERING MEGANUCLEASES BY A FUSION APPROACH 
In the second approach for generating highly specific nucleases a more rational 
strategy was pursued, which is based on already published approaches, where a DNA-binding 
module is fused to a DNA cleavage module, as for example Zinc-finger nucleases [32] or 
TFO-linked restriction enzymes [54].  
In this work, I-SceI was used as a DNA-binding module and the type IIP restriction 
endonucleases scPvuII or PvuII served as DNA cleavage module. To investigate what the 
fusion enzyme would look like, a model (Figure 3.12) was built. The enzymes were arranged 
in a way that they all approach the DNA from the same direction, resulting in a distance 
between the C-terminus of PvuII or scPvuII and the N-terminus of I-SceI of 26 Å. This 
distance has to be covered by a suitable peptide linker, which is not shown in the model. 
Furthermore in this model, the corresponding target sites of the enzymes, which are colored 
red and orange, are separated by 6 bp.  
 
Figure 3.12: Model of the engineered fusion enzyme. The whole picture would correspond to 
the fusion of PvuII (blue, pdb:1pvi) and I-SceI (green, pdb: 1r7m) resulting in a dimeric 
protein. The structure framed by the dashed box would correspond to the fusion of scPvuII to 
I-SceI resulting in a monomeric enzyme. This model was built using Pymol by aligning the 
recognition sites from the crystal structures of the individual proteins on a DNA composed of 
the PvuII recognition site (orange) and two I-SceI sites (red) 6 bp up- and downstream of it. The 
C-terminus of PvuII and the N-terminus of I-SceI, separated by 2.6 nm, are indicated by red 
spheres; this distance must be covered by a peptide linker of suitable length. 
3.2.1 GENERATION OF SCPVUII-I-SCEI FUSION ENZYME 
3.2.1.1 Purification of scP-L(H)-S(D44S) 
Cloning of the genes coding for scPvuII and the inactive form of I-SceI (D44S) was 
performed as described in section 2.2.2.5. The fusion protein was over-expressed in E.coli and 
purified (2.2.2.9) via the His6-tag which served in this case as linker (L(H)) between the 
C-terminus of scPvuII and the N-terminus of I-SceI_D44S. The SDS-PAGE following 
purification in Figure 3.13A shows that the eluate was not pure and it seemed possible that 
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there was still scPvuII in the fractions, which would later affect the activity assays of 
scP-L(H)-S(D44S). For this reason, a subsequent gel filtration was performed. The chromatogram 
(Figure 3.13B) shows a single peak eluting between 13 - 16 ml, which corresponds to pure 
scP-L(H)-S(D44S) (insert Figure 3.13B). The fractions containing the pure protein were dialyzed 
for long-term storage. This protein preparation with a concentration of 10 µM was used for 
the following experiments. 
 
Figure 3.13: Purification of scP-L(H)-S(D44S). The first purification step was with affinity 
purification over Protino® Ni-IDA columns (A), while scP-L(H)-S(D44S) elutes mainly in fraction 
E1 with an expected molecular weight of 65.6 kDa and is marked with an asterisk.(B) 
Chromatogram of fraction E1 from (A) after the second purification over Superdex 200 10/300 
GL column. The absorbance at 280 nm is plotted against the elution volume. Fractions eluting 
from 13.25 - 15.75 ml (red frame) were analyzed on SDS-PAGE (insert B) and those containing 
pure scP-L(H)-S(D44S) (*) were dialyzed overnight. M: PageRuler
TM
 unstained Protein Ladder; 
P:pellet; Lb/a: lysate before and after filtration through a 0.45 µm filter; F:flowthrough; 
W1/2: wash; E1/2/3: eluates  
3.2.1.2 Activity assay of scP-L(H)-S(D44S) 
To test if scP-L(H)-S(D44S) has any unspecific cleavage activity, a PCR fragment 
containing only an I-SceI site (and no PvuII site) was used for a first activity assay (2.2.2.11). 
This test showed a specific cleavage product for scP-L(H)-S(D44S), which was comparable to the 
cleavage product of I-SceI alone (Figure 3.14A). To spot the cleavage site, the products were 
gel-purified (2.2.2.1) and sent for sequencing. The results shown in Figure 3.14B revealed 
that the DNA was cleaved at the sequence CAG|CAG, which is in fact a PvuII “star” site (i.e. 
a site differing in one bp from the canonical PvuII recognition site) 6bp downstream of the 
I-SceI site. With this experiment, the proposed model (Figure 3.12) where the target sites for 
PvuII and I-SceI are separated by 6 bp could be confirmed. Furthermore, this seems to be 
consistent because only in this arrangement all enzymes bind the DNA from the same 
direction. 
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Figure 3.14: Activity test of scP-L(H)-S(D44S) and sequencing results of the cleavage fragments. 
(A) Cleavage of PCR fragment containing only an I-SceI recognition site. Lane 1 (-): uncleaved 
DNA fragment; Lane 2: cleavage products obtained by incubation of the PCR fragment with 
I-SceI (Fermentas); Lane 3 and 4: cleavage products obtained by incubation of the PCR 
fragment with PvuII and scP-L(H)-S(D44S), respectively. (B) Sequencing results of the cleavage 
product obtained with scP-L(H)-S(D44S) from (A). The fragments were gel-purified and sequenced 
in forward (upper panel) and reverse (lower panel) direction. The I-SceI recognition sequence 
is indicated by a red bar and the cleavage site which corresponds to a PvuII “star” site by an 
orange bar.  
To determine if there was any distance preference, scP-L(H)-S(D44S) was tested for 
activity on plasmids pAT_S3P, pAT_S8P, pAT_S10P and pAT_S12P (2.2.2.11), where now 
a PvuII site (P) was in certain distance (indicated by the number in the plasmid name) to the 
I-SceI site (S). 
 
Figure 3.15: Comparison of the cleavage activities of scPvuII and scP-L(H)-S(D44S). The 
percentage of cleavage of pAT_S3P (A), pAT_S8P (B), pAT_S10P (C) and pAT_S12P (D) by 
scPvuII (●) or scP-L(H)-S(D44S) (○) is plotted against time. 
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Figure 3.15 shows that there was no significant preference for any of the substrates. pAT_S3P 
(Figure 3.15A) was cleaved more slowly by scP-L(H)-S(D44S) but for some reason it is also 
cleaved more slowly by scPvuII. Overall, one has to point out that scP-L(H)-S(D44S) cleaves all 
the substrates slightly faster than scPvuII. 
3.2.1.3 Optimizing the buffer conditions 
For future applications, like gene targeting, meganucleases should be active in a 
cellular environment. To optimize the fusion enzymes in this direction, the activity buffer 
condition used should mimic physiological conditions. The chosen starting point was KGB 
[94], reported to be a suitable buffer for a number of restriction endonucleases and closer to 
physiological conditions then most buffers recommended by companies. The optimization of 
the buffer included adding 100 mM KCl and decreasing the amount of magnesium acetate, 
since the recommended 10 mM would be too high for cellular conditions (see 2.2.2.11). To 
test the optimal concentration of Mg
2+
, plasmid pAT_S8P was cleaved either by scPvuII or 
scP-L(H)-S(D44S) in the presence of different Mg-acetate concentrations. 
 
Figure 3.16: Titration of Mg-acetate in KGB. DNA cleavage experiment of plasmid pAT_S8P 
comparing scPvuII (A) and scP-L(H)-S(D44S) (B) in  KGB [94] (100 mM potassium glutamate, 
25 mM Tris-acetate pH 7.5, 100 mM KCl, 10 µg/ml BSA, 0.5 mM 2-Me) with different 
concentrations of magnesium-acetate. M: GeneRuler
TM
 1kB DNA Ladder, sc: supercoiled, 
li: linear 
Figure 3.16 shows that at a magnesium acetate concentration of about 0.8 mM the 
highest difference in activity between scPvuII and scP-L(H)-S(D44S) was observed, which 
means that the fusion construct cleaved an addressed site better than PvuII alone did. All 
further cleavage experiments with fusion enzymes were performed in an optimized version of 
KGB (100 mM potassium glutamate, 25 mM Tris-acetate pH 7.5, 100 mM KCl, 0.8 mM 
magnesium acetate, 10 µg/ml BSA, 0.5 mM 2-Me). PvuIIwt was also tested for activity in 
different buffers (Figure 3.17) as described in 2.2.2.11, but as already reported [95] the 
activity of PvuII is highly dependent on the Mg
2+
 concentration and there was no cleavage at 
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magnesium acetate concentrations of 0.8 mM observable, but only at 10 mM in KGB and as 
expected in the recommended buffer. Therefore, all further controls with PvuII or a variant 
thereof were performed in Buffer Green. 
 
Figure 3.17: PvuII activity in different buffer conditions. PvuII was incubated with equimolar 
concentration of 8 nM plasmid DNA containing one PvuII site either (A) in recommended 
Buffer Green, (B) in KGB with 10 mM Mg-acetate or (C) in KGB with 0.8 mM Mg-acetate. 
M: GeneRuler
TM
 1kB DNA Ladder sc: supercoiled, li: linear  
3.2.2 GENERATION OF PVUII-I-SCEI FUSION ENZYMES WITH DIFFERENT 
LINKER VARIANTS 
To extend the recognition sequence of the fusion enzyme, PvuIIwt was fused to I-SceI 
as described in 2.2.2.5, since this enzyme has to dimerize and it has to recognize a tripartite 
sequence consisting of a PvuII site flanked by two I-SceI sites (see model Figure 3.12).  
3.2.2.1 Changing the purification strategy 
Furthermore, it was planned to remove the His6-tag between PvuII and I-SceI. For this, 
the whole fusion construct was cloned into pASK IBA63b-plus (IBA), containing a 
C-terminal Strep-tag for protein purification. Additionally, two different variants of I-SceI 
were cloned, one full-length and the other one a shortened variant, where the last 9 amino 
acids were removed from the C-terminus, which is according to the sequence resolved in the 
co-crystal structure [77]. The nomenclature will be S for full-length and Ss for the shortened 
variant of I-SceI. The affinity purification (example P-L(H)-Ss Figure 3.18) using this Strep-
tag resulted in cleaner purification products than the previous one, using the His6-tag (see 
Figure 3.13) and no additional purification step via gel filtration was needed. All further 
fusion enzymes carry a C-terminal Strep-tag.  
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Figure 3.18: Example of an SDS-PAGE after purification of Strep-tagged fusion enzyme. The 
estimated size of P-L(H)-Ss was 47.2 kDa and the purified enzyme is indicated by an arrow. 
M: PageRuler
TM
 unstained Protein Ladder; L: lysate; F: flowthrough; W1/2: wash; 
E1/2/3/4: eluates  
3.2.2.2 Active site mutations of I-SceI 
To optimize the fusion enzymes even further, different catalytically inactive variants 
of I-SceI inspired by [74] were produced. Site-directed mutagenesis with oligonucleotides 
listed in Table 2.4 was done according to 2.2.2.4. The selected combinations were additional 
to the already existing I-SceI_D44S, D145, the variants I-SceI_D44S, D145A and 
I-SceI_D44N, D145A. These variants were chosen because it was reported that they are more 
soluble, and moreover with the double variants two negative charges next to the DNA were 
removed and by this possibly the binding affinity of I-SceI to DNA increased. The mutations 
were introduced into P-L(H)-Ss, over-expressed and purified as described in 2.2.2.9. The 
DNA-binding behavior of these variants was tested by anisotropy measurements (2.2.2.12) in 
KGB without and with 50 or 100 mM KCl, respectively. Table 3.3 lists the determined 
KD-values for DNA-binding of P-L(H)-Ss(D44S), P-L(H)-Ss(D44S, D145A) and P-L(H)-Ss(D44N, D145A) 
under various conditions.  
Table 3.3: DNA-binding constants (KD) of PvuII-I-SceI fusion enzymes with different active site 
variants of I-SceI  
name KGB KGB + 50 mM KCl KGB + 100 mM KCl 
P-L(H)-Ss(D44S) 13 ± 2 nM 31 ± 7 nM 39 ± 17 nM 
P-L(H)-Ss(D44S, D145A) 12 ± 2 nM 16 ± 4 nM 13 ±  5 nM 
P-L(H)-Ss(D44N, D145A)   8 ± 2 nM   5 ± 1 nM   9 ±  4 nM 
 
It was shown that the KD increases for all variants with increasing salt concentration, 
but overall the variant P-L(H)-S(D44N, D145A) has the highest binding affinity for DNA. For this 
reason, the active site mutations of I-SceI D44N and D145A were used in all further fusion 
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enzymes and were abbreviated as S* and Ss* respectively. The nomenclature for the I-SceI 
variants used is summarized in Table 3.4. 
Table 3.4: Summary of I-SceI nomenclature and corresponding meaning 
abbreviation meaning 
S* full length I-SceI_D44N, D145A 
Ss* ∆C9 I-SceI_D44N, D145A 
 
3.2.2.3 Engineering of the linker 
After removing the His6-tag which served so far as linker L(H), different linker variants 
were cloned in, using a building block strategy. The oligonucleotides to create linkers L(+), 
L(N) and L(-) are listed in Table 2.6 and all linkers eventually used are listed in Table 3.5. 
These linkers were cloned into the PvuII-I-SceI∆C9 fusion enzyme, resulting in P-L(6)-Ss*, 
P-L(N)-Ss*, P-L(+)-Ss* and P-L(-)-Ss*.  
Table 3.5: Overview of linkers used in the engineered PvuII-I-SceI fusions. 
Linker name length sequence source 
L(H) 10 AA GSHHHHHHGT engineered 
L(6)   6 AA ASRTTG engineered 
L(N) 10 AA ASGGSGSGSG engineered 
L(+) 10 AA ASTKQLVKSG FokI 
L(-) 10 AA ASGDSGSDSG engineered 
 
P-L(6)-Ss* and P-L(+)-Ss* are the most specific of the fusion enzymes with different linkers 
The enzymes were over-expressed and purified as described in 2.2.2.9 and tested for 
specificity using linearized pAT_PEB (contains one PvuII site) or linearized pAT_S6P6S_P 
(contains tripartite site and additional PvuII site) as described in 2.2.2.11. Figure 3.19B shows 
that all the variants cleaved the plasmid pAT_S6P6S_P first at the addressed tripartite site 
resulting in products indicated by an arrow. Still, they also cleaved the unaddressed site which 
results in the products marked with an asterisk. This unaddressed cleavage reached a 
maximum of 11 % after overnight digestion. P-L(6)-Ss* and P-L(+)-Ss* displayed the lowest 
unaddressed cleavage activity. This was confirmed by cleavage of plasmid pAT_PEB which 
contains only a PvuII site (Figure 3.19A), where again the previously mentioned variants 
cleaved less efficiently than the others. As control both plasmids were also cleaved by PvuII, 
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which showed cleavage at all PvuII sites independent of neighboring I-SceI. To some extent 
“star activity” by PvuII was also observable. 
 
Figure 3.19: Cleavage activity of fusion enzymes with different linkers on linearized DNA 
containing either (A) a single PvuII site (pAT_PEB; orange bar) or (B) the tripartite 
recognition site consisting of a PvuII site (orange bar) flanked by two I-SceI sites (red bars) 
each 6 bp away, and an additional unaddressed PvuII site (pAT_S6P6S_P). The products of 
addressed cleavage at the tripartite recognition site are indicated by arrows and the products of 
unaddressed cleavage at PvuII sites by asterisks. The percentage of unaddressed cleavage is 
shown at the bottom. 
P-L(6)-Ss* had the highest preference for 6 bp distance between PvuII and I-SceI sites 
Since the engineered linkers differ in length and amino acid composition it was also 
tested if there is any preference for a certain distance between the PvuII site and the flanking 
I-SceI sites. Furthermore, it was tested if there has to be a PvuII site at all between the I-SceI 
sites, or if it would be enough that the two binding modules bind to their respective sites and 
that PvuII cleaves the DNA only because of its close proximity to it. For this the activity of 
the fusion enzymes with different linker variants was tested on plasmids pAT_S4P4S, 
pAT_S6P6S and pAT_S8P8S, where the distance between I-SceI and PvuII sites is 4, 6 and 
8 bp respectively (see 2.2.2.11). Additionally, plasmid pAT_S6x6S, which harbors a random 
palindromic 6 bp sequence between the two I-SceI-sites separated by 6 bp on each site, was 
used for the cleavage experiment. Figure 3.20C shows first of all that none of the fusion 
enzymes cleaved substrate pAT_S6x6S, which mean that there has to be a PvuII site between 
the two I-SceI sites for specific cleavage. 
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Figure 3.20: DNA cleavage experiments with all linker variants and the different substrates 
at equimolar concentrations (8 nM): (A) S4P4S, (B) S6P6S, (C) S6x6S and (D) S8P8S were 
incubated with PvuII, P-L(H)-Ss*, P-L(6)-Ss*, P-L(N)-Ss*, P-L(+)-Ss* and P-L(-)-Ss*, respectively, 
for 3 h at optimized conditions. M: GeneRuler
TM
 1kB DNA Ladder sc: supercoiled, li: linear  
The substrates containing a PvuII site between the two I-SceI sites were all cleaved by 
the fusion enzymes, but with different efficiencies. It is obvious that P-L(6)-Ss* cleaved 
pAT_S6P6S to a higher extent than pAT_S4P4S and pAT_S8P8S, suggesting that it is more 
specific for the 6 bp distance between the target sites. P-L(H)-Ss* and P-L(N)-Ss* cleaved 
pAT_S6P6S also to a higher extent than the other two substrates, but not as prominent as 
P-L(6)-Ss* did. Surprisingly, P-L(+)-Ss* and P-L(-)-Ss*, the two variants with the charged 
linker, showed a high preference for the substrate with the smallest distance between the 
target sites (Figure 3.20A), although their linker is longer than the one of P-L(6)-Ss*. Taken 
together all the results for the different linker variants it was decided to do further 
optimization on the variants P-L(6)-Ss* and P-L(+)-Ss*. 
3.2.2.4 What is the oligomeric state of the PvuII-I-SceI fusion enzymes? 
Since it is known that PvuII occurs as dimer in solution [96], it had to be investigated 
if the fusion of I-SceI to PvuII may have changed the oligomeric state. As example for the 
PvuII-I-SceI fusion enzymes, the oligomerization was investigated by sedimentation velocity 
runs of P-L(6)-Ss* in an analytical ultracentrifugation. The experiments and analysis were 
performed in the lab of PD Dr. Ute Curth at the Medical School Hannover. The sedimentation 
experiments were done under high-salt (500 mM NaCl) and low-salt (100 mM NaCl) 
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conditions to see if there was a salt-dependent sedimentation behavior of the enzyme. Figure 
3.21 shows that under high-salt conditions P-L(6)-Ss* sediments as a single species with a 
s20,W of 4.4 S. This value slightly increases under low-salt conditions resulting in a s20,W of 
4.6 S. The analysis of the diffusion broadening of the sedimentation boundary using the 
program SEDFIT [97] yielded a molar mass of 83 kg/mol and 80 kg/mol, respectively. The 
molar mass for P-L(6)-Ss* calculated from the amino acid composition is about 46.7 kg/mol, 
suggesting that the enzyme is most probably a dimer in solution, which seems to be salt-
independent. Analysis of the frictional ratios, which would be 1.1 to 1.2 for a hydrated, 
spherical protein [98], revealed that, with a value of 1.58 for the dimeric P-L(6)-Ss*, it differs 
from a spherical shape and probably has a more elongated form, consistent with the proposed 
model (Figure 3.12).  
 
Figure 3.21: Sedimentation profile of the analytical ultracentrifugation run of P-L(6)-Ss* at 
low (red line) and high salt (blue line) conditions. The protein sediments under low salt 
conditions with a s20,W of 4.6 S and under high salt conditions with s20,W of 4.4 S. The purity and 
stability of the used protein was determined by SDS-PAGE (inset) of 1.7 µg of protein diluted in 
the respective buffer. The theoretical molecular mass of one subunit of P-L(6)-Ss* is 46.7 kDa. 
3.2.3 OPTIMIZING THE PVUII-I-SCEI FUSION ENZYMES 
The so far created fusion enzymes showed a certain specificity for the addressed site, 
but there was still residual activity on the unaddressed sites observable. To optimize the 
specificity further it was planned to weaken the cleavage module PvuII, so that in the ideal 
case it cleaves DNA only when it is in close proximity due to binding of the I-SceI modules. 
Therefore, two different approaches, namely a more functional and a more structural one, 
have been performed. On one side, PvuII was to be weakened by decreasing its catalytic 
activity and/or its DNA-binding affinity and on the other side the PvuII dimerization interface 
was to be disturbed. Both approaches involved introducing certain amino acid changes. The 
amino acids to be changed are indicated in Figure 3.22, with the right panel showing the 
Results 
 
74 
residues used to reduce the “star activity” (T46), decrease the binding affinity (H83) and 
weaken the catalytic activity (Y94). The residues mutated to disrupt the dimerization interface 
(L12, P14, H15) are shown in the lower panel. Mutagenesis was performed as described in 
2.2.2.4 using oligonucleotides listed in Table 2.4 . 
 
Figure 3.22: Overview of amino acids changed in PvuII (pdb 1pvi). Positions T46, Y94 and 
H83 changed to reduce ”star activity”, weaken the catalytic activity and reduce the DNA-
binding are depicted in yellow. To disrupt the dimer interface residues L12, P14 and H15 
shown in red were mutated. The catalytic center composed of the residues D58, E68 and K70 is 
highlighted green. 
3.2.3.1 Weakening the DNA-binding and catalytic properties of PvuII 
The first optimization step included mutation of residue Thr46 to Gly which is known 
to be responsible for reduced “star activity” of PvuII (Zheng, NEB; personal communication). 
This variant was combined either with the H83A or with the Y94F mutation or both. 
PvuII(H83A) [99] is known to have a reduced binding ability to DNA, and PvuII(Y94F) [100] is 
reported to have a decreased affinity for binding the second metal ion and by this a reduced 
catalytic activity. These mutations were introduced into P-L(6)-Ss*, P-L(+)-Ss*, and PvuII, 
either as double mutants in the combination T46G, H83A or T46G, Y94F or as triple mutants 
T46G, H83A, Y94F. The resulting proteins were over-expressed, purified and characterized 
for cleavage activity, specificity and DNA binding. 
Variants containing the Y94F mutation were specific for the tripartite recognition site 
Proteins P(T46G, H83A)-L(6)-Ss*, P(T46G, H83A)-L(+)-Ss*, P(T46G, Y94F)-L(6)-Ss* and 
P(T46G, Y94F)-L(+)-Ss* were tested for their cleavage activity (2.2.2.11) on linearized plasmid 
pAT_S6P6S_P (tripartite recognition site and single PvuII site) or pAT_S7P_P (dipartite 
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recognition site and single PvuII site). Figure 3.23 shows that all enzymes cleaved plasmid 
pAT_S6P6S_P after 1 h incubation only at the addressed site, while plasmid pAT_S7P_P was 
cleaved at the addressed site only by the variants containing the H83A mutation. This 
indicated that the variants containing the Y94F mutation have certain specificity for the 
tripartite recognition site over just the dipartite one. Overall, none of the tested enzymes 
cleave the unaddressed PvuII site which was also on the plasmids, indicated by the cleavage 
experiment with PvuII. Since the final nuclease with extended specificity should cleave as 
specific as possible, only the variants containing the mutations T46G, Y94F were further 
characterized. 
 
Figure 3.23: Comparison of cleavage activity of P(T46G,H83A)-L(6)-Ss*, P(T46G, H83A)-L(+)-Ss*, 
P(T46G, Y94F)-L(6)-Ss* and P(T46G, Y94F)-L(+)-Ss* of linearized plasmid containing the tripartite 
(pAT_S6P6S_P) or the dipartite (pAT_S7P_P) recognition sequence. Cleavage by PvuII serves 
as control, the anticipated unaddressed cleavage product is indicated by an asterisk. Addressed 
cleavage is shown by an arrow. M: GeneRuler
TM
 1kB DNA Ladder, li: uncleaved linear plasmid 
DNA 
Characterization of P(T46G, Y94F)-L(6)-Ss* and P(T46G, Y94F)-L(+)-Ss* 
In the previous experiment no unaddressed cleavage by the fusion enzymes was 
observable, but since in this assay the incubation time was only 1 h, it was tested if longer 
incubation of equimolar amounts of enzyme to plasmid DNA leads to unspecific products. 
The cleavage reaction was incubated up to 21 h. Even after this long time, no appearance of 
unaddressed cleavage products was visible (Figure 3.24). Both enzymes cleaved only the 
addressed site after 21 h under optimized conditions. 
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Figure 3.24: Overnight kinetics of P(T46G, Y94F)-L(6)-Ss* and P(T46G, Y94F)-L(+)-Ss* on linearized 
pAT_S6P6S_P. Equimolar amounts of enzyme and DNA were incubated at 37 °C for distinct 
time intervals. The product of addressed cleavage is indicated by an arrow, the expected range 
of unaddressed product appearance is indicated by an asterisk. M: GeneRuler
TM
 1kB DNA 
Ladder, li: uncleaved linear plasmid DNA 
Since at equimolar amounts of enzyme and DNA, no unaddressed cleavage could be 
detected after 21 h incubation, it was to be tested if increasing enzyme concentrations lead to 
unspecific cleavage. For this, either linearized pAT_S6P6S_P, as used before, or pAT_PEB, 
which contains only one PvuII site, were incubated with increasing amounts of 
P(T46G, Y94F)-L(6)-Ss* or P(T46G, Y94F)-L(+)-Ss* (4 - 256 nM).  
 
Figure 3.25: Overnight cleavage of plasmid by increasing amounts of P(T46G, Y94F)-L(6)-Ss* or 
P(T46G, Y94F)-L(+)-Ss*. 8 nM linearized pAT_S6P6S_P (A) or pAT_PEB (B) were incubated with 
enzyme concentrations of 4, 8, 16, 32, 64, 128 and 256 nM consecutively. The addressed 
cleavage product in (A) is indicated by arrows, the unaddressed cleavage product by an 
asterisk. M: GeneRuler
TM
 1kB DNA Ladder sc: supercoiled, li: linear  
Plasmid pAT_S6P6S_P (Figure 3.25A), which contains the addressed site along with 
the PvuII site, was cleaved unspecifically only at an > 8 - fold molar excess of protein over 
DNA for P(T46G, Y94F)-L(+)-Ss* and at an > 16 - fold molar excess of protein over DNA for 
P(T46G, Y94F)-L(6)-Ss*. Plasmid pAT_PEB (Figure 3.25B), containing only a PvuII site, was 
cleaved by P(T46G, Y94F)-L(+)-Ss* already at equimolar concentrations and by 
P(T46G, Y94F)-L(6)-Ss* at > 8 - fold molar excess of protein over DNA. These results indicated 
that in the presence of an addressed site, this is preferred over an unaddressed site. All 
previous tests for specificity were done with plasmid DNA which was then analyzed on 
agarose gels stained with ethidium bromide. To have a more sensitive and accurate 
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quantification method, competition experiments using radiolabeled PCR-fragments were 
performed (2.2.2.11). For this, equimolar concentrations of internally [α32P]dATP-labeled 
DNA fragments containing either the addressed site S6P6S or the unaddressed single PvuII 
site were incubated with the same molar concentration of fusion enzymes containing either 
the L(6) or the L(+) linker and either PvuIIwt or PvuII(T46G, Y94F) as cleavage modules. Cleavage 
was analyzed after certain time points for up to 3 h. 
 
Figure 3.26: Competition cleavage experiments with fusion enzyme variants of internally 
[α32P]dATP-labeled PCR-fragments containing the tripartite recognition site S6P6S (a) or a 
single PvuII site (u) at equimolar concentrations of both substrates. The two substrates were 
incubated with (A) P-L(6)-Ss*, (B) P(T46G, Y94F)-L(6)-Ss*, (C) P-L(+)-Ss* and (D) 
P(T46G, Y94F)-L(+)-Ss* for up to 3 h at 37 °C. The cleavage product obtained by cleavage at the 
addressed site is indicated by an arrow, the position of the expected cleavage product obtained 
after unaddressed cleavage by an asterisk. (E) The autoradiograms (A-D) were quantified and 
the percentage of cleavage plotted against time. Filled symbols show addressed, open ones 
unaddressed cleavage. 
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Fusion enzymes P-L(6)-Ss* and P-L(+)-Ss* (Figure 3.26A and C) containing PvuIIwt as 
cleavage module cleaved the addressed site highly preferentially, leading to a specificity 
factor of 338 and 72, respectively (see also Table 3.8). In contrast, the variants 
P(T46G, Y94F)-L(6)-Ss* and P(T46G, Y94F)-L(+)-Ss* (Figure 3.26B and D) showed only 11 and 13 % 
addressed cleavage product after this time and ~ 2 % unaddressed cleavage (Figure 3.26E), 
which results in a specificity factor of 18 and 11 (Table 3.8). With this, overall reduced 
activity of around 18-fold, the variants containing PvuII(T46G, Y94F) as cleavage module do not 
show an obvious preference for the addressed site. It was remarkable that even fusion 
enzymes containing PvuIIwt as cleavage module reached some kind of a plateau after certain 
time, but this was not at full cleavage. To investigate the reason for this, radiolabeled DNA-
fragments containing the tripartite recognition site (S6P6S) were cleaved by P-L(6)-Ss* and 
P-L(+)-Ss* as described in 2.2.2.11. One cleavage reaction was stopped by heating the sample 
for 10 min at 80 °C and the other one not. If the cleavage reaction was not heated up, the 
protein sticked to the cleavage products, resulting in an enzyme-product complex, indicated 
by a shift in Figure 3.27. After heating, the complex was destroyed and free cleavage product 
was observable. This might be indicating that the fusion enzymes do not have a turn over like 
classical enzymes or only a really slow one. 
 
Figure 3.27: Product release experiment of 80 nM P-L(6)-Ss* and P-L(+)-Ss* with 2 nM 
internally [α32P]dATP-labeled PCR fragment containing the tripartite recognition site (S6P6S) 
incubated 30 min at 37 °C. One reaction mixture per protein was heated to 80 °C for 10 min, 
the other one not. The free DNA, without addition of enzyme, the bound DNA and the cleavage 
products are indicated on the right side. 
Since I-SceI is the part of the fusion enzymes responsible for DNA-binding, and it was 
shown that these enzymes bind even their product, it was to be investigated whether the 
binding of the fusion enzymes is corresponding to the reported KD for I-SceI of 9.7 nM [19]. 
For this purpose, internally radiolabeled PCR-fragments, containing either the site S6P6S or 
just an I-SceI site, were used for gel shift experiments (2.2.2.12) under non-cleavage 
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conditions (Table 3.6). Overall, the binding constants on the addressed substrate for the fusion 
enzymes P-L(6)-Ss*, P(T46G, Y94F)-L(6)-Ss*, P-L(+)-Ss* and P(T46G, Y94F)-L(+)-Ss* were around 
2 - 3 times higher than for I-SceI. A single I-SceI site was bound at least 12 times less 
effectively by the fusion enzymes. Obviously the variant of PvuII fused to I-SceI has no 
dramatic effect on the binding behavior of the fusion enzyme, but on the contrary the fusion 
of PvuII might have a disruptive effect on binding of I-SceI to DNA. 
Table 3.6: Summary of determined binding constants for P-L(6)-Ss*, P(T46G, Y94F)-L(6)-Ss*, P-L(+)-Ss* 
and P(T46G, Y94F)-L(+)-Ss* on DNA substrates containing the tripartite site (S6P6S) or a single I-SceI site 
(S) 
enzyme substrate KD [nM] 
P-L(6)-Ss* S6P6S 31 ± 3 
 S 144 ± 20 
P(T46G,Y94F)-L(6)-Ss* S6P6S 31 ± 2 
 S 119 ± 16 
P-L(+)-Ss* S6P6S 18 ± 1 
 S 212 ± 29 
P(T46G,Y94F)-L(+)-Ss* S6P6S 31 ± 3 
 S > 250 
 
Comparing the cleavage activity of PvuIIwt, PvuII(T46G, Y94F) and PvuII(T46G, H83A, Y94F) 
The competition cleavage experiment shown in Figure 3.26 revealed that the fusion 
enzyme variants containing PvuII(T46G, Y94F) showed a low catalytic activity compared to the 
fusion enzymes containing PvuIIwt as cleavage module. To characterize this further, the single 
cleavage modules PvuIIwt, PvuII(T46G, Y94F) and PvuII(T46G, H83A, Y94F) were tested in a plasmid 
cleavage assay. Figure 3.28 shows that introducing the substitutions T46G and Y94F 
decreases the catalytic activity of PvuII about 100-fold and the triple variant with substitutions 
T46G, H83A, Y94F has an even 200-fold decreased activity compared to PvuIIwt. 
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Figure 3.28: Comparison of cleavage percentage of plasmid DNA over time of PvuIIwt (●), 
PvuII (T46G, Y94F) (▲) and PvuII(T46G, H83A, Y94F) (■). 8 nM of plasmid DNA containing one PvuII 
site and 400 pM enzyme were incubated in Buffer Green at 37 °C. After certain time intervals 
samples were withdrawn, reaction was stopped and analyzed on 0.8 % agarose gels.  
In vivo test of fusion enzymes 
Since the engineered meganucleases were to be used for gene targeting experiments in 
cells, the off-site target cleavage was measured by an in vivo test in E.coli as described in 
section 2.2.1.6. Therefore, E.coli cells either expressing the PvuII methyltransferase or not 
were transformed with plasmids coding for P-L(6)-Ss*, P-L(+)-Ss* (Figure 3.29A), 
P(T46G, Y94F)-L(6)-Ss*, P(T46G, Y94F)-L(+)-Ss* (Figure 3.29B), P(T46G, H83A, Y94F)-L(6)-Ss* and 
P(T46G, H83A, Y94F)-L(+)-Ss* (Figure 3.29C). As control the same assay was also performed with 
plasmids coding for PvuIIwt (Figure 3.29A), PvuII(T46G,Y94F) (Figure 3.29B) and 
PvuII(T46G, H83A,Y94F) (Figure 3.29C).  
The control plates with cells expressing the PvuII methyltransferase showed for all 
transformed plasmids independent of the expressed protein, full colony growth (Figure 3.29, 
left panel). In absence of methyltransferase, cells transformed with plasmids coding for 
PvuIIwt and PvuII(T46G, Y94F) showed no surviving colonies, indicating that these variants 
cleaved the genomic PvuII site. The cells transformed with plasmids coding for the fusion 
enzymes showed, independent of the linker variant, surviving colonies in absence of 
methyltransferase. The amount of surviving cells depended on the variant of PvuII used as 
cleavage module, with cells expressing the fusion enzyme containing PvuII(T46G, H83A, Y94F) 
showing the most survivors. Unfortunately, cells expressing this variant of PvuII alone also 
showed growth in the absence of methyltransferase, indicating that this variant was not able to 
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cleave the genomic PvuII site. Obviously the triple mutant of PvuII has a too low cleavage 
activity, as was already shown in Figure 3.28. 
 
Figure 3.29: Overview of in vivo tests with either PvuII alone or with fusion enzymes 
containing PvuIIwt (A), PvuII(T46G, Y94F) (B) or PvuII(T46G, H83A, Y94F) (C). Control plates 
representing the amount of grown colonies in presence of M.PvuII (left panel) show exemplarily 
the results from transformation of plasmids expressing PvuII alone or one of its variants. 
 
3.2.3.2 Disrupting the dimer interface of PvuII 
In section 3.2.2.4 it was demonstrated that the fusion enzymes occur as dimers in 
solution. The next approach was trying to destabilize the dimerization interface of PvuII, so 
that dimerization, and by this activity, is dependent on binding of both I-SceI modules to their 
respective target site in a defined manner. Since the activity of PvuII should not be affected, 
the residues to be chosen had to lie as far as possible away from the active center, but should 
be still involved in forming the PvuII dimer. As depicted in Figure 3.22 (lower panel), 
residues from the first α-helix were used. In the crystal structure of the PvuII dimer, these 
symmetry related helices interact with each other and are involved in stabilizing the dimer 
formation. Residue His15 was chosen, since this residue lies in both subunits next to each 
other and by mutating it to Asp, a negative patch will be introduced so these residues could 
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repel each other and affect the dimerization interface. The same strategy was followed by 
mutating Leu12 to Glu. The substitution of Pro14 in the middle of the helix for Gly was 
suggested by X. Cheng (personal communication). This was supposed to change the bending 
behavior of the helix and by this reduce the interface contacts. All these mutations were 
introduced individually in PvuII or in P-L(6)-Ss*, which showed the highest specificity for the 
substrate, in which the I-SceI and PvuII sites are separated by 6 bp (Figure 3.20) and which 
showed over-all the lowest unspecific cleavage (Figure 3.25). The resulting enzymes were 
over-expressed and purified. 
Characterization of PvuII(L12E), PvuII(P14G), PvuII(H15D) 
The influence of the introduced substitutions was first tested in PvuII, to exclude that 
they have such a negative effect on the catalytic activity of PvuII as the mutations reported 
above (T46G, H83A, and Y94F). For this, steady state beacon cleavage assays were 
performed as described in 2.2.2.11. As shown in Table 3.7, the kinetic parameters for the 
newly created variants are over-all lower than those reported for PvuII [85], namely 7 - fold 
for PvuII(L12E),  1.5 - fold for PvuII(P14G) and 4 - fold for PvuII(H15D).  
Table 3.7: Kinetic parameter represented by kcat/KM values for PvuII variants determined by steady 
state beacon cleavage assay.  
 
Enzyme kcat/KM [min
-1
 M
-1
] 
PvuIIwt  3.5 x 10
9
 * 
PvuII(L12E) 4.8 x 10
8
 
PvuII(P14G) 2.4 x 10
9
 
PvuII(H15D) 9.0 x 10
8
 
* taken from [85] 
Since the activity was decreased by these substitutions only to a maximum factor of 7, 
these results were promising and so all three fusion enzymes P(L12E)-L(6)-Ss*, P(P14G)-L(6)-Ss* 
and P(H15D)-L(6)-Ss* were further characterized. 
P(L12E)-L(6)-Ss*, P(P14G)-L(6)-Ss* and P(H15D)-L(6)-Ss* have comparable activity as P-L(6)-Ss* 
The results for the PvuII alone variants with the substitutions L12E, P14G or H15D 
showed that their activity is comparable to that of PvuIIwt. Therefore, it was tested if this 
would be influenced by the fusion of I-SceI to them. The first assay performed with the 
variants P(L12E)-L(6)-Ss*, P(P14G)-L(6)-Ss* and P(H15D)-L(6)-Ss* was a DNA cleavage experiment 
(2.2.2.11) with linearized plasmid DNA containing either just the PvuII site (pAT_PEB) or 
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the tripartite site and an additional single PvuII site (pAT_S6P6S_P). Figure 3.30A shows that 
none of the fusion enzymes cleaved the plasmid containing only a PvuII site, whereas 
pAT_S6P6S_P was cleaved by them only at the addressed site (Figure 3.30B). 
 
Figure 3.30: DNA cleavage experiment of linearized plasmid pAT_PEB (A) and 
pAT_S6P6S_P (B). Equimolar amounts of DNA and enzymes PvuII, P-L(6)-Ss*, P(L12E)-L(6)-Ss*, 
P(P14G)-L(6)-Ss* or P(H15D)-L(6)-Ss* were incubated for 3 h under optimal conditions. The expected 
unaddressed cleavage product is indicated by an asterisk, the addressed cleavage product by an 
arrow. M: GeneRuler
TM
 1kB DNA Ladder, li: uncut linearized plasmid DNA 
P(L12E)-L(6)-Ss*, P(P14G)-L(6)-Ss* and P(H15D)-L(6)-Ss* are highly specific for the addressed site 
To investigate the specificity for the addressed site of the variants P(L12E)-L(6)-Ss*, 
P(P14G)-L(6)-Ss* and P(H15D)-L(6)-Ss* further and with a more sensitive method, competition 
cleavage experiments over time with internally [α32P]dATP-labeled PCR fragments were 
performed (2.2.2.11). Figure 3.31 shows that the previously obtained results could be 
confirmed. The specific activity of the variants with amino acid substitutions in the dimer 
interface, more precisely P(L12E)-L(6)-Ss*, P(P14G)-L(6)-Ss* and P(H15D)-L(6)-Ss*, is ~
 
2 - fold 
lower than that for P-L(6)-Ss* (Table 3.8).   
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Figure 3.31: Competition cleavage experiments with fusion enzymes P(L12E)-L(6)-Ss* (A), 
P(P14G)-L(6)-Ss* (B) and P(H15D)-L(6)-Ss* (C) and internally [α
32
P]dATP-labeled DNA fragments 
containing the addressed tripartite recognition site (S6P6S) or the unaddressed PvuII site (P). 
The autoradiograms are shown as inserts; the result of the quantification is shown as a reaction 
progress curve (percent cleavage vs. time). The products obtained by addressed cleavage (●) 
are indicated by an arrow, the products expected by unaddressed cleavage (○) are indicated by 
an asterisk. 
In contrast, the unaddressed cleavage could not be detected for any of them even after 3 h 
incubation, leading to a degree of specificity of over 1000 for all the variants (Table 3.8), 
compared to the variant containing PvuIIwt as cleavage module, which showed a specificity of 
~ 300. Again, after certain time the enzymes reached a kind of plateau in activity, which could 
be explained as before with the enzymes sticking on the cleavage products and by this not 
having a turnover. 
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Table 3.8: Summary of activities and specificities derived from competition cleavage experiments
§
 for 
all tested fusion enzyme variants 
 
 
 
 
 
 
 
 
 
 
a
 below detection limit 
§
 carried out in triplicate 
 
Determination of the binding constant 
As for all the other variants described before, the binding constant for the enzymes 
P(L12E)-L(6)-Ss*, P(P14G)-L(6)-Ss* and P(H15D)-L(6)-Ss* was determined by EMSA (2.2.2.12), to 
investigate if the introduced substitutions have an influence on the specific binding behavior 
of the fusion enzyme. Surprisingly, the determined binding constants, now on substrate 
S6P6S (Table 3.9) were similar to the reported KD of I-SceI. For P(L12E)-L(6)-Ss* and 
P(P14G)-L(6)-Ss* the KD was about 9 nM and for P(H15D)-L(6)-Ss* with 2 nM even better than for 
I-SceI. It was not possible to determine any binding parameters for these enzymes on 
substrate containing only an I-SceI site, since the gel shift experiments always resulted in 
undefined bands, which could be a sign for unspecific interaction of the enzyme with this site. 
Table 3.9: Summary of the determined binding constants for P(L12E)-L(6)-Ss*, P(P14G)-L(6)-Ss* and 
P(H15D)-L(6)-Ss* on DNA substrate containing the tripartite site (S6P6S).  
enzyme substrate KD [nM] 
P(L12E)-L(6)-Ss* S6P6S 9 ± 1  
P(P14G)-L(6)-Ss* S6P6S 9 ± 1  
P(H15D)-L(6)-Ss* S6P6S 2.3 ± 0.4  
 
  
enzyme activity [nM min
-1
] specificity  
 addressed unaddressed [addressed/ 
unaddressed] 
P-L(6)-Ss* 0.88 ± 0.07 0.0025 ± 0.0004 338 
P-L(+)-Ss* 1.00 ± 0.08 0.014 ± 0.004 72 
P(T46G, Y94F)-L(6)-Ss* 0.018 ± 0.005 0.0010 ± 0.0004 18 
P(T46G, Y94F)-L(+)Ss* 0.025 ± 0.009 0.0023 ± 0.0004  11 
P(L12E)-L(6)-Ss* 0.39 ± 0.05 < 0.0001
a
 > 1000 
P(P14G)-L(6)-Ss* 0.47 ± 0.02 < 0.0001
a
 > 1000 
P(H15D)-L(6)-Ss* 0.44 ± 0.06 < 0.0001
a
 > 1000 
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P(P14G)-L(6)-Ss* has a high preference for the target site S6P6S 
As already reported, the variant P-L(6)-Ss* shows preferred cleavage for the substrate 
where I-SceI and PvuII sites are separated by 6 bp (Figure 3.20). To see if the variants with 
substitutions in the dimer interface, which are based on this enzyme, show the same or even a 
higher substrate preference, plasmid DNA containing either the target S4P4S, S6P6S or 
S8P8S was cleaved by these enzymes (2.2.2.11). The DNA cleavage experiments were 
performed three times and the mean percentage of cleaved DNA is plotted for each enzyme-
substrate combination in Figure 3.32. 
 
Figure 3.32: Evaluation of DNA cleavage assays with three different plasmid substrates 
containing the sites S4P4S (light gray), S6P6S (gray) and S8P8S (dark gray). The variants 
P(L12E)-L(6)-Ss*, P(P14G)-L(6)-Ss* and P(H15D)-L(6)-Ss* were tested for cleavage of these substrates 
in equimolar concentration of DNA:protein for 3 h at 37 °C under optimized conditions. The 
amount of linear DNA was estimated by densitometry of the ethidium bromide stained agarose 
gels and the mean and standard deviation were calculated and plotted (n=3). 
All tested enzymes, P(L12E)-L(6)-Ss*, P(P14G)-L(6)-Ss* and P(H15D)-L(6)-Ss*, showed 
preferential cleavage of target site S6P6S, but to different extents. While P(L12E)-L(6)-Ss* has a 
~ 2 - fold preference for S6P6S over S4P4S and S8P8S, and P(H15D)-L(6)-Ss* a 1.5 - and 
2 - fold preference over S4P4S and S8P8S respectively, the variant P(P14G)-L(6)-Ss* shows 
with 8 – 10 - fold the highest preference for S6P6S over the other substrates. 
3.2.4 OFF-SITE TARGET CLEAVAGE TEST 
Off-site target cleavage is a common problem for all engineered nucleases with 
extended specificity and had to be tested for the here created variants as well. The previously 
mentioned in vivo test is one method to test this and worked good for the variants P-L(6)-Ss*, 
Results 
 
87 
P(T46G, Y94F)-L(6)-Ss*, P-L(+)-Ss* and P(T46G, Y94F)-L(+)-Ss* (Figure 3.29), but not for the variants 
with substitutions in the dimer interface (data not shown). Since there is no obvious 
explanation for this, the potential of these variants for off-site target cleavage was tested by 
incubating the enzymes with bacteriophage λ DNA (2.2.2.11), which contains 15 PvuII sites. 
The concentrations were chosen in a way that the ratio between PvuII sites to enzyme was 1:1 
(Figure 3.33).  
 
Figure 3.33: DNA cleavage experiment of bacteriophage λ-DNA with all created fusion 
enzymes and all PvuII variants. DNA and enzyme concentration were chosen such that the 
molar ratio between enzyme and PvuII sites was 1:1. 
The first variants (P-L(H)-Ss*, P-L(6)-Ss*, P-L(+)-Ss*, P-L(N)-Ss* and P-L(-)-Ss*), 
having PvuIIwt as cleavage module, showed cleavage of λ-DNA, even though not as complete 
as PvuII alone. As expected, the catalytically weakened variants P(T46G, Y94F)-L(6)-Ss* and 
P(T46G, Y94F)-L(+)-Ss*, having PvuII(T46G, Y94F) as cleavage module, showed no cleavage of 
λ-DNA, but since PvuII(T46G, Y94F) alone showed also just reduced cleavage activity compared 
to PvuIIwt, the specific effect is not so prominent (comparable to Figure 3.26). Variants 
P(L12E)-L(6)-Ss* and P(P14G)-L(6)-Ss* showed no cleavage of λ-DNA although PvuII(L12E) and 
PvuII(P14G) alone cleaved the DNA as complete as PvuIIwt. This result is also consistent with 
the finding in Figure 3.31, where these fusion enzymes did not cleave unaddressed substrate 
at all. Surprisingly, P(H15D)-L(6)-Ss* which did not show unaddressed cleavage in the before 
mentioned experiment, seemed to cleave λ-DNA at least once, resulting in two faint cleavage 
product bands (Figure 3.33). 
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4. DISCUSSION 
Homing endonucleases with their large recognition sequences (14 - 40 bp) and their 
high specificity for DNA binding and cleavage are suitable tools for gene targeting and 
genome engineering approaches. In this work, two different strategies were pursued to create 
enzymes utilizable for exactly these applications. The first method used was directed 
evolution to change the specificity of a well-studied homing endonuclease, namely PI-SceI. 
This enzyme, consisting of two domains [101], a DNA binding domain (I) and a DNA 
cleavage domain (II), was thought to be a good candidate for this study since the DNA-
binding specificity can be changed without necessarily affecting the catalytic center of the 
enzyme. The second approach aimed in the same direction, by rational engineering of a 
nuclease with an extended specificity composed of a DNA-binding and a DNA-cleavage 
module. As already mentioned above, homing endonucleases have advantageous features 
making them good DNA-binders. For this purpose, as DNA-binding module in the 
engineering approach a catalytically inactive but DNA binding competent variant of the 
homing endonuclease I-SceI was fused to the restriction enzyme PvuII. Since restriction 
enzymes are well studied enzymes and used for several molecular biology methods to cleave 
DNA, PvuII was considered to be a suitable choice as cleavage module. Therefore, I-SceI and 
PvuII were fused with an exchangeable linker and optimized in direction of application as 
nuclease with extended specificity for gene targeting approaches. 
4.1 DIRECTED EVOLUTION OF PI-SCEI 
In 1997 Seligman et al. [102] described the first in vivo assay linking DNA-cleavage 
activity of an enzyme to the survival of E.coli cells. Since this time, a few groups tried to use 
comparable assays to find enzymes, i.e. homing endonucleases, with new cleavage 
specificities. All these approaches are described as directed evolution, meaning selection of 
suitable enzyme variants out of a library of mutant enzymes. These assays were performed as 
phage-display [20], as screening assays in yeast [21] or mammalian cells [103] or as selection 
assays in E.coli cells [17-19]. The selection assays in E.coli especially are based on two-
plasmid systems, where one plasmid is the reporter carrying the target site of choice and 
expressing a toxin and the second plasmid encoding the homing endonuclease library. The 
assay developed in this work relies on the same principle. In the past, several efforts have 
been made to find a suitable selection assay for the directed evolution of PI-SceI. The 
problem was that this enzyme cleaves DNA relatively slowly and the toxin-expression was 
not repressed tightly enough, leading to background expression of toxic reporter before 
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cleavage of the respective target site on the reporter plasmid by the homing endonuclease. 
This caused selection pressure on the cells, which in turn could cause mutations in the gene 
coding for the toxin, producing a too high number of false positive cells surviving, even 
though PI-SceI did not cleave. To circumvent these problems, the selection assay was 
optimized in previous work (Diploma thesis Ines Fonfara, Giessen 2008). The optimization 
consisted of using the tightly regulated PL-promoter [61] for the reporter gene and gvpA as 
toxic reporter, which is a structural rather than a functional toxin. Mutations caused by 
selection pressure would perhaps not have such drastic effects, which mean that there are no 
functional residues in the protein which could be affected. This protein only forms gas 
vesicles, which are likely to also be formed, if there are some residues mutated. Further 
optimization on the assays used before, were inserting the target site in the coding region of 
the reporter gene and using low-copy number plasmids for the reporter and high-copy number 
plasmids for the expression of the homing endonuclease. By this, the efficiency of the assay 
should be increased. 
In this work, the previously developed selection assay, as described in Figure 3.2A, 
was tested for its limitations in terms of activity of the homing endonuclease used. As 
indicator for a working system, the doubling time of cells containing the reporter plasmid, 
carrying the respective target site, and transformed with plasmid expressing the corresponding 
homing endonuclease was calculated. At 28 °C, the cells grew normally independent of the 
expressed enzyme, since toxin-expression is not induced under these conditions. In contrast, 
at 42 °C, when toxin expression is induced, only those cells will grow where an active homing 
endonuclease is expressed and able to recognize and cleave the target site on the reporter 
plasmid. The assay was applied in liquid culture, since the success of the selection can be 
measured in real time, while for the selection of clones this would not be appropriate. To 
select a single active and specifically cleaving enzyme variant out of a library of variants, it 
has to be feasible to select single colonies. This was achieved by the selection assay “on 
plate” (Figure 3.2B). To evaluate the limitations of the first assay “in liquid”, different 
variants of I-SceI (overview in Figure 3.3), the so-called “gold-standard” [56] in terms of 
inducing homologous recombination, were created. These enzymes showed in vitro step-wise 
decreased activity compared to the wild type enzyme (see Figure 3.4A) and gave an idea of 
how active an enzyme has to be to be suitable for the selection system. Although the variant 
I-SceI_D150C, N152K showed the lowest activity compared to wild type enzyme, the 
doubling time determined in vivo under inducible conditions was just slightly higher than for 
I-SceI_wt. For this reason, it was decided to test the assay also with PI-SceI which has a lower 
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activity compared to I-SceI. In order to have a more promising starting position 
PI-SceI_T225A, reported to have a 3-fold higher activity than PI-SceI_wt [89], was also 
examined in the selection assay. The increased activity of this variant compared to the wild 
type enzyme was confirmed by in vitro cleavage experiments (Figure 3.6A) and had also an 
effect on the doubling time under inducible conditions, which was ~ 1.5 - fold lower for cells 
expressing PI-SceI_T225A compared to cells expressing PI-SceI_wt. These first experiments, 
with the selection assay “in liquid”, showed that there is a link between the in vitro activity of 
an enzyme and the survival of cells, harboring the reporter plasmid with the respective target 
site, under inducible conditions. The less active an enzyme was, the higher was the doubling 
time at 42 °C, since less cells could survive the inducible conditions at 42 °C, due to the 
reporter plasmid not being cleaved by the homing endonuclease.  
As already described above, the selection assay “in liquid” is not suitable for selection 
of variants out of a library and for this, the selection assay “on plate” was tested for its 
feasibility. It turned out that the position of the target site on the reporter plasmid and the 
duration of the incubation at 28 °C before incubating the plate at 42 °C have an influence on 
the efficacy of the assay. If the target site is positioned in the coding region of gvpA 
(gvpA_P) less than 5 % of the transformed cells were able to survive 42 °C, whereas those 
cells harboring reporter plasmid with the target site in the region of the PL promoter 
(gvpA_PL_P) showed up to ~ 70 % survivors (Figure 3.7A). These plates also contained 
IPTG to induce the expression of the homing endonuclease, and the longer the pre-incubation 
at 28 °C, the more enzyme molecules have been expressed and have cleaved the target site on 
the reporter plasmid. This results in a direct correlation between pre-incubation at 28 °C and 
the number of surviving colonies. On the other hand, the pre-incubation should not be too 
long, as seen in Figure 3.7B, where on the plate which was incubated for 3 h at 28 °C colonies 
grew, even though the cells were transformed with an inactive variant of PI-SceI. It is possible 
that even at 28 °C there is a slight background expression of the toxin, which sets the cells 
under selection pressure, leading to loss of the reporter plasmid, because there was no 
chloramphenicol on the plate to maintain the plasmid. For this, a real fine-tuned system 
between giving the enzyme enough time to cleave the target site and not incubating the cells 
too long to get false positives, is needed. The difference in activity between PI-SceI_wt and 
PI-SceI_T225A is also observable in Figure 3.7B, where again PI-SceI_T225A showed 
always a ~ 1.5 – 2 - fold increased number of surviving cells. The following selection assays 
“on plate” were therefore performed using gvpA_PL_P as reporter plasmid, PI-SceI_T225A 
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as starting point for creating libraries and 1 h pre-incubation at 28 °C before incubating the 
plates at 42 °C.  
The practicability of the developed assay to select specific active variants out of a 
library was tested with a mixture of plasmids expressing the active variant and the inactive 
one in relation one to hundred. As shown in Figure 3.8, after four generations of selection the 
active variant PI-SceI_T225A could be enriched completely over the inactive 
PI-SceI_D218A. This experiment was also performed with a relation of one active in a 
thousand, but no enrichment of the active variant was observable after four generations, 
meaning that the library of variants should not be too large. For this reason, it was decided not 
to do random mutagenesis over the whole PI-SceI gene, but only to select a few residues to 
randomize using degenerated primers. These residues were chosen according to previously 
published studies on DNA-binding of PI-SceI, since the goal was to find an enzyme variant 
recognizing a new target sequence.  
To have predominantly catalytically active variants in the library, and by this increase 
the chance of selecting an active enzyme, residues in domain I were chosen. Cluster of two to 
three residues were used to create enzyme libraries (Figure 3.9A). Residues R90 and R94 
form a positive cluster, which was examined by alanine substitutions [89] and turned out to be 
crucial for DNA-binding, this cluster contained the residues, R90, L92 and R94. The other 
two clusters, namely Q55/H56 and S169/H170 were chosen after analysis of the co-crystal 
structure of PI-SceI [66] and identification of potential hydrogen bonds and hydrophobic 
interactions between these amino acid residues and the PI-SceI target sequence (summarized 
in [92]). The successful generation of the enzyme-pools was confirmed by sequencing (Figure 
3.10), which showed that the distribution of the nucleotides was not equal at all positions, 
especially the first positions of the triplets coding for S169 and H170, and the last position of 
every triplet coding for Q55, H56, R90, L92 and R94, which was strived for, to decrease the 
chance of generating stop-codons. Overall, at all other chosen positions every nucleotide was 
present to at least 10 %, so it was decided to test these pools in the selection assay “on plate”. 
Since R90 and R94 in the pool RLR (R90, L92, R94) were already experimentally confirmed 
to be involved in DNA-binding and this pool has the highest variability with three residues to 
change, it was decided to examine this one first in the selection assay. Gimble et al. [93] 
substituted all positions in the PI-SceI recognition sequence to other nucleotides individually, 
and tested the influence of these positions as PI-SceI cleavage activity on the substrate. These 
changes were then introduced at the positions of the target site, known from the co-crystal 
Discussion 
 
92 
structure to be involved in contacts to the before mentioned amino acids used to generate the 
enzyme variant pools (Figure 3.9B). After two rounds of selection of pool RLR against the 
targets B and C, colonies surviving on the 42 °C plates were examined for the obtained 
enzyme variant. As listed in Table 3.1 five colonies were obtained, two against target B and 
three against target C, while PI-SceI_B2 is the same as PI-SceI_C1 and PI-SceI_C3 has the 
same amino acid composition as PI-SceI_wt. Overall, it was obvious that only one or two of 
the three amino acids were substituted by others and at least one of them was the same as in 
the wild type enzyme.  
To investigate if the selected variants really show a specific cleavage of the new target 
sequences, as expected, considering that they had to cleave the respective target site on the 
reporter plasmid to survive, in vitro plasmid cleavage assays were performed. Figure 3.11 
summarizes the results of this test, where plasmids containing either the wt-target, target B or 
target C were cleaved by PI-SceI_wt, PI-SceI_B1, PI-SceI_C1 and PI-SceI_C2 under 
different buffer and temperature conditions. Surprisingly, under none of the buffer conditions 
the newly selected variants cleaved the sequences they were selected for, except for the buffer 
containing Mn
2+
 as divalent metal ion. But PI-SceI_wt also cleaved the targets B and C under 
these conditions, and it is already known that PI-SceI shows relaxed specificity in presence of 
Mn
2+
 [73]. It is also noteworthy that, even under Mn
2+
 conditions, only PI-SceI_B1 showed 
some preference for its target B, while the other variants selected against target C did not 
show a preferred cleavage of exactly this sequence in vitro. Furthermore, the newly selected 
variants still cleaved the wild type target, under Mn
2+
 conditions completely and under the 
other buffer conditions to different extents, with PI-SceI_C1 cleaving less than the others. It 
was thought that possibly the temperature has an influence on the activity, since the selection 
assay was mainly performed at 42 °C. Unfortunately, this did not make the new variants 
cleave their target in vitro nor did it affect the cleavage of the wild type target. Taken all this 
into account, it was not possible to confirm the results obtained by the selection assay. 
Because of this, it was attempted to reproduce it in vivo by transforming cells harboring the 
reporter plasmid gvpA_PL_C with a plasmid coding for PI-SceI_T225A or one of the selected 
variants. The obtained survival rates reflected the specificity of the new enzyme variants for 
the target C. Above all, a difference between the wild type enzyme and the selected variants 
was now observable. The survival rate of PI-SceI_T225A was at least 40 times less than for 
the selected variants.  
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Obviously it is not as easy as expected to compare results obtained in vivo and in vitro. 
Reasons for this could be the different conditions in vivo, which are not fully reproducible in 
vitro and the selection pressure present in the cell due to the expression of toxic reporter gene, 
if the homing endonuclease is not able to cleave the target sequence. Apparently, all selected 
amino acid substitutions were from large amino acids as arginine and leucine (Figure 4.1B) to 
smaller amino acids like glycine, serine and valine. Figure 4.1C shows the most frequently 
obtained amino acids at the corresponding positions, namely glycine at position 90 and 92 and 
valine at position 94. The amino acids of pool RLR are all located in a loop, which is possibly 
flexible, because it is not completely resolved in the crystal structure, but probably ordered in 
the wild type enzyme due to the two positive charges (R90 and R94) interacting with the 
DNA in the co-crystal. It is also striking, that at least one of these two arginines is recovered 
in all the selected variants, indicating that these two residues may be important for the 
integrity of the DNA-binding by the loop-region.  
 
Figure 4.1: (A) PI-SceI co-crystal structure with LAGLIDADG helices shown in red and the 
catalytic active aspartates in blue. (B) Cut-out showing pool RLR consisting of R90, L92 and 
R94 colored yellow. (C) Overview of mainly obtained amino acids after selection against target 
B or target C shown in orange; this figure is a model made by in silico mutagenesis using 
Pymol and not reflecting the real structure of the enzyme. The changed base pairs of the DNA in 
target B and target C are colored dark gray and gray respectively. 
If now one of these amino acids is changed to an uncharged one, this loop may 
become more flexible again and will not have such a strong influence on DNA-recognition 
and binding. This might be a reason for selecting exactly these amino acids, because then the 
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DNA recognition and specificity is more relaxed. If this was the case, the selected variants 
should also cleave the new targets in vitro. Since they do not cleave the target sites they were 
selected for, but only the wild type sequence, there has to be a more complex network of 
amino acids communicating with each other, and this relatively rational approach with 
selecting only a few amino acids to change may be not suitable. For this reason, it was 
decided not to pursue the selection assays with pools QH and SH, since these libraries were 
made each only of two amino acid residues and the comprising amino acids were not 
investigated experimentally for DNA-binding before. 
This work showed that it is not straight-forward to predict the residues of such large 
enzymes, like homing endonucleases, possibly involved in DNA-recognition and just 
changing them. Maybe it would be more promising to do mutagenesis of not only three 
residues but the whole binding domain of PI-SceI and apply this library to the selection 
system. But for this, the assay described here has to be improved to find an active and specific 
variant in the large amount of variants. For this, possibly the first generations of selection 
could be performed in liquid media to enrich the active and specific variants and then only the 
last step would be performed on plate, to select single enzyme variants.  
A further improvement of the assay would be introducing the wild type recognition 
sequence for PI-SceI on the homing endonuclease expressing library plasmid as a kind of 
feedback control, preventing selection of enzyme variants with a broadened rather than a 
more specific cleavage activity, which was perhaps the case for the variants selected here. 
Summing all this up, an assay was developed with which it is theoretically possible to select 
enzyme variants with new specificities, although this new cleavage pattern was only observed 
in vivo. The assay is the first one developed which couples cleavage activity of PI-SceI to 
survival of E.coli cells. All previously mentioned and published selection assays for directed 
evolution of homing endonucleases were based on cleavage activity of I-SceI or I-CreI and 
for PI-SceI only one assay based on DNA-binding was reported [15] so far.  
Directed evolution of homing endonucleases as it was described above, is neither a 
rational nor an easy to control approach. Stringent selection systems are needed to find 
homing endonucleases with a new specificity and not just a broadened one. Furthermore, only 
a few base pairs in the recognition sequence should be altered at once, meaning a lot of 
selection cycles are required and moreover, assays based on negative selection always carry 
the problem of false positive results, due to the loss of the reporter plasmid. This could be 
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another reason for the variants selected in this work, since the obtained in vitro activity does 
not correspond to the in vivo activity of the enzymes. 
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4.2 ENGINEERING PVUII-I-SCEI FUSION ENZYMES 
A more rational approach to create endonucleases with new specificities was aimed for 
by fusion of a DNA-binding module to a DNA-cleavage module, a method widely applied 
currently by several groups as well as by biotech and pharmaceutical companies. The most 
popular DNA-cleavage module in most cases is the unspecific catalytic domain of the 
restriction endonuclease FokI, which was fused to several DNA-binding modules, including 
Zinc fingers e.g. [104,105], TALEs (transcription activator like effectors) e.g. [50-52] and an 
inactive form of the homing endonuclease I-SceI [74]. Using this DNA-cleavage module 
could be problematic, since it does not specifically recognize and bind DNA by itself, which 
could lead to unspecific cleavage without binding of the DNA-binding modules to their 
respective target sites, the so-called off-site target cleavage. For this reason, it was decided to 
use a specific type IIP restriction enzyme as DNA-cleavage module, namely PvuII. As DNA-
binding module, an inactive form of the LAGLIDADG homing endonuclease I-SceI was used 
and the aim was to combine the recognition sequences of the restriction enzyme and the 
homing endonuclease resulting in a long sequence, appearing ideally only once in a genome. 
As a first attempt a model of the PvuII I-SceI fusion enzyme was constructed (Figure 
3.12), which indicates a distance of 6 bp between the two recognition sequences for the 
respective enzymes as the best arrangement of the proteins, entering the DNA all from the 
same direction. It is to mention that the fusion was planned by connecting the C-terminus of 
PvuII with the N-terminus of I-SceI, since this N-terminus, consisting of two α-helices, seems 
to “hang out” of the otherwise compact structure of I-SceI and by this could maybe serve as a 
kind of linker between the proteins. The distance to be covered by a linker was estimated from 
the model to be ~ 26 Å, assuming that the N-terminal part of I-SceI is located as in the co-
crystal structure. The first fusion protein consisted of scPvuII fused to I-SceI_D44S, a 
catalytically inactive variant of I-SceI, also used in the directed evolution project as negative 
control. This fusion protein carried a His6-tag as linker L(H) between the genes coding for 
scPvuII and I-SceI, used for affinity purification of the enzyme. As shown in Figure 3.13A the 
proteins resulting from this purification were not completely pure, which could have been due 
to either breaking of the fusion enzyme or incomplete translation. In either case, there was the 
danger that scPvuII alone was purified, since it harbors the C-terminal His6-tag and free 
scPvuII in the protein preparation would falsify DNA-cleavage experiments. To prevent this, 
a subsequent gel filtration was performed (Figure 3.13B), resulting in pure fusion protein 
which could now be tested for activity and particularly specificity, since the main goal of the 
whole fusion enzymes approach was finding an enzyme recognizing and cleaving a sequence 
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consisting of the target sites for PvuII and I-SceI together in a certain arrangement, which has 
to be identified.  
In the first test, controlling if there is any unspecific activity of scP-L(H)-S(D44S), 
performed with substrate containing only an I-SceI site but no PvuII site, cleavage of exactly 
this substrate was observed. Surprisingly, these cleavage products seemed to run at the same 
height as the products obtained by cleavage of the substrate with I-SceI (Figure 3.14A), 
indicating that the cleavage occurred at the I-SceI site, which would be unlikely since the 
fusion enzyme contained the inactive variant of I-SceI. To pinpoint the exact cleavage 
position, the products were gel-purified and sequenced, revealing that the substrate was 
cleaved by scP-L(H)-S(D44S) at a position 9 bp downstream the I-SceI site. It turned out that this 
cleavage position lies in the middle of the PvuII “star” site CAG|CAG which is coincidentally 
located 6 bp downstream of the I-SceI site, exactly like it was proposed in the model. “Star” 
sites are sequences which differ in one base pair position from the cognate recognition site of 
the enzyme. PvuII by itself has a certain potential to attack “star” sites, if the buffer conditions 
are not ideally chosen, if there is too much enzyme in relation to DNA or if the incubation is 
too long, but in this activity assay PvuII alone did not show any unspecific cleavage, although 
there are in total four potential “star” sites on the substrate used, differing in one base pair 
from the PvuII target sequence CAG|CTG. The fact that the fusion protein cleaves also just 
the one site, addressed by the 6 bp upstream I-SceI site, shows that, due to binding of I-SceI to 
its respective site, PvuII is directed to the DNA and cleaves a site which it would normally not 
attack. This already shows a certain specificity of the fusion protein and it also shows that the 
fusion is done correctly, since I-SceI is obviously able to bind DNA and PvuII is able to 
cleave DNA at a certain distance away from the I-SceI binding site, the two prerequisites 
necessary for further improvements.  
The model and the first activity test suggest a distance of 6 bp between I-SceI and 
PvuII target sites, which could not be confirmed completely by the plasmid cleavage assay 
summarized in Figure 3.15, where target sites with different distances of 3, 8, 10 and 12 bp 
between the I-SceI and the PvuII site were assayed for cleavage by scP-L(H)-S(D44S) and 
scPvuII. It turned out, that there is no obvious preference for any of the substrates, although 
the cleavage rate of scP-L(H)-S(D44S) of plasmid pAT_S3P is slower than for the other 
substrates, but scPvuII also shows decreased activity on this substrate. Evidently 
scP-L(H)-S(D44S) shows, for all the substrates, a faster cleavage than scPvuII does, which could 
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be due to binding of I-SceI to its site and by this directing PvuII to the DNA and its 
recognition site, while scPvuII has to search for it and then cleave.  
The first activity assays of scP-L(H)-S(D44S) were performed in Buffer Green  
recommended as ideal cleavage buffer for PvuII, which is otherwise not suitable for further 
improvements. Nucleases with extended specificity as they were created here are supposed to 
be used in vivo later, and because of this the buffer conditions should already imitate 
physiological conditions. In this work, KGB was the initial point for optimizing the buffer 
conditions, including addition of 100 mM KCl, to end up with an ionic strength close to that 
of the cellular milieu. Furthermore, the concentration of Mg-acetate had to be decreased, 
compared to the 10 mM originally used in the published KGB [94]. The activity of 
scP-L(H)-S(D44S) compared to scPvuII was tested with plasmid containing the addressed site 
S8P, with Mg-acetate concentrations ranging from 0 - 1 mM (Figure 3.16). At a concentration 
of 0.8 mM Mg-acetate, which is closer to cellular conditions than the reported 10 mM, the 
difference in cleavage activity between scP-L(H)-S(D44S) and scPvuII was the highest, which 
means that scP-L(H)-S(D44S) cleaved the plasmid completely while scPvuII showed nearly no 
cleavage under these conditions. For this reason, all further experiments were performed in 
the so-called optimized KGB supplemented with 100 mM KCl and 0.8 mM Mg-acetate. Since 
PvuII is not active under these conditions and its activity is dependent on the concentration of 
Mg
2+
 [95] in the buffer (Figure 3.17), all control experiments with PvuII or a variant thereof 
were still performed in the recommended buffer. This observation was already a first hint that 
a specific nuclease with extended specificity was created by fusion of a catalytically inactive 
homing endonuclease to the restriction enzyme PvuII. Obviously, I-SceI is the dominating 
binding part of the fusion enzyme, bringing PvuII in close proximity to the DNA and its 
respective target site, and by this promoting the cleavage activity of PvuII, which would 
otherwise, under the buffer conditions mentioned (optimized KGB), not bind and cleave its 
recognition sequence on its own.  
To increase the recognition sequence of the meganuclease and by this create an even 
more specific enzyme, PvuIIwt was fused to I-SceI instead of the single chain variant, which 
needs the dimerization of PvuII prior to catalysis and by this the fusion enzyme has to 
recognize a tripartite sequence consisting of the PvuII target site, flanked by two I-SceI sites. 
Further improvement of the fusion enzyme included cloning of the construct into a different 
vector system coding for a C-terminal Strep-tag (pASK IBA-63b plus) and by this being 
independent of the His6-tag in between the genes coding for PvuII and I-SceI. With this, it 
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was possible to remove this linker variant (L(H)) and exchange it for others. A further 
advantage of using the C-terminal Strep-tag for affinity purification was that now no 
additional purification by gel filtration was needed, since only completely translated fusion 
enzymes can be purified (Figure 3.18).  
 
Figure 4.2: Summary of all optimization steps applied to the PvuII-I-SceI fusion enzyme 
shown here as cartoon, with I-SceI in green and PvuII in blue. (A) The C-terminal deletion of 
9 amino acids, (B) substitutions in the LAGLIDADG motif of I-SceI making it a catalytically 
inactive enzyme, (C) different linker variants used, (D) substitutions in PvuII decreasing its 
catalytic activity and (E) substitutions in PvuII disrupting the dimerization interface. 
The DNA-binding module was also subjected to improvements by using a 
C-terminally shortened variant lacking nine amino acids (∆C9) and substituting Asp 145 from 
the second LAGLIDADG motif, in addition to Asp 44, the catalytically active residue in the 
first LAGLIDADG motif, to ensure that there is absolutely no residual cleavage activity by 
I-SceI. Furthermore, by this the negatively charged residues lying close to the DNA were 
removed which might increase the binding affinity of I-SceI. The combinations of active site 
variants created are listed in Table 3.3, with their respective binding constants determined 
with substrate containing a PvuII site with an I-SceI site 6 bp away. The variant 
P-L(H)-Ss(D44N, D145A) turned out to have the lowest KD and by this the best binding behavior, so 
∆C9 I-SceI(D44N, D145A) was chosen to be the binding module for all further fusion enzymes 
(Figure 4.2B). Interestingly, exactly this variant of I-SceI, except for the deletions at the 
C-terminus (Figure 4.2A), was reported in [74] to be the most soluble variant of I-SceI in their 
experiments, a fact that could also be profitable for the work described here. As already 
mentioned in Table 3.4, I-SceI(D44N, D145A)∆C9 will be called Ss* throughout the text.  
Discussion 
 
100 
The different linker variants chosen (Table 3.5, Figure 4.2C) were, with one exception, 
all ten amino acids long, since this length turned out to be suitable, based on the experiments 
performed with the fusion enzyme containing the His6-tag (L(H)), also composed of ten amino 
acids. The stated exception L(6), consisting of 6 amino acids, was actually not planned to be a 
linker, but it arose by introducing three restriction enzyme sites between the genes for PvuII 
and Ss*. However, the resulting fusion enzyme was also tested. Other linker variants used 
were L(N) composed of Gly and Ser, L(+) as a part of the FokI linker [106] and, since there was 
a neutral and a positively charged linker, also L(-) composed of Gly and Ser and two additional 
Asp as negatively charged linker was used. A first specificity test of the fusion enzymes 
carrying the different linker, using plasmid DNA containing an addressed site (I-SceIsite-6bp-
PvuIIsite-6bp-I-SceI; S6P6S) and a single PvuII site (Figure 3.19B), revealed that P-L(6)-Ss* 
and P-L(+)-Ss* showed the least unaddressed cleavage at the single PvuII site. Overall, it has 
to be mentioned that all the fusion enzymes cleaved the addressed site (S6P6S) first. Since 
PvuIIwt cleaves both sites (addressed and unaddressed) with the same efficiency, resulting in 
three major cleavage products, it can be ruled out that there is a common preference for one of 
the sites due to sequence context, which means the fusion enzymes show a specific cleavage 
of the addressed target site. The activity test with plasmid DNA containing only a PvuII 
(Figure 3.19A) site showed that there is still a need to optimize the fusion enzymes, since all 
of them still attack this site, resulting in 30 - 40 % of cleavage product after overnight 
incubation. To determine if there are any distance constraints, meaning that the 6 bp distance 
between the target sites as proposed in the model, is a prerequisite for cleavage, different 
substrates with 4 and 8 bp between I-SceI and PvuII sites were also generated. As further 
control, a substrate with no PvuII site, but only a random palindromic 6 bp sequence between 
the two I-SceI sites in a 6 bp distance, was constructed. Figure 3.20 summarizes the results of 
cleavage assays on different targets, and it is obvious that all of the fusion enzymes cleave 
substrate S6P6S with nearly the same efficiency, but surprisingly the variants containing a 
charged linker (P-L(+)-Ss* and P-L(-)-Ss*) showed a high preference for the substrate with the 
shortest distance between I-SceI and PvuII sites. These enzymes were also able to cleave the 
substrates with the 8 bp distance. The other fusion enzymes, containing either the His6-tag 
L(H) or the neutral linker L(N), cleaved the substrates with following preference: 
S4P4S < S8P8S < S6P6S and only the variant with the shortest linker P-L(6)-Ss* showed the 
preference predicted from the model (Figure 3.12), with substrate S6P6S being the best 
cleaved substrate. This could be explained by the length of this linker which is maybe too 
short, since although the target sites are closer together in S4P4S, it has to be considered that 
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in this arrangement, the target sites moved along the torsion of the DNA and the enzymes 
would not enter the DNA from the same direction anymore, which would again necessitate a 
longer linker. The same would of course be true for the 8 bp distance between the target sites. 
From the first cleavage experiment, where a PvuII “star” site 6 bp away from an I-SceI site 
was cleaved, it could be expected that, although there is no PvuII site between the binding 
module sites, this substrate would be cleaved. But as shown in the cleavage experiment with 
S6x6S as substrate, there has to be a PvuII site between the two I-SceI sites for cleavage 
(Figure 3.20C), which means that PvuII is not just a cleavage module but that it also 
contributes to the specificity of the fusion enzyme. This finding is different from the fusion 
enzymes where the catalytic domain of FokI was used as cleavage module (e.g. Zn-finger 
nucleases [107]), which by itself does not recognize and bind DNA specifically. 
As shown in the model (Figure 3.12), the fusion enzymes having PvuIIwt as cleavage 
module have to dimerize to form an active enzyme and the question arising from this was if 
the enzyme is already present as dimer in solution, as it is known for PvuII alone [96], or if 
the fusion to I-SceI affects the dimerization potential. This would mean that the PvuII 
subunits of the fusion enzyme dimerize on the DNA due to binding of the I-SceI binding 
modules to their target sites in a distinct manner. This property would be advantageous for the 
purpose of using the fusion enzyme as nuclease with extended specificity in gene targeting 
and would avoid a so-called “hanging monkey” situation, where the cleavage module by itself 
binds its recognition sequence without being specifically directed by the binding modules. 
Sedimentation velocity runs of P-L(6)-Ss* in an analytical ultracentrifugation performed under 
high- and low-salt conditions revealed that the fusion enzyme occurs also as dimer in solution, 
independent of protein concentration and salt content of the buffer, indicating that the I-SceI-
fusion had no effect on the oligomeric state of PvuII. This experiment also confirmed the 
structure proposed in the model of the fusion enzyme, having an elongated shape, rather than 
forming a spherical protein-complex, which is obvious, since the fusion enzyme is composed 
of formerly stand-alone proteins probably having no tendency to interact with each other.  
Summarizing all obtained results so far, a homodimeric fusion protein was 
constructed, showing a pronounced specificity for an addressed tripartite recognition site 
consisting of a PvuII site flanked by two I-SceI sites ideally 6 bp apart. Different linker 
variants show different extents of specificity, with P-L(6)-Ss* and P-L(+)-Ss* being the 
favorites so far. For this reason, these two protein variants were the starting point for further 
optimization. All further improvements were planned to happen on the cleavage module, to 
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increase the specificity and make the cleavage activity of PvuII more dependent on binding of 
I-SceI to the DNA. As described in Figure 3.22, two different approaches were followed. One 
was based on the catalytic properties of PvuII, which should be decreased by certain amino 
acid substitutions and the other one relied on the dimeric structure of PvuII, which should be 
disturbed by mutagenesis in the dimer interface of the protein.  
In the first more functional approach, substitutions T46G, Y94F or H83A (Figure 3.22, 
right panel; Figure 4.2D) were introduced into PvuII in different combinations, with T46G 
always being present. This mutation is responsible for abolishing the “star activity” of PvuII 
(Zheng, NEB, personal communication), a feature suitable for the goal pursued here. 
Additional to this, Y94F was reported to have a reduced binding ability to the second metal 
ion [100], resulting in a reduced catalytic activity while H83A was reported to be involved in 
DNA-binding [99]. These mutations were introduced as double or triple mutants into PvuII, 
either in the fusion enzyme context or alone. That these substitutions already have a big 
impact on the catalytic activity of PvuII is shown in Figure 3.28. PvuII(T46G, Y94F) has a 
100 - fold reduced cleavage activity and PvuII(T46G, H83A, Y94F) an even 200 - fold reduced 
activity compared to PvuIIwt. The variant PvuII(T46G, H83A) was not tested, since an experiment, 
accomplished before, showed that fusion enzyme variants containing this cleavage module 
did not have a specificity only for the tripartite recognition site but also for the dipartite, 
consisting of a PvuII site with just one I-SceI site next to it. However, this experiment (Figure 
3.23) showed that all tested variants (P(T46G,H83A)-L(6)-Ss*, P(T46G,Y94F)-L(6)-Ss*, 
P(T46G,H83A)-L(+)-Ss* and P(T46G,Y94F)-L(+)-Ss*) did not cleave the unaddressed site also present 
on the substrates. The variants containing PvuII(T46G, Y94F) as cleavage module in addition 
showed a specificity for the addressed tripartite site (S6P6S) consisting of a PvuII site flanked 
by two I-SceI sites 6 bp apart and did not cleave the dipartite site (S7P). Since this 
observation already means a gain in specificity, only variants containing PvuII(T46G, Y94F) were 
used for further characterization, including detailed enzyme kinetics. Both enzymes tested, 
P(T46G, Y94F)-L(6)-Ss* and P(T46G, Y94F)-L(+)-Ss*, showed no cleavage of the unaddressed site on a 
plasmid containing the addressed (S6P6S) and the unaddressed (P) PvuII site even after 
overnight incubation (Figure 3.24), although they did cleave the addressed site completely 
after this time. Since in this experiment enzyme and DNA were incubated in equimolar 
amounts, but the plasmid has two sites for the enzyme to attack, the ratio of enzyme to 
cleavable sites is 1:2. To test if the enzyme will still be specific if this ratio changes, enzyme 
titration experiments were performed with enzyme to DNA ratios of 0.5:1 – 32:1, with 
plasmid DNA containing the addressed and the unaddressed site (S6P6S_P) (Figure 3.25A) or 
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plasmid DNA containing only a PvuII site (Figure 3.25B). Actually, P(T46G, Y94F)-L(6)-Ss* 
cleaves the PvuII site in presence of the addressed site only at a 16 - fold excess of protein 
over DNA and in absence of an addressed site at 8 - fold excess. The other fusion protein with 
the linker L(+) is not as specific, cleaving PvuII sites in presence of S6P6S at 8 - fold excess 
and in absence of the addressed site already at equimolar concentrations of protein and DNA.  
So far, the evaluation of the cleavage activity was performed by ethidium bromide 
staining, which is not sensitive enough to also detect small traces of cleavage product, why 
competition cleavage experiments using internally radiolabeled PCR-fragments harboring 
either the addressed site (S6P6S) or a single PvuII site (P) were done. These experiments, 
summarized in Figure 3.26, revealed that there is at least some unaddressed cleavage (~ 3 % 
after 3 h) in the presence of equimolar amounts of addressed site by the fusion proteins, 
independent of the linker (L(6) or L(+)) or the PvuII variant (wt or T46G, Y94F) used. In terms 
of addressed cleavage, the variants with PvuIIwt as cleavage module show remarkably specific 
cleavage activity while the variants P(T46G, Y94F)-L(6)-Ss* and P(T46G, Y94F)-L(+)-Ss* showed 34 
and 16 times less activity, which is indeed not as dramatic as for the variants with PvuII alone, 
showing a 100 - fold drop in activity (compare Figure 3.28), but still too little to see any effect 
on the specificity of these variants, particularly because these enzyme variants show nearly 
the same extent of unaddressed cleavage as P-L(6)-Ss* and P-L(+)-Ss*. This results in a 
specificity factor of 18 for P(T46G, Y94F)-L(6)-Ss* and 11 for P(T46G, Y94F)-L(+)-Ss* (Table 3.8), 
which indicates a loss in specificity compared to the same variants having PvuIIwt as cleavage 
module.  
During all cleavage experiments by the fusion enzyme, it was observable that after a 
certain time the cleavage activity of the enzymes did not increase anymore, although not all 
substrate was turned over, the activity reached a plateau. One explanation for this could be, 
that not all enzyme molecules, which of course absorb at A280 and by this contribute to the 
concentration, were still active. Another explanation was derived from the knowledge that 
homing endonucleases have the tendency to stick to their cleavage products after cleavage 
[70,108]. This was tested by simply analyzing the cleavage products of P-L(6)-Ss* and 
P-L(+)-Ss* on a native gel either after heating the sample or not (Figure 3.27). When not 
heated up, the DNA appeared as shifted in the gel, while after heating, and by this denaturing 
the enzyme sticking on the DNA, the cleavage products were observed. This result indicated 
that the fusion enzymes are per se no “real” enzymes which must have a turn-over, a fact that 
could be useful for application in vivo, since in the ideal case the fusion enzyme has to cleave 
Discussion 
 
104 
only once at the desired position. Sticking to the products should not be an obstacle for 
initiating homologous recombination, as homing endonucleases also tend to do this and still 
their only function is stimulation of homologous recombination to preserve the propagation of 
genes coding for them [65]. These results obtained were already a sign for I-SceI being the 
major part of the fusion enzymes involved in DNA-binding, as it was aimed to. The binding 
constants derived by EMSA on specific substrate (S6P6S) confirmed this, although these KDs 
were 2 - 3 times higher than the one reported for I-SceI alone [19]. A single I-SceI site is 
bound at least 12 times less efficient by the fusion enzyme, which indicates that PvuII also 
contributes to the binding ability of the fusion enzyme to its specific site but disrupts the 
binding of I-SceI to its site alone. The obtained data were in principle independent of the 
linker and the PvuII variant used.  
Although the so far created and optimized fusion enzyme variants P(T46G, Y94F)-L(6)-Ss* 
and P(T46G, Y94F)-L(+)-Ss* did not show any increase in specificity compared to the enzymes 
containing PvuIIwt as cleavage module, an in vivo test in E.coli was performed, investigating 
the potential off-site target cleavage by these variants. Figure 3.28 summarizes the results 
obtained thereby, indicating that the plasmids expressing PvuIIwt or PvuII(T46G, Y94F) need the 
presence of their companion methyltransferase to protect the E.coli genome from 
autodigestion, while E.coli transformed with plasmids encoding the different fusion enzymes 
(P-L(6)-Ss*, P-L(+)-Ss*, P(T46G, Y94F)-L(6)-Ss*, P(T46G, Y94F)-L(+)-Ss*, P(T46G, H83A, Y94F)-L(6)-Ss* 
and P(T46G, H83A, Y94F)-L(+)-Ss*) in the absence of methyltransferase showed surviving colonies, 
indicating that these enzymes did not attack genomic PvuII sites (whereof there are ~ 1800 in 
the E.coli DH10B genome) to the same extent as PvuII does. It is to mention that E.coli 
transformed with plasmid coding for PvuII(T46G, H83A, Y94F) also showed surviving colonies in 
the absence of M.PvuII confirming the too low activity of this enzyme variant (compare 
Figure 3.28). Overall, the amount of surviving cells in presence of fusion enzyme and absence 
of methyltransferase is not as high as would be expected from the control plates, showing the 
number of colonies growing in presence of M.PvuII, an indication that there is still off-site 
target cleavage by the fusion enzymes. Additionally, there is again a discrepancy between in 
vitro and in vivo data observable, because the variants having PvuII(T46G, Y94F) as cleavage 
module show by trend a higher amount of surviving cells although the factor for specificity of 
these variants obtained in vitro was at least one order of magnitude lower than for the fusion 
proteins containing PvuIIwt (Table 3.8). The higher survival of cells for these variants could 
possibly be explained by their overall decreased activity. 
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After trying to optimize the fusion proteins by decreasing the catalytic properties of 
PvuII, which turned out to be not as successful as expected, the second approach by 
interrupting the dimerization interface of PvuII was undertaken (Figure 4.2). This time, first 
of all the PvuII alone variants harboring the substitutions L12E, P14G or H15D were 
examined for their catalytic properties (Table 3.7), which turned out to be at maximum 
7 -  fold lower (PvuII(L12E)) than those for PvuIIwt. Since all the substitutions were located in 
the first N-terminal α-helix (Figure 3.22, lower panel), distant from the active center of PvuII, 
these results were expected. The aim of introducing the mutations into this helix was 
disturbing the dimer interface by creating on one hand a negative patch (L12E and H15D) and 
on the other hand changing the bending behavior of the helix (P14G) and by this reducing the 
interface contacts. The resulting fusion enzymes containing the before mentioned mutations 
individually in the PvuII cleavage module showed cleavage activity of plasmid DNA 
containing the addressed (S6P6S) and an additional unaddressed PvuII site (P) only at the 
addressed site and no cleavage of plasmid DNA containing only a PvuII site (Figure 3.30). 
Since the addressed cleavage obtained in this experiment was nearly complete and the PvuII 
alone variants containing the mutations L12E, P14G or H15D also showed activity 
comparable to PvuIIwt it was expected that these variants also show higher cleavage activity in 
the competition assay than the variants containing PvuII(T46G, Y94F) as cleavage module. This 
was exactly the case as shown in Figure 3.31, where all three variants P(L12E)-L(6)-Ss*, 
P(P14G)-L(6)-Ss* and P(H15D)-L(6)-Ss* showed remarkable cleavage of the addressed site, while 
no unaddressed cleavage could be observed, resulting in a factor of specificity of these 
enzymes for the addressed site of over 1000 (Table 3.8). This factor might be even higher, 
since the amount of unaddressed cleavage is below the detection limit. The activity of these 
variants at the addressed substrate is only slightly lower than the addressed activity of 
P-L(6)-Ss* (Table 3.8), which again confirms the results obtained before that show that the 
substitutions in the dimer interface do not have such a strong impact on the overall activity of 
the fusion enzyme but a large effect on their specificity. Surprisingly, also the binding affinity 
on the addressed site of the variants P(L12E)-L(6)-Ss*, P(P14G)-L(6)-Ss* and P(H15D)-L(6)-Ss* 
(Table 3.9) is higher than for the variants containing PvuIIwt or PvuII(T46G, Y94F) as cleavage 
module (Table 3.3), while no specific binding of a stand-alone I-SceI site could be observed 
(not shown). A possible explanation for this could be that due to the mutations in the 
interface, PvuII is more flexible and by this maybe interferes with I-SceI and disturbs the 
binding of I-SceI to its site alone, while in the presence of a PvuII site between two I-SceI 
sites, PvuII can bind and is not affecting I-SceI anymore.  
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In the very first modeling approach of the fusion enzyme (Figure 3.12), it was 
suggested that a 6 bp distance between I-SceI and PvuII target sites would be the best, since 
then all enzymes enter the DNA from the same side, and also in the DNA cleavage assay of 
the different linker variants, pAT_S6P6S was the preferred substrate for P-L(6)-Ss* (Figure 
3.20), which is the variant used in the optimized enzymes last. If the fusion enzymes had not 
only a preference for an addressed site, meaning PvuII site flanked by two I-SceI sites, but 
furthermore had a preference for a certain distance between these sites, this enzyme would be 
even more specific. Plasmid cleavage assays with substrates containing the sites S4P4S, 
S6P6S and S8P8S (Figure 3.32), respectively, comparing the activity of P(L12E)-L(6)-Ss*, 
P(P14G)-L(6)-Ss* and P(H15D)-L(6)-Ss*, revealed that indeed P(P14G)-L(6)-Ss* showed a 
8 - 10 - fold preference for S6P6S over S4P4S and S8P8S, making this enzyme the most 
specific of all. The other two variants also showed a preference for S6P6S over the other 
substrates, but with at maximum two fold. Finally, all fusion enzyme variants obtained so far, 
containing the different linker and PvuII variants, were tested for cleavage at unaddressed 
PvuII sites by λ-DNA digestion (Figure 3.33). When using equimolar concentration of 
enzyme and PvuII sites, the “early” variants, containing PvuIIwt as cleavage module and the 
different linker, showed cleavage of λ-DNA, albeit not as extensive as PvuII alone does. The 
variants containing PvuII(T46G, Y94F) as cleavage module did not show any cleavage of λ-DNA, 
which is not surprising, since PvuII(T46G, Y94F) by itself does not cleave as much as PvuIIwt and 
was also shown to have a 100 - fold less efficient cleavage than PvuIIwt (Figure 3.28). More 
impressive are the results obtained for P(L12E)-L(6)-Ss* and P(P14G)-L(6)-Ss* which do not show 
any cleavage of λ-DNA, although PvuII(L12E) and PvuII(P14G) cleaved the DNA completely, 
comparable to PvuIIwt. This result confirmed the calculated specificity of over 1000 (Table 
3.8) for addressed over unaddressed sites for these variants. For some reason, P(H15D)-L(6)-Ss* 
showed some cleavage of λ-DNA, even though this enzyme also has a specificity of > 1000 
for addressed over unaddressed cleavage. It could be that this enzyme attacks addressed sites 
first in the presence of unaddressed ones, and then sticks to the cleavage product (see Figure 
3.27), which makes it unable to attack unaddressed sites, but if there are just PvuII sites, it 
will attack these, which shows that the calculated specificity does not necessarily refer to the 
“real” specificity of the enzyme.  
Summing all the results up, it was possible to engineer a highly specific nuclease by 
fusing a catalytically inactive homing endonuclease to the restriction enzyme PvuII. The final 
fusion enzyme P(P14G)-L(6)-Ss* cleaves with > 1000 - fold preference addressed sites in the 
presence of unaddressed sites, but also does not attack PvuII sites alone. Furthermore, it has 
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specificity for the 6 bp distance between I-SceI and PvuII target sites. Of course the last step 
has to be in vivo testing of this enzyme, which should ideally be in eukaryotic cells, e.g. plant 
cells, where already endeavors have been made to introduce I-SceI target sequences as so-
called “safe harbors” into crop plant cells for gene targeting [84] [109].  
4.3 CONCLUSION 
In this work, two different approaches for generating meganucleases have been 
described, with both having their advantages and disadvantages. The first assay based on 
directed evolution aims for changing the specificity of an already existing meganuclease, 
while the second approach based on rational engineering enlarges the specificity of a 
restriction enzyme by fusion to a catalytically inactive homing endonuclease. Advantage of 
the directed evolution approach is that one can select for enzymes recognizing a specific 
sequence existing in a genome and afterwards target this sequence directly by the 
meganuclease for gene targeting as it is done in high throughput by the company Cellectis 
SA. They created a large library of I-CreI subunits recognizing different sequences and are 
able to combine these subunits to engineer enzymes recognizing sequences at specific loci i.e. 
XPC [23], RAG1 [24] or HSV1 [27].  
For PI-SceI, the object of investigation in this work, until now, no selection assays 
have been presented, although it was thought that this enzyme with its large recognition 
sequence of > 31 bp would be a suitable candidate. Development of a selection assay for PI-
SceI revealed the disadvantages of directed evolution systems, i.e. the selection pressure in 
negative selection leading to false positive clones, the high expenditure of time, since only a 
few base pairs in the recognition sequence should be changed at once and particularly the lack 
of rationality in these approaches. The last fact is the striking one, since homing 
endonucleases like PI-SceI are complex enzymes with a large network of residues responsible 
for DNA-recognition and it turned out not to be straight forward to pick out certain residues 
that are maybe involved in DNA-binding and just changing them, as it was done here. For a 
successful changing of the recognition pattern, larger parts of the enzyme have to be assayed 
in a selection system, which could be problematic, since the larger the region to mutate, the 
higher the probability to affect also the activity of the enzyme. A further obstacle in the 
selection assay and also in the later described fusion enzyme approach is always the 
discrepancy between in vivo and in vitro results for the meganucleases. In the directed 
evolution part, in vivo variants of PI-SceI with an obviously new specificity have been 
obtained, which could not be confirmed by in vitro studies.  
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The advantage of the second approach is the rationality by combining a DNA-binding 
and a DNA-cleavage module to enlarge the recognition sequence of the last mentioned, a 
principle used at the moment intensively to generate highly specific nucleases. In this context 
Zinc-finger nucleases, e.g. [110], and TALE-nucleases, e.g. [50], have to be noted, both 
relying on fusion of the catalytic domain of FokI as cleavage module to programmable DNA-
binding modules. In this work, a catalytically inactive form of the homing endonuclease 
I-SceI served as binding module which is per se not programmable, unless by directed 
evolution approaches as described before to find variants with new specificities. Still, this 
does not have to be a disadvantage, since there have already been a lot of efforts made on 
introducing I-SceI target sites for example in plant cells. For this reason, the here developed 
fusion enzyme could be a candidate for gene targeting in crop species, a field which is right 
now under intensive investigation. In contrast to the above mentioned approaches, where they 
used an unspecific cleavage module, which by itself does not contribute to the specificity of 
the nuclease, in this work the specific type IIP restriction endonuclease PvuII was used. This 
might have the advantage that the number of off-site target cleavage sites would be reduced, 
since PvuII recognizes the 6 bp sequence CAGCTG, which still occurs 10
4 
- 10
8
 times in 
complex genomes. However, by optimizing the linker between I-SceI and PvuII and by 
introducing certain substitutions into PvuII, affecting the dimer interface, it could be shown 
that the final fusion enzyme variant, namely P(P14G)-L(6)-Ss*, cleaves addressed sites with 
> 1000-fold preference over unaddressed sites, does not attack stand-alone PvuII site in 
λ-DNA and has also a preference for a specific distance of 6 bp between the I-SceI and PvuII 
target sites. The results obtained so far in vitro for the fusion enzyme are very promising and 
the next step would be in vivo testing of the enzyme. Since there have also been efforts made 
in controlling the activity of PvuII by either caging [111] or light inducible switches [112], 
this could also be applied to the fusion enzyme, making its cleavage activity controllable. 
Nevertheless it could be shown, that a specific restriction endonuclease, rather than only the 
catalytic domain of FokI, is a suitable alternative cleavage module to be used in creating 
highly specific nucleases. 
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5. SUMMARY 
In the post-genomic era, highly specific nucleases became important tools for directed 
gene targeting and gene therapy. They are used to specifically cleave genomic sequences, 
involved in for instance diseases and by creating this double-strand break, homologous 
recombination, an otherwise rarely occurring event in the cell, will be stimulated. Most 
commonly used are zinc-finger nucleases, consisting of specific zinc-finger modules 
responsible for recognizing DNA, fused to the catalytic domain of the restriction enzyme 
FokI. Some of these zinc-finger nucleases are already in clinical trial phases. As alternative in 
the past three years so-called TALE-nuclease came into the focus of research. Their 
advantage might be the high predictability of specificity and their possibly lower cytotoxic 
effects due to off-site target-cleavage, which have to be confirmed in the future. 
In this work, two other approaches for generating highly specific nucleases were 
presented. The first one is based on directed evolution, where the specificity of a naturally 
occurring meganuclease was to be changed. The investigated enzyme belonging to the 
LAGLIDADG family of homing endonucleases was PI-SceI. Mutant libraries of this enzyme 
were assayed in a two-plasmid selection system, selecting for variants cleaving a target site 
differing from the natural PI-SceI target in up to seven bp. Since structural and biochemical 
data for PI-SceI are available, only residues known to be involved in DNA-binding were used 
for mutagenesis. The obtained variants, showing in vivo an up to 100 - fold increase in 
specificity did not show the same result in vitro, under all conditions tested. This showed that 
results obtained in vivo and in vitro do not necessarily correspond to each other and that the 
developed selection assay needs further optimization. 
As second approach, a more rational strategy similar to zinc-finger or TALE nucleases 
was pursued, by fusion of a catalytically inactive variant of the LAGLIDADG homing 
endonuclease I-SceI to the type IIP restriction enzyme PvuII. With this, an alternative to the 
often used catalytic domain of FokI as cleavage module was presented. After optimizing the 
linker between the two proteins and several mutations in I-SceI to abolish any catalytic 
activity (D44N, D145A) and mutations in PvuII to either decrease its activity (T46G, H83A 
or Y94F) or disturb the dimerization interface (L12E, P14G or H15D) a final variant, namely 
P(P14G)-L(6)-Ss*, was obtained. This enzyme showed in vitro an over 1000 - fold preference for 
the addressed (PvuII site flanked by two I-SceI sites) over an unaddressed site (PvuII site 
alone). Furthermore, this protein had an up to 10 - fold preference for the distance of 6 bp 
between the respective I-SceI and PvuII sites and showed no cleavage of genomic DNA 
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(bacteriophage λ-DNA). The next step would be in vivo testing of this enzyme variant, ideally 
in planta, since there are already I-SceI target sites in several crop species available that could 
serve as “landing platforms” for gene targeting. 
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6. ZUSAMMENFASSUNG 
In der post-genomischen Ära haben sich hoch spezifische Nukleasen als wichtige 
Werkzeuge für die Gentherapie entwickelt. Sie sollen genutzt werden, um genomische DNS-
Sequenzen, die zum Beispiel in monogenetisch vererbbaren Krankheiten involviert sind, 
spezifisch zu spalten. Der erzeugte Doppelstrangbruch stimuliert den zelleigenen Reparatur-
mechanismus der homologen Rekombination, ein Ereignis, das ansonsten selten in der Zelle 
vorkommt. Die momentan am Häufigsten genutzten hochspezifischen Nukleasen sind 
sogenannte Zink-Finger Nukleasen. Diese bestehen aus Zink-Finger Modulen, die ver-
antwortlich für die spezifische DNS-Bindung sind, fusioniert an die katalytische Domäne des 
Restriktions-Enzyms FokI. Einige dieser Zink-Finger Nukleasen befinden sich schon in 
klinischen Versuchs-Phasen. In den letzten drei Jahren sind, als Alternative zu den Zink-
Finger Nukleasen, sogenannte TALE-Nukleasen in den Fokus der Forschung gerückt. Ihr 
Vorteil ist die Programmierbarkeit ihrer Spezifität und die damit verbundene wahrscheinlich 
geringere Zytotoxizität. All das wird sich allerdings in der Zukunft noch bestätigen müssen. 
In der hier vorgestellten Arbeit werden zwei andere Ansätze zur Generierung hoch 
spezifischer Nukleasen präsentiert. Der erste basiert auf gerichteter Evolution, wobei die 
Spezifität einer natürlich vorkommenden Meganuklease geändert werden soll. Das dabei 
untersuchte Enzym, PI-SceI, gehört der Familie der LAGLIDADG-Homingendonukleasen an. 
Bibliotheken von Enzym-Varianten wurden in einem zuvor entwickelten Zwei-Plasmid 
System gegen Erkennungssequenzen, die sich von der natürlichen PI-SceI Erkennungs-
sequenz in bis zu sieben Basenpaaren unterscheiden, selektioniert. Aufgrund bekannter 
struktureller und biochemischer Daten bezüglich PI-SceI, wurden nur Aminosäuren der 
Mutagenese unterworfen, welche in der DNS-Bindung involviert sind. Die in dieser Arbeit 
selektionierten Varianten von PI-SceI zeigten in vivo eine bis zu 100 - fach gesteigerte 
Spezifität gegenüber der neuen Erkennungssequenz, ein Ergebnis, dass in vitro unter keiner 
der getesteten Bedingungen bestätigt werden konnte. Dies ließ darauf schließen, dass in vivo 
und in vitro beobachtete Ergebnisse nicht notwendigerweise übereinstimmen und dass der 
hier entwickelte Assay weiter optimiert werden muss. 
Der zweite Ansatz verfolgt eine rationalere Strategie, ähnlich derer von Zink-Finger 
und TALE-Nukleasen. Hierbei wurde eine katalytisch inaktive Variante der LAGLIDADG 
Homingendonuklease I-SceI an das spezifische Typ IIP Restriktionsenzym PvuII fusioniert. 
Letzteres soll eine Alternative zur ansonsten so häufig genutzten katalytischen Domäne von 
FokI darstellen. Das entstandene Fusions-Enzym wurde weiterhin in der Linker-Region, 
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welche I-SceI und PvuII miteinander verbindet, optimiert. Außerdem wurden Mutationen in 
I-SceI eingeführt, um sämtliche katalytische Aktivität zu unterbinden (D44N und D145A). 
Auch PvuII wurde optimiert, indem entweder durch Aminosäure-Substitutionen die 
katalytische Aktivität reduziert wurde (T46G, H83A oder Y94F) oder indem das 
Dimerisierungspotential verringert wurde (L12E, P14G oder H15D). Das Resultat all dieser  
Optimierungen stellt die finale Variante P(P14G)-L(6)-Ss* dar. Dieses Enzym zeigt in vitro eine 
über 1000 - fache Präferenz für eine adressierte Erkennungssequenz (PvuII Erkennungs-
sequenz flankiert von zwei I-SceI Erkennungssequenzen) gegenüber einer unadressierten 
Sequenz (PvuII Erkennungssequenz allein). Außerdem hat es eine bis zu 10 - fache Präferenz 
für einen Abstand von sechs Basenpaaren zwischen den I-SceI und PvuII 
Erkennungssequenzen und zeigt keinerlei Spaltung von genomischer DNS (Bakteriophagen λ 
DNS). Als nächsten Schritt sollte P(P14G)-L(6)-Ss* in vivo getestet werden. Dies könnte 
idealerweise in Pflanzen stattfinden, da es mittlerweile in einer Auswahl von bestimmten 
Kulturpflanzen I-SceI Erkennungssequenzen als Insertionsstellen für genetische 
Modifikationen gibt.   
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